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CHAPTER I 
INTRODUCTION 
Cyclooxygenase Structure and Function 
Cyclooxygenase Biochemistry and Pharmacology 
 The cyclooxygenase (COX) enzyme was first prepared and characterized in 1967 from sheep vesicular 
gland.1 Further work identified that the COX enzyme exists in two separate isoforms, COX-1 and COX-2. 
COX-1 was first purified and identified in 1976 from bovine and sheep vesicular glands, while COX-2 was 
discovered in 1991.2-4 The COX enzymes are membrane-bound homodimers that localize to the nuclear 
envelope, the lumen of the endoplasmic reticulum, and Golgi apparatus.5 The COX enzymes consist of three 
domains, an epidermal growth factor (EGF)-like domain a membrane-binding domain, and a catalytic domain 
(Figure 1). In addition, the COX enzymes associate with a molecule of heme (Fe3+-protoporphyrin IX), which is 
required for catalysis.3,6 
 
Figure 1: Structure of COX enzyme domains. The epidermal growth factor-like domain is shown in purple, 
the membrane-binding domain in green, and the catalytic domain is shown in grey. Heme is pictured in red. 
PDB ID: 3PGH. 
 
 The COX enzymes catalyze the conversion of arachidonic acid (AA) to prostaglandin endoperoxide H2 
(PGH2) in two steps at two separate active sites. The cyclooxygenase active site catalyzes the bis-dioxygenation 
and cyclization of AA to form the hydroperoxy endoperoxide prostaglandin G2 (PGG2).7 PGG2 then exits the 
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cyclooxygenase active site and diffuses to the peroxidase active site, where a two-electron reduction of PGG2 
occurs to form the hydroxy endoperoxide PGH2.8 Although the two active sites are structurally separate, the 
cyclooxygenase reaction is functionally dependent upon the two-electron oxidation of the heme at the 
peroxidase active site. This two-electron oxidation of heme at the peroxidase activate site is coupled to the two-
electron reduction of a hydroperoxide substrate, such as PGG2.9 The oxidation of the heme results in the 
formation of a ferryloxo protoporphyrin radical cation ((PPIX•)+Fe4+O), which has been termed Compound 
I.10,11 After formation, Compound I can abstract the phenolic hydrogen of Tyr-385 in the cyclooxygenase active 
site to form a tyrosyl radical, which can then initiate the cyclooxygenase reaction.  
 The free radical mechanism of the cyclooxygenase reaction was initially identified through biochemical 
and isotopic labeling studies.1,12,13 The binding of AA within the L-shape of the cyclooxygenase active site 
positions its 13-pro-(S)-hydrogen adjacent to the tyrosyl radical at amino acid 385. The tyrosyl radical then 
abstracts the 13-pro-(S)-hydrogen of AA to form a carbon-centered arachidonyl radical, which can be trapped at 
carbon 11 by molecular oxygen to produce an 11-(R)-peroxyl radical (Figure 2). The 11-(R)-peroxyl radical 
then undergoes two cyclizations to form a bicyclic endoperoxide and an allylic radical between carbons 13 and 
15. The allylic radical then reacts with a second molecule of molecular oxygen to form a peroxyl radical at 
carbon 15. Finally, the peroxyl radical abstracts the phenolic hydrogen of Tyr-385 to generate PGG2 and 
regenerate the tyrosyl radical, which can further catalyze fatty acid oxygenation. PGG2 then diffuses out of the 
cyclooxygenase active site and into the peroxidase active site, where it is reduced to form PGH2. COX can also 
generate alternate products that result from no cyclization such as 11-hydroperoxyeicosatetraenoic acid (11-
HpETE) if the 11-(R)-peroxyl radical does not undergo cyclization to form the endoperoxide ring at carbon 9 or 
15-HpETE if molecular oxygen reacts with the initial arachidonyl radical at carbon 15. 
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Figure 2: The mechanism of the cyclooxygenase reaction. In the peroxidase (POX) active site, the heme 
moiety ((PPIX)Fe3+) undergoes a two-electron oxidation to form Compound I ((PPIX•)Fe4+O), while the 
hydroperoxide substrate (ROOH) undergoes a two-electron reduction. The enzyme can be brought back to its 
resting state by two subsequent one-electron reductions or the radical can abstract the phenolic hydrogen of Tyr-
385 in the COX active site. When AA is bound within the cyclooxygenase (COX) active site, the tyrosyl radical 
can abstract the 13-pro-(S) hydrogen and initiate a series of radical rearrangements and two additions of 
molecular to form the hydroperoxy endoperoxide PGG2. The radical is then transferred back to the tyrosine 
residue to allow the initiation of subsequent catalytic cycles. 
 
 The generation of PGH2 from AA by the COX enzymes represents the committed step in the synthesis 
of prostaglandins (PGs). After synthesis by the COX enzymes, PGH2 is processed by tissue specific synthases 
to form the prostaglandins PGE2, PGD2, and PGF2α, as well as prostacyclin (PGI2) and thromboxane (TXA2) 
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(Figure 3).14 The prostanoids are bioactive lipids that mediate a plethora of physiological and 
pathophysiological processes through their actions at discrete G-protein coupled receptors (GPCRs) and nuclear 
receptors.15-17 The differential expression of PG synthases and PG GPCR isoforms results in a complex, non-
uniform response to COX action that is tissue-specific. For example, PGE2 potentiates platelet aggregation, 
regulates kidney function, and provides gastrointestinal cytoprotection.18-21 PGD2 produces anti-inflammatory 
effects via Nrf2 and is cytoprotective in models of acute brain injury and heart ischemia-reperfusion injury.22-24 
PGI2 is a potent vasodilator and anti-thrombotic agent, whereas TXA2 induces vasoconstriction and 
thrombosis.25-27 Prostanoids also have prevalent roles in pain, fever, inflammation, and tumorigenesis.26,28-30 
 
Figure 3: Formation of PGs from PGH2. PGH2 is processed by tissue specific synthases to form the 
prostaglandins PGD2, PGE2, and PGF2α, prostacyclin (PGI2), and thromboxane (TXA2). 
 
Cyclooxygenase Structure 
 The first three-dimensional structure of COX-1 was published in 1994, followed two years later by the 
crystal structure of COX-2.31,32 A 14-amino acid deletion at the N-terminus of COX-2 causes the numbers of 
most COX-2 amino acids to be 14 units lower than those of COX-1, but by convention, the amino acids of both 
isoforms are referred to by the numbering of COX-1. Comparison of the crystal structures of COX-1 and COX-
2 reveals that the two isoforms have virtually superimposable structures.  
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Each monomer is comprised of three domains: an EGF-like domain, a membrane binding domain, and a 
large globular catalytic domain, which houses the COX and POX active sites.31-33 The COX enzymes are 
present as homodimers with an extensive dimer interface created by the EGF-like and catalytic domains.34 The 
EGF-like domain is made up by resides 34-72 of the N-terminus and its precise function remains unknown. 
However, it has been suggested that this domain may initiate or maintain interactions necessary for the insertion 
of COX into the membrane bilayer or homodimer formation.35 
 COX-2 associates with the outer leaflet of phospholipid bilayers with its membrane-binding domain, 
which is composed of residues 73-116 and contains four short amphipathic α-helices (A-D). The helices are 
positioned orthogonal to one another, creating a hydrophobic surface for insertion into the membrane bilayer. 
The helices of the membrane-binding domain also form an open area termed the “lobby”, which substrates and 
inhibitors travel through to enter the active site located within the catalytic domain. 
The catalytic domain is structurally homologous to mammalian myeloperoxidase, suggesting that the 
COX enzymes evolved from soluble heme-dependent peroxidases.35 The catalytic domain is largely composed 
of α-helices. The COX active site is composed of an L-shaped hydrophobic channel that extends from the 
membrane-binding domain into the interior of the catalytic domain. Within the COX channel, a constriction site 
composed of Arg-120, Tyr-355 and Glu-524 separates the catalytic and membrane-binding domains. The 
catalytic residue, Tyr-385, is located at the turn of the L-shaped channel. While the COX-1 and COX-2 active 
sites are relatively similar, the COX-2 active site is 20-30% larger than that of COX-1 due to the substitution of 
Ile-523 in COX-1 for Val-523 in COX-2 (Figure 4).36 COX-2 also contains substitutions of Val-434 and Arg-
513 compared to Ile-434 and His-513 in COX-1. The POX active site is located in a solvent-accessible groove 
at the top of the catalytic domain. The POX active site consists of a heme binding pocket formed by His-388 as 
the proximal heme ligand and Gln-203 and His-207 distal to the heme (Figure 5).31 Mutation of His-388, Gln-
203, or His-207 causes a dramatic reduction in POX activity, but the mutation of Gln-203 retains full COX 
activity.11,37,38  
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Figure 4: COX active site structures in COX-1 and COX-2. Substitution of Ile-523 in COX-1 for Val-523 in 
COX-2 increases the solvent-accessible surface area of the COX active site of COX-2. Reproduced from.18 
 
 
Figure 5: Structure of the POX active site. Heme (red) is bound in the POX active site by coordination to 
His-388, Gln-203, and His-207. The catalytic Tyr-385 is positioned below the heme. PDB ID: 1Q4G.  
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 Crystal structures of AA bound to COX-2 have identified the basis of substrate binding to the COX 
active site.39,40 The COX-2 crystal structure identified that AA binds in two distinct conformations to the two 
monomers of COX-2. In the productive conformation, AA binds in an L-shaped conformation with its 
carboxylic acid hydrogen-bonded to Tyr-355 at the base of the active site and the fatty acid tail projecting into 
the catalytic site with the ω-tail in a hydrophobic groove above Ser-530 and Leu-534 (Figure 6). This 
conformation positions the 13-pro-(S)-hydrogen of AA for abstraction by the catalytic Tyr-385 radical. In the 
non-productive conformation, AA binds in an inverted fashion with its carboxylic acid coordinated to Tyr-385 
and Ser-530 at the apex of the COX active site.41 In this orientation, the 13-pro-(S)-hydrogen is over 10 Å away 
from the catalytic Tyr-385 and cannot be abstracted to initiate the COX reaction. AA makes 49 interactions with 
the active site of COX-1 and 54 interactions with COX-2 active site residues.39,40 Mutation of either Val-349 or 
Trp-387 causes a shift in the product profile of both COX-1 and COX-2, such that an increased amount 11- or 
15-HpETE is formed, while the amount of the PGG2 is correspondingly decreased.42 This occurs with mutation 
of Trp-387 to Phe due to elimination of the interactions of COX-2 with C-11 and C-12 of AA, leading to greater 
conformational flexibility of the 11-peroxyl radical and suboptimal alignment for endoperoxide formation.42,43 
 
Figure 6: Crystal structures of the productive and non-productive conformations of AA within the COX 
active site. In the productive binding mode of AA (left), the carboxylate moiety of AA (green) participates in 
hydrogen-bonding interactions with Tyr-355 at the constriction site of COX-2. The catalytic residue, Tyr-385, is 
positioned above the 13-pro-(S)-hydrogen. In contrast, AA is shown in two possible arrangements in non-
productive conformations in the active site of COX-2 (right). The carboxylate of AA is coordinated to Tyr-385 
and Ser-530 at the top of the COX active site. PDB ID: 3HS5. 
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  Ser-530 also plays a role in promoting cyclization and PGG2 stereochemistry.42 When Ser-530 is 
mutated to Thr in either murine or human COX-2, the ratio of PG to HpETE products is similar to that of wild-
type COX-2, but there is a dramatic shift in the stereochemistry around C-15 to the (R)-conformation.44 
Mutation of Ser-530 to Met or Val in COX-2 also results in almost complete stereochemical inversion of the 
oxygenation at C-15 and leads to increased amounts of HpETE products. Because both polar and non-polar 
substitutions for Ser-530 alter the stereospecificity of the COX-2 reaction, the stereochemistry of the reaction is 
regulated by steric interactions between the substrate and Ser-530.  
COX Enzyme Regulation and Isoforms  
 Although COX-2 shares 60% sequence identity with COX-1 and performs the same enzymatic reaction, 
the two isoforms have several principal structural and function differences. Ptgs-1, the gene coding for COX-1, 
is constitutively expressed through the body and encodes a relatively stable 2.8 kb mRNA. In contrast, Ptgs-2, 
the gene for COX-2, is an immediate early gene that is expressed in response to stimuli such as cytokines, 
growth factors, and tumor promoters.4,45 The Ptgs-2 gene encodes a 4 kb mRNA that contains an instability 
sequence in the 3’-untranslated region, which leads to rapid turnover.46 Although true in some settings, the 
dogma that COX-1 is constitutively expressed and COX-2 is solely an inducible isoform has been challenged by 
several recent studies. COX-2 is constitutively expressed in the cerebral cortex, kidney, and spinal cord myelin 
sheaths.47-49 The constitutive expression of COX-2 in these tissues and the induction of COX-1 in some settings 
suggest that there are other important differences between the isoforms. 
 The activity and stability of the COX enzymes are regulated by several mechanisms after protein 
translation. While COX-1 protein is quite stable, COX-2 is a target of the endoplasmic reticulum-associated 
degradation pathway.50 This is due to the fact that while COX-1 has three N-glycosylation sites, COX-2 
contains an additional N-glycosylation site at Asn-594 due to an additional 19 amino acids at the C-terminus. 
This additional glycosylation at Asn-594 mediates the endoplasmic reticulum-associated degradation pathway 
and mutation of Asn-594 to remove this glycosylation site increases the stability of COX-2. 
 Additionally, The COX enzymes are suicide-inactivated by a first-order, irreversible hydroperoxide-
dependent process.51 The oxoferryl heme produces radical species that can lead to either heme or protein 
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modification and subsequent loss of enzymatic activity.52 This suicide inactivation may serve as an alternative 
regulatory mechanism for COX activity, as reducing co-substrates prevent COX suicide inactivation.53 In 
contrast, a hydroperoxide product of platelet lipoxygenase, 12-HpETE, inactivates COX in platelets.54 Thus, 
oxidative processes modulate COX action. 
 Although the two COX isoforms catalyze the same reactions and have similar sequences, the two COX 
isoforms are not functionally transposable. Insertion of the Ptgs-1 gene after the regulatory sequence controlling 
Ptgs-2 expression in mice causes functional differences.55 In these knock-in mice, stimuli that induce COX-2 
expression cause COX-1 expression. Despite the fact that the urinary levels of PGEM (the metabolite of PGE2) 
are restored relative to COX-2 null mice, there is a decrease in PGI2 levels. The differences in PG production 
could be a result of the marked difference between hydroperoxide activation sensitivity, as COX-2 is activated 
at much lower hydroperoxide levels than COX-1.56 The hydroperoxide sensitivity difference between COX-2 
and COX-1 is mediated by the mutation of His-383 in COX-1 to Thr-383 in COX-2.57 Additionally, COX-1 and 
COX-2 may interact with specific downstream PG synthases, which may account for some of the differences 
observed in the knock-in mice.58 
 
The Endocannabinoid System 
Endocannabinoid biology 
 The endocannabinoid system consists of the endogenous cannabinoids (endocannabinoids, eCBs), 
cannabinoid receptors, and the enzymes responsible for the synthesis and degradation of eCBs. The 
endocannabinoid system was initially identified as the target of Δ9-tetrohydrocannabinol (THC), the 
psychoactive component of Cannabis sativa.59 After decades of research, the cannabinoid receptor 1 (CB1) was 
cloned and its brain localization mapped in 1990.60,61 A second peripheral cannabinoid receptor, CB2, was 
identified in 1993.62 Arachidonoyl ethanolamide (anandamide, AEA) was the first endogenous ligand identified 
for the CB1 and CB2 receptors.63 The second eCB, 2-arachidonoyl glycerol (2-AG), was discovered in 1997.64 
Both AEA and 2-AG are carboxylate-modified AA derivatives and act as neuromodulators.  
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 AA, 2-AG, and AEA are synthesized from phospholipids via discrete pathways in an “on demand” 
fashion. A primary source of AA is the hydrolysis of phospholipids at the sn-2 position by cytosolic 
phospholipase A2 (cPLA2). There are six identified isoforms of cPLA2 found in mice, α, β, γ, δ, ε, and ζ. These 
isoforms are expressed in different tissues and respond to different stimuli. In activated macrophages, AA 
formation is primarily mediated by the action of cPLA2α, a 85-kDa protein containing an N-terminal C2 domain 
and a C-terminal catalytic domain.65 Importantly, cPLA2α hydrolysis of phospholipid substrate has high 
substrate specificity for phospholipids containing AA at the sn-2 position.36 The activity of cPLA2α is regulated 
by intracellular calcium and calcium binding to the C2 domain causes localization of the enzyme to the 
phospholipid membrane.66 After translocation to the membrane, cPLA2α utilizes an active site Ser-228/Asp-549 
dyad within the α/β hydrolase domain to catalyze the hydrolysis of the sn-2 position of phospholipids 
containing AA including phosphatidylcholine (PC), phosphatidylethanolamine (PE), phosphatidylserine (PS), 
and phosphatidylinositol (PI).37 In addition to calcium, cPLA2α activation is also mediated by phosphorylation 
by MAP kinase, ceramide-1-phosphate, and phosphatidylinositol 4,5-bis phosphate (PIP2).38,67-69  
 While cytosolic phospholipase A2 (cPLA2) has been identified as a primary synthetic route for AA in 
many settings, recent studies have identified 2-AG hydrolysis as a major source of AA (and hence PGs) in the 
brain.70,71 Multiple pathways have been described for the synthesis of 2-AG (Figure 7). The primary synthetic 
route for 2-AG is the phospholipase C (PLC)-diacylglycerol lipase (DAGL) pathway.72 PLC hydrolyzes 2-
arachidonoyl-PI to form arachidonoyl-diacylglycerols (DAGs), which are then hydrolyzed to 2-AG by 
DAGL.73,74 In neurons, 2-AG is synthesized by PLCβ isoforms in response to the stimulation of Gq/11-coupled 
receptors.75 These receptors include the group I metabotropic glutamate receptors, mGluR1 and mGluR5, and 
the muscarinic acetylcholine receptor M1.76 Alternatively, DAGs can be formed by the hydrolysis of either 
phosphatidic acid (PA) in ionomycin stimulated neuroblastoma cells or PC in phorbol ester treated mouse ear 
tissue.77,78 Alternative routes that do not involve the formation of DAGs have also been identified, such as the 
hydrolysis of PI by PLA1 to form lyso-PI (LPI), followed by LPI-PLC hydrolysis to form 2-AG or the 
hydrolysis of phospholipids by phospholipase D (PLD) to form 2-arachidonoyl-lysophosphatidic acid (LPA) 
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and then dephosphorylation to form 2-AG.79-81 Thus, 2-AG biosynthesis can occur through multiple routes 
depending on the stimulation method and tissue of interest. 
 
Figure 7: Biosynthetic routes of 2-AG. 
 DAGL is a membrane-associated enzyme that preferentially hydrolyzes DAGs at the sn-1 position.82,83 
In most mammals there are two DAGL isoforms, α and β, and each contains a lipase-3 motif, a serine lipase 
motif, and four putative transmembrane domains.84 DAGLα is primarily expressed in the nervous system and 
pancreas in humans and mice and co-localizes with Gq/11-coupled receptors and PLCβ in neurons.60 In 
neuroblastoma cells DAGLα mediates the mGluR-dependent formation of 2-AG and in DAGLα-deficient mice 
there is a reduction in brain 2-AG levels.85-87 In contrast, DAGLβ is the major source of 2-AG in macrophage 
cell lines as evidenced by a reduction in the levels of 2-AG upon treatment with selective DAGLβ inhibitors or 
genetic deletion of DAGLβ.88  
 AEA can also be synthesized through multiple distinct pathways. Classically, AEA is synthesized 
through a transacylation-phosphodiesterase pathway in the brain (Figure 8).89 The first step in this pathway 
involves the transfer of AA by an N-acyltransferase (NAT) onto the terminal amine of PE to form N-
arachidonoyl-PE (NAPE).90-92 NAT is stimulated by Ca2+ and utilizes PC, 1-acyl-lyso-PC, PE, or cardiolipin as 
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the AA donor.93-95 NAPE is then hydrolyzed by NAPE-PLD to form AEA and PA.96,97 NAPE-PLD utilizes zinc 
as a co-factor and is activated by PE and divalent cations such as Ca2+ and Mg2+.98,99 Alternate pathways to 
synthesize AEA from NAPE have also been described. NAPE can be converted to 1-acyl-lyso-NAPE by 
secretory PLA2 (sPLA2) isoforms and then converted to AEA by a lyso-PLD enzyme.100 NAPE can also be 
double O-deacylated by α/β-hydrolase domain 4 (ABHD4) to form glycerophospho-AEA (Gp-AEA), which can 
then be hydrolyzed to AEA and glycerol 3-phosphate by glycerophosphodiester phosphodiesterase 1 
(GDE1).101,102 However, GDE1–/– mice do not have lower levels of brain AEA despite having no formation of 
Gp-AEA or lyso-NAPE in brain homogenates.103 In lipopolysaccharide (LPS) treated RAW 264.7 
macrophages, NAPE can also be hydrolyzed by PLC to form phospho-AEA (p-AEA), which is then 
dephosphorylated by protein tyrosine phosphatase non-receptor type 22 (PTPN22) or SH2-containing inositol 
phosphatase 1 (SHIP1) to generate AEA.104-106 
 
Figure 8: Biosynthetic pathways for AEA. 
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Endocannabinoid Function and Degradation 
 After being synthesized, AEA and 2-AG activate CB1 and CB2 receptors to exert biological actions. The 
CB receptors are GPCRs that couple to Gi/o and inhibit adenylyl cyclase and activate MAP kinase.107 The CB2 
receptor is widely expressed in immune cells, while the CB1 receptor is expressed in the central nervous system, 
particularly in areas involved in nociception, including periaqueductal gray matter, the dorsal horn of the spinal 
cord, and dorsal root ganglion neurons.98,108-110 CB1 activation mediates the inhibition of either inhibitory 
GABAergic or excitatory glutamatergic neurotransmitter release from axon terminals in the central nervous 
system.111-114 Activation of synaptic CB1 receptors by either endogenous or exogenous agonists inhibits 
neurotransmitter release directly through inhibitory coupling to voltage-dependent calcium channels or through 
activation of potassium channels, which truncates action potential duration and diminishes the amount of 
neurotransmitter release per action potential.105,107,115-117 These effects are mediated through the direct 
interaction of βγ G-protein subunits with the ion channels.106  
 CB receptor activation by AEA and 2-AG occurs in response to neuronal activation and the resulting 
“on-demand” synthesis and release of the eCBs. After synthesis and release, the eCBs activate CB1 receptors on 
axon terminals to inhibit the release of GABA or glutamate.118 In the case of inhibitory GABAergic neurons, 
eCBs exhibit depolarization-induced suppression of inhibition (DSI), while in excitatory glutamatergic neurons 
eCBs exhibit depolarization-induced suppression of excitation (DSE).119,120 Thus, eCBs action can lead to both 
excitatory responses or inhibit responses in neurons. In addition, activation of CB1 receptors by eCBs can also 
modulate long-term depression (LTD) and long-term potentiation (LTP).121,122 The mechanism of retrograde 
signaling exhibited by eCBs differs considerably from those of classic neurotransmitters system (e.g., 
cholinergic, aminoacidergic, and monoamigeric), where depolarization of the presynaptic neuron by an action 
potential results in the release of neurotransmitters, which then traverse the synaptic cleft to bind and activate 
their cognate receptors on the postsynaptic neuron.  
 In addition to having a distinct signaling mechanism from classic neurotransmitters, eCBs also differ in 
their release and clearance from axon terminals. Most classic neurotransmitters are water-soluble and are 
packaged, stored, and released in synaptic vesicles.123 Following release into the extracellular space and 
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postsynaptic receptor activation, classic neurotransmitter signaling is terminated by a combination of cellular 
reuptake and enzymatic degradation. Inhibition of neurotransmitter clearance through blockade of reuptake, 
such as selective serotonin reuptake inhibitors, or metabolism, such as monoamine oxidase inhibitors, is a 
widely employed strategy for both therapeutic pharmacological treatments and drugs of abuse.124,125 AEA and 
2-AG levels, and therefore their effect on CB receptors, are primarily regulated by their “on demand” synthesis 
from membrane phospholipids and subsequent enzymatic inactivation. Pharmacological inhibition of eCB 
inactivating enzymes enhances eCB signaling and is a promising strategy for therapeutic interventions. AEA is 
primarily degraded by the enzyme fatty acid amide hydrolase (FAAH) to form AA and ethanolamine. 126-128 
Similarly, 2-AG is primarily degraded by hydrolysis to AA and glycerol by several enzymes including 
monoacylglycerol lipase (MAGL), α/β-hydrolase domain 6 (ABHD6), α/β-hydrolase domain 12 (ABHD12), 
carboxylesterases 1 and 2 (CES1 and CES2), and palmitoylprotein thioesterase 1 (PPT1).60,129-132 Thus, AEA 
and 2-AG are biosynthesized and degraded by distinct sets of enzymes. 
 FAAH is a 60-kDa integral membrane protein and is highly expressed in the mammalian brain, where it 
localizes to intracellular membranes of postsynaptic somata and dendrites.133 FAAH and CB1 exhibit 
complementary subcellular distributions in many brain regions including the neocortex, cerebellar cortex, and 
hippocampus.134 FAAH contains an active site serine nucleophile and utilizes a lysine residue as a catalytic base 
that allows it to hydrolyze both amides and esters, in contrast to the histidine residue utilized by most serine 
hydrolases.135 Mice bearing a targeted deletion of the Faah gene (FAAH–/–) have been generated and confirm 
FAAH’s role as the principal hydrolase of AEA in vivo.136 FAAH–/– mice exhibit anti-nociceptive, anti-
inflammatory, anxiolytic, and anti-depressive phenotypes without motor or cognitive defects.134 Several 
selective pharmacological inhibitors for FAAH have been developed and validated. The first selective FAAH 
inhibitor was URB597, a carbamate compound that irreversibly carbamoylates the catalytic serine 
nucleophile.137,138 URB597 administration increases AEA and other N-acylethanolamide (NAE) levels in vivo 
and reduces pain, anxiety, depression, and nausea in rodents.132,139-141 In contrast to direct CB1 agonists, 
URB597 does not cause hypothermia, hypolocomotion, catalepsy, or increased appetite.132 However, URB597 
also inhibits multiple CES enzymes in the liver and has a relatively short half-life in vivo, limiting its use in 
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chronic dosing studies.142-144 A significant pharmaceutical effort to develop a series of FAAH inhibitors has 
been undertaken by Pfizer. This effort resulted in a series of covalent and irreversible urea-based FAAH 
inhibitors with exceptional potency, selectivity, and duration of action in vivo.145-147 The most widely used 
compound, PF-3845, selectively blocks FAAH activity in mouse brain for up to 24 hours after a single 10 
mg/kg i.p. dose and maximally elevates AEA for 7-12 hours.142 PF-3845 was further optimized for human 
clinical trials to PF-04457845 and this compound is efficacious in rat models of inflammatory and non-
inflammatory pain.148,149 Despite inhibiting FAAH activity and elevating plasma AEA and other NAE levels in 
humans, PF-04457845 failed to show efficacy in Phase II clinical trials in patients with osteoarthritic knee 
pain.150,151 
 The primary hydrolytic enzyme for 2-AG in the brain is MAGL, which accounts for 85% of 2-AG 
hydrolysis in mouse brain membranes.152 MAGL is a 33-kDa soluble serine hydrolase that contains a serine-
histidine-aspartic acid catalytic triad and peripherally associates with cell membranes.153-155 MAGL is highly 
expressed in the cerebellum, cortex, thalamus, and hippocampus, where it is primarily localized to presynaptic 
axon terminals.129,154 MAGL is highly selective for the hydrolysis of monoacyl glycerols (MAGs), with 
negligible activity on DAGs, triacylglycerols, phospholipids, or cholesterol esters.156 The primary selective 
MAGL inhibitor utilized is JZL184, which is an in vivo active inhibitor and elevates brain 2-AG levels and 
elicits a subset of cannabinoid behaviors.157,158 JZL184 enhances eCB retrograde signaling, attenuates 
neuropathic pain, and produces anxiolytic effects.159-161 However, JZL184 has also been shown to inhibit CES1 
and CES2, which also can hydrolyze 2-AG, and FAAH.162 Second generation MAGL inhibitors with O-
hexafluoroisopropyl carbamate scaffolds, such as KML29, have superior selectivity toward MAGL over other 
serine hydrolases.163 
 Although MAGL is the primary 2-AG hydrolytic enzyme in the brain, ABHD6 also modulates 2-AG 
levels. ABHD6 is a 30-kDa integral membrane serine hydrolase with an intracellular orientation.149 The murine 
microglial BV2 cell line efficiently hydrolyzes 2-AG despite lacking MAGL expression, and this hydrolysis is 
mediated by ABHD6.164 ABHD6 is abundantly expressed in the brain and multiple peripheral tissues and cell 
types.165,166 In the brain, ABHD6 is expressed in cortical areas and preferentially localizes to postsynaptic 
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dendrites adjacent to presynaptic CB1 receptors.163 ABHD6 regulates 2-AG degradation and signaling in 
primary murine neurons and cortical slices as well as Neuro2A cells.163,164 The ABHD6 inhibitor WWL70 
produces CB1 and CB2-mediated anti-inflammatory and neuroprotective effects in a mouse model of traumatic 
brain injury.167 More recent studies have identified a series of potent and selective 2-substituted-piperidyl-1,2,3-
triazole ABHD6 inhibitors that are active in vivo.168 
 Inhibition of eCB degradation by FAAH and MAGL has demonstrated a multitude of therapeutic 
effects. Inhibition of FAAH reduces nociceptive and hyperalgesic behavior in acute, inflammatory, and 
neuropathic pain models.169 Complete inhibition of FAAH by PF-3845, at a 10 mg/kg i.p. dose, or MAGL by 
JZL184, at a 40 mg/kg i.p. dose, produces antinociceptive effects in tests of acute thermal pain, visceral pain, 
neuropathic pain, and inflammatory pain.154,155,166,170-175 These effects are mediated by CB1 and/or CB2 receptor 
activation depending on the model and inhibition mode used.  
 In addition to analgesic effects, FAAH and MAGL inhibitors have demonstrated anxiolytic effects in 
preclinical models of anxiety and depression.176 URB597 produces anxiolytic effects in multiple preclinical 
models of anxiety, including the elevated zero maze and elevated plus maze in both acute and chronic settings 
in a CB1-dependent manner.132,177,178 JZL184 also produces anxiolytic-like effects in rats in the elevated zero 
maze and elevated plus maze, however, these effects are CB2-dependent. In highly aversive contexts, JZL184 
produces anxiolytic-like effects in the elevated plus maze in a CB1-dependent manner.157 FAAH inhibition by 
URB597 or PF-3845 and MAGL inhibition by JZL184 also decrease anxiety as measured in the marble burying 
assay in mice through a CB1-receptor dependent mechanism.179,180 These studies demonstrate the pleiotropic 
therapeutic effects of eCB augmentation via FAAH and MAGL inhibition and the resulting modulation of 
cannabinoid receptor signaling.  
 
Oxygenation of Endocannabinoids by Cyclooxygenase-2 
 In addition to the oxygenation of AA, COX-2 also catalyzes the oxygenation of AEA and 2-AG to form 
prostaglandin ethanolamides (PG-EAs) and prostaglandin glyceryl esters (PG-Gs), respectively (Figure 9).181,182 
Kinetic studies identified that the oxygenation of AEA by COX-2 occurs with an approximately 6 fold higher 
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Km relative to AA.183,184 In contrast, the oxygenation of 2-AG by COX-2 is as efficient as that of AA as 
evidenced by steady-state kinetic analyses indicating that AA and 2-AG have comparable kcat/Km values.32 
Thus, COX-2 can utilize neutral ester and amide derivatives of AA as substrates. 
 
Figure 9: Oxygenation of AEA and 2-AG by COX-2.  
 Initial studies on the amino acid determinants of eCB oxygenation by COX-2 using site-directed 
mutagenesis identified the constriction site as a major determinant of eCB oxygenation. Mutation of Arg-120 to 
Gln causes a 9-fold reduction in 2-AG oxygenation and a 3-fold reduction in AEA oxygenation relative to wild-
type enzyme, while mutation of Glu-524 to Leu reduces the oxygenation of 2-AG, AEA, and AA.184,185 
Interestingly, Tyr-355 mutation to Phe has no effect on eCB oxygenation but decreases AA oxygenation. The 
lack of eCB oxygenation by COX-1 predicts that the side pocket comprised of Val-523, Arg-513, and Val-434 
in COX-2 may bind the eCBs. Mutation of all three COX-2 side pocket residues to their COX-1 counterparts, 
Val-523 to Ile, Arg-513 to His, and Val-434 to Ile, causes a 75% reduction in 2-AG and AEA oxygenation but 
has no effect on AA oxygenation.184,185  
 More recently, a crystal structure of murine COX-2 complexed to 1-AG (an isomerization from 2-AG to 
1-AG occurred over the course of the crystallization) has been solved. The COX-2:1-AG structure identifies 
that, like AA, 1-AG binds in both a productive and non-productive conformation to the two monomers of COX-
2 (Figure 10).186 In the productive conformation, the ω tail of 1-AG is projected into the hydrophobic channel at 
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the apex of the COX active site with the 13-pro-(S)-hydrogen positioned for abstraction by Tyr-385 and the 2,3-
dihydroxypropyl of 1-AG bound in a pocket vacated by rotation of Leu-531. In contrast to the inversion of AA 
in the non-productive conformation, the non-productive conformation of 1-AG has the same overall binding 
orientation as observed in its productive conformation but lacks sufficient insertion of its ω tail into the 
hydrophobic channel to bring the 13-pro-(S)-hydrogen close enough for abstraction by Tyr-385.40,186 Of note, 
the side pocket of COX-2 does not serve as a binding site for 1-AG in the crystal structure and mutation of Arg-
513 to His had no effect on either AA or 1-AG binding in structures with R513H mutant enzyme.186 This is in 
contrast to the site-directed mutagenesis studies, which suggested that the constriction site residues and side 
pocket are important for eCB oxygenation. However, both sets of studies agree that the overall binding 
orientation and reaction mechanisms for eCB oxygenation and AA oxygenation are the same. 
 
Figure 10: Crystal structure of the productive and non-productive conformations of 1-AG in the COX 
active site. 1-AG (teal) bound to the COX active site in the productive conformation (left) and non-productive 
conformation (right). C-13 of 1-AG is highlighted in orange, to indicate the change in distance between Tyr-385 
in the two conformations. PDB ID: 3MDL.   
 
 While PGH2 is converted to PGE2, PGD2, PGF2α, PGI2, and TxA2 by downstream synthases, PGH2-EA 
and PGH2-G are not good substrates for thromboxane synthase; thus, they each form PGE2, PGD2, PGF2α, and 
PGI2 ethanolamide or glycerol analogs, but not TxA2 products.187 The production of PG-EAs has been 
demonstrated in several settings including in FAAH knockout mice treated with AEA, lipopolysaccharide-
stimulated mouse dorsal root ganglia cultures, mouse renal medulla, rat spinal cord, and in mouse 
adipocytes.188-192 PG-Gs have been detected in rat paws and multiple stimulated macrophage cell lines including 
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RAW 264.7 cells, resident peritoneal macrophages, and J774 macrophages.193-197 Several studies have 
demonstrated that PG-Gs are unstable due to enzymatic hydrolysis to PGs, which may account for the fewer 
reports of their formation in vivo compared to PG-EAs.131,132,198  
Emerging evidence reveals that PG-EAs and PG-Gs have discrete functions that appear to be mediated 
by receptors distinct from classical PG receptors. PGE2-EA reduces the expression of IL-12p40 in activated 
macrophages and microglial cells.199 AEA also negatively regulates IL-12p40 production, thereby inhibiting the 
expression of the cytokines IL-12 and IL-23. The inhibitory effects of AEA and PGE2-EA on IL-12p40 are 
partially reduced by an EP2 receptor antagonist, but not an EP4 receptor antagonist. These results indicate that 
the specific activation of EP2 may play a role in the down regulation of IL-12p40 induction by AEA and PGE2-
EA. A structural analog of PGF2α-EA, bimatoprost, is an ocular hypotensive agent marketed for the treatment of 
glaucoma and ocular hypertension.200 Neither bimatoprost nor PGF2α-EA exhibits significant activity at PG 
receptors. Extensive ocular distribution and metabolism studies indicate that bimatoprost exerts its effects as the 
intact, PGF2α-EA-like molecule through signaling via a heterodimer comprised of the F prostanoid (FP) receptor 
and a splice variant of the FP receptor with a truncated C-terminus.201,202 More recently, PGF2α-EA has also 
been shown to negatively regulate adipogenesis.192 
PGE2-G, but not PGE2, potently mobilizes Ca2+ and stimulates a transient increase in inositol 1,4,5 
phosphate (IP3) levels, activation of PKC, and ERK phosphorylation.203 The affinity of PGE2-G for E 
prostanoid receptors is at least two orders of magnitude lower than that of PGE2, and binding to the 
thromboxane, prostacyclin, D prostanoid, or F prostanoid receptors are negligible. PGE2-G also causes a 
concentration-dependent increase in the frequency of miniature inhibitory post-synaptic currents (mIPSCs) in 
mouse hippocampal neurons.204 The frequency of mIPSCs is also increased by PGD2-G, PGF2α-G, and PGD2-
EA, but not by PGE2-EA and PGF2α-EA, while 2-AG and AEA reduce the frequency of mIPSCs. The ability of 
PG-Gs and PG-EAs to increase the frequency of mIPSCs is not due to hydrolysis to PGs or binding to PG 
receptors, as classical PGs act to reduce the frequency of mIPSCs or have no effect. Treatment with an IP3 
receptor agonist or a MAPK inhibitor blocks the PGE2-G-mediated increase in the frequency of mIPSCs. PGE2-
G also increases the frequency of miniature excitatory postsynaptic currents (mEPSCs) in mouse hippocampal 
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neurons in culture through the MAPK and IP3 signaling pathways.205 PGE2-G may be neurotoxic, as it causes a 
dose-dependent increase in terminal transferase dUTP nick end labeling (TUNEL) staining and time-dependent 
cleavage of caspase-3 in rat hippocampal neurons. PGE2-G also induces hyperalgesia through modulation of 
NF-κB in carrageenan-treated rat paws.193 In contrast, PGD2-G exhibits anti-inflammatory activity in isolated 
macrophages and in vivo.197 
A study in human vascular endothelial cells has suggested that PGI2-G may activate the nuclear receptor 
PPARδ.206 Treatment of human umbilical vein endothelial cells expressing COX-2 with 2-AG leads to PPARδ 
activation in a non-CB1 or CB2-dependent manner. Both COX-2 and prostacyclin synthase activity were 
required for 2-AG-induced PPARδ activation, suggesting that 2-AG is converted to PGI2-G, which can then 
activate PPARδ. The COX-2-PGI2-G-PPARδ pathway appears to lead to the attenuation of prothombotic tissue 
factor gene expression. Taken together, these studies have identified distinct functions of PG-EAs and PG-Gs 
that are mediated by signaling at non-prostanoid receptors. 
 
Inhibition of Cyclooxygenases 
Non-steroidal anti-inflammatory drugs 
 Natural products have been used in the treatment of pain, fever, and inflammation since ancient times. 
Egyptians used myrtle leaf extracts to treat pain and fever as early as 1550 BC and the Greeks utilized willow 
bark and leaf extracts for the same purpose around 500 BC. In 1763, Edward Stone presented a scientific study 
of the anti-pyretic effects of willow bark to the Royal Society of London. Henri Leroux then isolated and 
identified salicin as the active analgesic and anti-pyretic ingredient in willow bark in 1829. An industrial 
process for synthesizing salicylic acid from phenol was developed in the mid 19th century and the first factory, 
Salicylic Acid Works, for producing a drug was built in 1874.207 
 After the advent of mass production, salicylic acid was widely used but several notable issues arose. The 
drug was not very potent and required several grams to be taken per day to be effective. Salicylic acid 
treatments also lead to gastric irritation and poor tolerance, leading to the need for an improved drug. Felix 
Hoffman acetylated the hydroxyl group of salicylic acid to create acetylsalicylic acid, which improved the taste 
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and gastric tolerance. Acetylsalicylic acid was unveiled as aspirin in 1899 by Hoffman’s company, Bayer, and 
became the best selling drug worldwide. Further drug discovery efforts identified several other anti-
inflammatory and analgesic drugs using animal models of pain and inflammation. However, the mechanism of 
action was not discovered until 1971, when it was found that treating guinea pig lung with aspirin, sodium 
salicylate, or indomethacin causes a dose-dependent decrease in PG biosynthesis and treatment of platelets with 
aspirin leads to inhibition of PG biosynthesis.208,209 These studies identified the COX enzyme as the molecular 
target of non-steroidal anti-inflammatory drugs (NSAIDs).  
 Further studies into aspirin identified that it inhibits PG production in both a time- and concentration-
dependent manner.210 Incorporation of aspirin radioactivity into COX when incubated with [3H]-aspirin 
revealed that it inhibits COX through covalent modification of the enzyme at Ser-530 by acetylation.211-213 A 
crystal structure with an aspirin analog revealed that acetylation of Ser-530 leads to steric blockade of the 
catalytic residue, Tyr-385, which prevents catalysis.214 Although aspirin inhibits both COX-1 and COX-2, it 
preferentially inhibits COX-1. This preferential inhibition leads to sustained inhibition of COX-1 in platelets at 
low doses, which leads to inhibition of TxA2 biosynthesis and vasoconstriction.215 Thus, aspirin is commonly 
taken to reduce cardiovascular risk. 
 While aspirin remains a commonly used NSAID, it is the only COX inhibitor that covalently modifies 
the enzyme. All other NSAIDs act in one of two possible kinetic modes of inhibition: competitive and rapidly 
reversible, or time-dependent, functionally irreversible inhibitors.210 Rapid, reversible inhibitors interact with 
the COX enzymes in a single-step kinetic mechanism governed by the concentration of substrate and the 
dissociation constant, KI (Figure 11). In contrast, time-dependent inhibitors associated with the COX enzymes 
via a two-step process by which the inhibitor associates with the enzyme in an analogous bimolecular 
association, but a time-dependent second step leads to the formation of a more tightly associated inhibitor-
enzyme complex.210 
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Figure 11: Kinetic modes of COX-2 inhibition.  
 Several seminal studies on the phenylpropionic acid class of inhibitors have identified the determinants 
of COX inhibition and kinetics. The two kinetic modes of inhibition do not appear to be mediated by specific 
binding modes, as (S)-ibuprofen, a rapid, reversible inhibitor, and (S)-flurbiprofen, a slow, tight binding 
inhibitor, exhibit different kinetic modes of inhibition but bind similarly to the COX active site (Figure 
12).31,32,216 Both inhibitors hydrogen-bond and ion-pair with Arg-120 and Tyr-355 at the constriction site of 
COX and mutation of these residues abrogates inhibition of both COX-1 and COX-2.217,218  
 
Figure 12: Crystal structures of (S)-ibuprofen and (S)-flurbiprofen bound to COX-1 and COX-2. The 
crystal structure of (S)-ibuprofen (orange) bound to COX-1 reveals hydrogen bonding and ion-pairing 
interactions between its carboxylate and Tyr-355 and Arg-120 (left, PDB ID: 1EQG). (S)-flurbiprofen (pink) 
binds in the COX-2 active site in an analogous manner (right, PDB ID: 3PGH).  
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In addition to the hydrogen bonding and ion-pairing interactions between the carboxylic acid of 
phenylpropionic acids, such as ibuprofen and flurbiprofen, there are several other interactions that may account 
for their kinetic differences. The (S)-α-methyl group participates in Van der Waals interactions with Val-349 
and Leu-359 at the base of the active site.31,32 A notable difference in binding between ibuprofen and 
flurbiprofen is that the second phenyl ring of flurbiprofen interacts with amino acid residues at the apex of the 
COX active site, while the isobutyl group of ibuprofen does not.216  
A striking example of the subtle differences that may give rise to differential inhibitor kinetics has been 
identified through a study of flurbiprofen and its methyl ester. Whereas flurbiprofen acts as a slow, tight binding 
inhibitor, flurbiprofen methyl ester acts as a rapid, reversible inhibitor.216 Crystal structures of the two 
molecules bound to COX revealed no major differences in the interactions between the two inhibitors and the 
enzyme, suggesting that the kinetic mode of inhibition is not due to different interactions between an inhibitor 
and the enzyme that are evident from the crystal structures.216  
The second major class of NSAIDs is the arylacetic acids. The first arylacetic acid to be identified as an 
inhibitor of PG biosynthesis was indomethacin.210 Indomethacin is a slow, tight binding inhibitor and several 
studies have elucidated the molecular determinants of indomethacin inhibition of COX.219 The crystal structure 
of indomethacin bound to COX-2 reveals that it binds to the COX active site and forms ion-pairing and 
hydrogen-bonding interactions between its carboxylic acid and Arg-120 and Tyr-355, as with the 
phenylpropionic acids (Figure 13). Interestingly, the interaction between indomethacin and Arg-120 is essential 
for time-dependent inhibition of COX-1, but not COX-2, and modification of the carboxylic acid of 
indomethacin to neutral esters or amides results in COX-2-selective inhibitors.220-222 A second important 
determinant of kinetic inhibition by indomethacin is the insertion of its 2’-methyl group into a hydrophobic 
pocket formed by Val-349, Ala-527, Ser-530, and Leu-531.223 Mutation of Val-349 to Leu decreases the 
potency of indomethacin and causes indomethacin to become a rapid-reversible inhibitor. Removal of the 
methyl group, as in the case of 2’-desmethyl-indomethacin, results in a rapid-reversible inhibitor of both COX-1 
and COX-2.224 
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 A second member of the arylacetic acid class of NSAIDs, diclofenac, exhibits some striking differences 
from indomethacin and phenylpropionic acids. While diclofenac acts as a time-dependent inhibitor of COX-1 
and COX-2, it binds in an inverted fashion to the COX active site with its carboxylic acid hydrogen-bonded to 
Ser-530 and Tyr-385 at the bend of the channel.225 In stark contrast to indomethacin and phenylpropionic acids 
and in agreement with this binding mode, mutations of Arg-120 or Tyr-355 have no effect on the inhibition of 
diclofenac, but mutation of Ser-530 to Ala or Met eliminates its inhibition.195,226 Despite the inverted orientation 
of its carboxylic acid, diclofenac also inserts a chlorine atom into the hydrophobic pocket formed by Val-349, 
Ala-527, Ser-530, and Leu-531 in an analogous fashion to the 2’-methyl group of indomethacin. Thus, NSAIDs 
can exhibit multiple binding orientations within the COX active site, but each binding mode involves both 
hydrophilic and hydrophobic interactions. 
 
Figure 13: Binding of Indomethacin and Diclofenac to COX-2. Indomethacin (yellow) coordinates to 
constriction site residues Arg-120 and Tyr-355. The 2′-methyl group inserts into a small hydrophobic pocket 
comprised of Ser-530, Val-349, Leu-531, and Ala-527 (left, PDB ID: 4COX). In contrast, diclofenac (green) 
binds in an inverted conformation in the active site with the carboxylate hydrogen-bonded to Ser-530 and Tyr-
385 (right, PDB ID: 1PXX).  
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 The discovery of COX-2 as a second inducible isoform of COX lead to concerted drug discovery efforts 
to develop COX-2-selective inhibitors. These efforts were spurred on by the association of COX-2 with 
inflammation, pain, and fever, while COX-1 has been attributed to the negative side effects of NSAIDs, 
particularly gastrointestinal bleeding. Multiple animal models and human clinical trials have since demonstrated 
that COX-2-selective inhibitors have anti-inflammatory effects and present decreased gastrointestinal 
complications.227-229 
 The majority of COX-2-selective inhibitors are diarylheterocycles. The first diarylheterocycle, DuP-697, 
is an aryl methyl sulfonyl compound that was developed by Dupont-Merck before COX-2 was discovered. 
DuP-697 inhibits PG biosynthesis in macrophages, but not platelets, in agreement with the fact that platelets 
primarily express COX-1, while macrophages primarily express COX-2.230,231 Kinetic studies indicate that 
diarylheterocycles are rapid, reversible inhibitors of COX-1, but time-dependent inhibitors of COX-2.232 
Surprisingly, diarylheterocycles exhibit a three-step inhibition mechanism with COX-2 consisting of an initial 
association of inhibitor with enzyme followed by two unimolecular events.233-235 While the first two events are 
similar to traditional time-dependent NSAIDs, the third step results in the formation of a pseudo-irreversible 
inhibitor-enzyme complex.234,235 
 The molecular determinants of COX-2 selective inhibition by diarylheterocycles have been elucidated 
through extensive structure-activity studies, site-directed mutagenesis, and crystal structures. COX-2 selective 
inhibition requires a heterocycle or carbocycle with two aromatic rings at adjacent positions and a 4-
sulfonamide or 4-methylsulfone substitution on one of the phenyl rings.236 A crystal structure of the COX-2 
selective inhibitor SC-558 revealed that the substituted phenyl ring interacts with Leu-352, Tyr-355, Phe-518, 
and Val-523 while the sulfonamide or sulfone group interacts with His-90, Gln-192, and Arg-513.223 The COX-
2 selectivity arises due to the substitution of Val-523 to Ile in COX-1 and mutation of Val-523 to Ile in COX-2 
abrogates time-dependent inhibition of COX-2 by diarylheterocycles.237,238 The secondary shell substitutions of 
Arg-513 and Val-434 in COX-2 for His and Ile in COX-1 also regulate the ability of diarylheterocycles to bind 
in the side pocket.223,239  
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 In addition to the diarylheterocycles, an analog of diclofenac, lumiracoxib, is also a COX-2-selective 
inhibitor. As with diclofenac, lumiracoxib binds in an inverted conformation with its carboxylic acid hydrogen 
bonded to Ser-530 and Tyr-385 at the bend of the COX active site. Lumiracoxib is a COX-2 selective inhibitor 
due to the insertion of its methyl group into a hydrophobic pocket next to Leu-384, where in COX-1 there are 
larger secondary shell residues that clash with the methyl group.240 Removal of the methyl group from 
lumiracoxib results in a non-selective COX-1 and COX-2 inhibitor.241 
 
Side effects of selective COX-2 inhibitors  
 While COX-2 selective inhibitors display reduced gastrointestinal toxicity than non-selective COX 
inhibitors, the Vioxx Gastrointestinal Outcome Research (VIGOR) study suggested that this COX-2-selective 
inhibitor has an increased risk of cardiovascular events.228 The VIGOR study examined the efficacy and safety 
of the COX-2 selective inhibitor rofecoxib (Vioxx) in comparison to the non-selective NSAID naproxen in 
patients with rheumatoid arthritis. While rofecoxib is as efficacious as naproxen for the treatment of rheumatoid 
arthritis, patients taking rofecoxib had fewer adverse gastrointestinal events compared to naproxen. However, 
patients treated with rofecoxib exhibited a 4-fold increase in acute myocardial infarction compared to those 
treated with naproxen. The apparent increase in cardiovascular toxicity with rofecoxib compared to naproxen 
was attributed to a cardioprotective effect of naproxen. The long half-life of naproxen in humans leads to 
sustained inhibition of COX-1 in platelets, which reduces the production of the prothrombotic and atherogenic 
product TxA2.242 When patients are treated with naproxen at doses of 500 mg twice daily, the biosynthesis of 
platelet-derived TxA2 is inhibited throughout the dosage interval.  
 Another study examining the efficacy and safety of COX-2-selective inhibitors was the Celecoxib Long-
term Arthritis Safety Study (CLASS). The CLASS trial compared celecoxib to diclofenac and ibuprofen in 
patients with osteoarthritis or rheumatoid arthritis.229 Initial reports indicated that celecoxib was associated with 
fewer gastrointestinal events compared to the traditional NSAIDS, but no statistically significant differences 
were observed after twelve months of follow up, consistent with reports that celecoxib and diclofenac show a 
similar degree of COX-2 selectivity in the human whole blood assay.243,244 In contrast to the VIGOR study, no 
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significant differences in the incidence of cardiovascular events between the celecoxib, diclofenac, and 
ibuprofen groups was found.  
 Additional studies evaluated the cardiovascular risk of rofecoxib in the Adenomatous Polyp Prevention 
on Vioxx (APPROVE) trial. COX-2-selective inhibitors are possible therapeutic agents in human colon cancers 
due to the role that COX-2 overexpression plays in tumorigenesis. In agreement with this, patients who received 
25 mg of rofecoxib had a 24% reduction in colon polyp recurrence after treatment for three years. However, the 
rofecoxib treatment group also had a 2-fold increase in cardiovascular events, including myocardial infarction 
and stroke, compared to placebo.245,246	  This increase in cardiovascular events reported in the APPROVE trial 
led to the immediate withdrawal of rofecoxib from the market. In a parallel study, the Adenoma Prevention with 
Celecoxib (APC) trial measured polyp recurrence in patients receiving either 200 or 400 mg celecoxib twice 
daily compared to placebo. Celecoxib treatment resulted in a dose-dependent reduction in the recurrence of 
polyps following treatment. However, celecoxib also increased cardiovascular events in a dose-dependent 
manner with a 2.6-fold increase in patients allocated to low-dose celecoxib and a 3.4-fold increase in the high-
dose group. These clinical trials reveal that COX-2-selective inhibitors are effective therapeutics for arthritis 
and colon polyp recurrence, but prolonged use of COX-2-selective inhibitors is associated with an increased 
risk of cardiovascular events.  
 Several studies have examined the underlying mechanisms of the cardiovascular toxicity of COX-2-
selective inhibitors. The most prominent hypothesis is that the cardiovascular toxicity of COX-2-selective 
inhibitors occurs from the inhibition of PGI2 or PGI2-G production by vascular endothelial cells, both of which 
have anti-thrombotic and anti-atherogenic effects.206,247 Importantly, although COX-2-selective inhibitors have 
increased cardiovascular toxicity relative to placebo, meta-analyses of clinical trials have identified that 
traditional NSAIDs including ibuprofen, indomethacin, and diclofenac, also have an increased cardiovascular 
risk similar to that of celecoxib.248-250 The only exception identified thus far is that naproxen, a non-selective 
inhibitor of COX-1 and COX-2, does not increase cardiovascular events. The lack of cardiovascular toxicity of 
naproxen may be due to its persistent inhibition of TxA2 biosynthesis throughout the dosing interval, which is 
not observed with other commonly used NSAIDs.251 
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Cyclooxygenase Subunit Communication 
 A growing body of evidence has identified that although the two monomers of COX are composed of 
identical sequences, they are functional heterodimers. Initial studies identified monomer cooperation by 
determining that binding of only one molecule of a slow, tight-binding inhibitor such as (S)-flurbiprofen, 
indomethacin, or diclofenac, is sufficient to inhibit oxygenation by both COX monomers.219 The generation of 
COX heterodimers consisting of a wild-type monomer and a G533A monomer identified that these 
heterodimers retain maximal catalytic activity despite the fact that G533A results in the improper positioning of 
AA and G533A homodimers have impaired AA oxygenation relative to wild-type homodimers.252,253  
 As with substrate utilization, inhibitors also demonstrate intriguing behavior in heterodimers. (S)-
flurbiprofen does not inhibit R120Q COX-2 homodimers, but it is a potent time-dependent inhibitor of a 
heterodimer consisting of a wild-type monomer and a R120Q monomer, as it is with wild-type COX-2 
homodimers.252 These studies with heterodimers are in agreement with the early findings that COX enzymes 
exhibit half-of-sites reactivity with only a single functional monomer and a single association of heme with the 
dimer.254 Additionally, they are in agreement with the structures revealing that substrates bind in a productive 
conformation in one monomer and a non-productive conformation in the second monomer.235,241 
 More recent efforts have identified portions of the enzyme that mediate dimer crosstalk. The COX-2 
monomers can be identified as a catalytic subunit, which binds a heme prosthetic group, and an allosteric 
subunit, which does not.255,256 Cross-linking studies have identified that binding of an inhibitor to COX-2 alters 
two loops located at the dimer interface: one containing Ser-126 and Pro-127 and a second containing Ser-531 
and Ala-543.257 A crystal structure of the COX-2 selective inhibitor celecoxib bound to COX-1 identified an 
alternate conformation of the loop consisting of residues 121-129 (Figure 14).258 In this alternate conformation 
the loop positions Ser-126 adjacent to Glu-543, which may form the basis of subunit communication. 
Movement of the loop consisting of residues 121-129 is also apparent in the crystal structure of (S)-flurbiprofen 
bound to the COX heterodimer consisting of a wild-type monomer and a R120Q monomer, revealing that 
multiple inhibitors cause movement of this loop.259  
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Figure 14: Conformational changes in the dimer interface upon binding of celecoxib to COX-1. The loop 
consisting of residues 121-129 exists in different conformations upon binding of celecoxib to COX-1, shown in 
blue and purple. Reproduced from.258 
 
 A particularly striking example of dimer crosstalk has been revealed in our laboratory. Despite the fact 
that AA and 2-AG have comparable kcat/Km ratios for oxygenation, inhibition of COX-2 oxygenation of 2-AG 
by the rapid-reversible inhibitors (S)-ibuprofen and mefenamic acid occurs at much lower inhibitor 
concentrations than inhibition of COX-2 oxygenation of AA.260,261 Surprisingly, kinetic studies revealed that 
(S)-ibuprofen and mefenamic acid act as non-competitive inhibitors of 2-AG oxygenation by COX-2, but 
competitive inhibitors of AA oxygenation (Figure 15). 
 
Figure 15: Inhibition of COX-2 oxygenation of AA and 2-AG by ibuprofen. Ibuprofen acts as a competitive 
inhibitor of AA (left), but a non-competitive inhibitor of 2-AG (right). Reproduced from.261 
 
 These studies reveal that (S)-ibuprofen and mefenamic acid inhibit COX-2 oxygenation of AA and 2-
AG through different inhibition mechanisms and with different potencies. Given the potential for dimer cross-
talk upon binding of an inhibitor to one monomer, a model was hypothesized (Figure 16).252 Binding of a single 
molecule of either (S)-ibuprofen or mefenamic acid to the first monomer is sufficient to inhibit 2-AG 
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oxygenation in the second monomer, but not AA. To inhibit AA oxygenation in the second monomer, a second 
inhibitor molecule needs to bind to the second active site. This model is consistent with the kinetic data 
indicating that (S)-ibuprofen and mefenamic acid are non-competitive inhibitors of 2-AG oxygenation and 
competitive inhibitors of AA oxygenation. The model also accounts for the differences in inhibition potencies 
between 2-AG and AA as the binding of (S)-ibuprofen to the first monomer increases the KI of the second 
binding event. Thus, the model accounts for both the difference in inhibition modes and inhibition potencies 
between the two substrates. 
 
Figure 16: Model for differential inhibition of 2-AG and AA oxygenation by COX-2. Reproduced from.262 
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Dissertation Aims 
The major goal of the research described herein was to provide further insight into substrate-selective 
COX-2 inhibition. These studies will provide an understanding of the mechanisms by which NSAIDs function 
and identify the biological effects of COX-2 inhibition. Taken together with previous studies, these studies are 
critical to developing novel therapeutic agents with beneficial effects and potentially reduced side-effect 
profiles. An investigation of the molecules that exhibit substrate-selective inhibition and the molecular 
mechanisms of substrate-selective COX-2 inhibition are presented in chapter II. These studies comprise 
analyses of the COX-2 inhibitors that exhibit substrate-selective inhibition, the identification of novel substrate-
selective inhibitors and their binding modes, and the enzymatic mechanism of substrate-selective inhibition in 
vitro. We then furthered our examination of substrate-selective COX-2 inhibition by developing cellular model 
systems to study the effects of substrate-selective COX-2 inhibitors, which is discussed in chapter III. After 
validating several substrate-selective COX-2 inhibitors in vitro and in cellular systems, we sought to 
characterize the effects of substrate-selective COX-2 inhibition in vivo in chapter IV. These studies lead to the 
development of novel substrate-selective COX-2 inhibitors and the characterization of the biochemical and 
behavioral effects of a series of NSAIDs. We then characterized the pharmacokinetics and pharmacodynamics 
of the in vivo substrate-selective inhibitor of LM-4131 in chapter V. The short half-life and lack of substrate-
selective COX-2 inhibition displayed by LM-4131 led to the characterization of alternative in vivo substrate-
selective COX-2 inhibitors, which is discussed in chapter VI. As outlined in chapter VII we also determined the 
biosynthetic route of PG-Gs in multiple macrophage cell lines. Chapter VIII contains a summary of this 
research and a discussion of the repercussions. 
             
  
	   32	  
References 
1. Hamberg, M. & Samuelsson, B. Oxygenation of unsaturated fatty acids by the vesicular gland of sheep. 
The Journal of biological chemistry 242, 5344-5354 (1967). 
2. Hemler, M. & Lands, W.E. Purification of the cyclooxygenase that forms prostaglandins. Demonstration 
of two forms of iron in the holoenzyme. The Journal of biological chemistry 251, 5575-5579 (1976). 
3. Miyamoto, T., Ogino, N., Yamamoto, S. & Hayaishi, O. Purification of prostaglandin endoperoxide 
synthetase from bovine vesicular gland microsomes. The Journal of biological chemistry 251, 2629-
2636 (1976). 
4. Xie, W.L., Chipman, J.G., Robertson, D.L., Erikson, R.L. & Simmons, D.L. Expression of a mitogen-
responsive gene encoding prostaglandin synthase is regulated by mRNA splicing. Proceedings of the 
National Academy of Sciences of the United States of America 88, 2692-2696 (1991). 
5. Morita, I., et al. Different intracellular locations for prostaglandin endoperoxide H synthase-1 and -2. 
The Journal of biological chemistry 270, 10902-10908 (1995). 
6. Ogino, N., Ohki, S., Yamamoto, S. & Hayaishi, O. Prostaglandin endoperoxide synthetase from bovine 
vesicular gland microsomes. Inactivation and activation by heme and other metalloporphyrins. The 
Journal of biological chemistry 253, 5061-5068 (1978). 
7. Hamberg, M. & Samuelsson, B. Detection and isolation of an endoperoxide intermediate in 
prostaglandin biosynthesis. Proceedings of the National Academy of Sciences of the United States of 
America 70, 899-903 (1973). 
8. Ohki, S., Ogino, N., Yamamoto, S. & Hayaishi, O. Prostaglandin hydroperoxidase, an integral part of 
prostaglandin endoperoxide synthetase from bovine vesicular gland microsomes. The Journal of 
biological chemistry 254, 829-836 (1979). 
9. Dietz, R., Nastainczyk, W. & Ruf, H.H. Higher oxidation states of prostaglandin H synthase. Rapid 
electronic spectroscopy detected two spectral intermediates during the peroxidase reaction with 
prostaglandin G2. European journal of biochemistry / FEBS 171, 321-328 (1988). 
10. Smith, W.L. & Lands, W.E. Oxygenation of polyunsaturated fatty acids during prostaglandin 
biosynthesis by sheep vesicular gland. Biochemistry 11, 3276-3285 (1972). 
11. Landino, L.M., Crews, B.C., Gierse, J.K., Hauser, S.D. & Marnett, L.J. Mutational analysis of the role 
of the distal histidine and glutamine residues of prostaglandin-endoperoxide synthase-2 in peroxidase 
catalysis, hydroperoxide reduction, and cyclooxygenase activation. The Journal of biological chemistry 
272, 21565-21574 (1997). 
12. Samuelsson, B. On the Incorporation of Oxygen in the Conversion of 8, 11, 14-Eicosatrienoic Acid to 
Prostaglandin E1. Journal of the American Chemical Society 87, 3011-3013 (1965). 
13. Hamberg, M. & Samuelsson, B. On the mechanism of the biosynthesis of prostaglandins E-1 and F-1-
alpha. The Journal of biological chemistry 242, 5336-5343 (1967). 
14. Smith, W. Molecular biology of prostanoid biosynthetic enzymes and receptors. Advances in 
experimental medicine and biology 400B, 989-1011 (1997). 
15. Funk, C.D. Prostaglandins and leukotrienes: advances in eicosanoid biology. Science 294, 1871-1875 
(2001). 
16. Rizzo, G. & Fiorucci, S. PPARs and other nuclear receptors in inflammation. Current opinion in 
pharmacology 6, 421-427 (2006). 
17. Bos, C.L., Richel, D.J., Ritsema, T., Peppelenbosch, M.P. & Versteeg, H.H. Prostanoids and prostanoid 
receptors in signal transduction. The international journal of biochemistry & cell biology 36, 1187-1205 
(2004). 
18. Rouzer, C.A. & Marnett, L.J. Non-redundant functions of cyclooxygenases: oxygenation of 
endocannabinoids. The Journal of biological chemistry 283, 8065-8069 (2008). 
19. Shio, H. & Ramwell, P. Effect of Prostaglandin E2 and Aspirin on Secondary Aggregation of Human 
Platelets. Nature-New Biol 236, 45-& (1972). 
20. Patrono, C. & Dunn, M.J. The Clinical-Significance of Inhibition of Renal Prostaglandin Synthesis. 
Kidney Int 32, 1-12 (1987). 
	   33	  
21. Robert, A. Gastrointestinal Cytoprotection by Prostaglandins. Gastroen Clin Biol 8, 819-827 (1984). 
22. Ahmad, A.S., Ahmad, M., Maruyama, T., Narumiya, S. & Dore, S. Neuroprotective Effect of PGD2 
DP1 Receptor Against Acute Brain Damage in Young and in Aged Mice. Stroke 41, E382-E382 (2010). 
23. Katsumata, Y., et al. Lipocalin-type prostaglandin D synthase-mediated biosynthesis of PGD2 and its 
metabolites 15-deoxy-delta 12,14-PGJ2 synergistically stimulate nrf2 and protect hearts from 
ischemia/reperfusion injury. Am J Resp Crit Care 183, 687-687 (2011). 
24. Kim, K., et al. Anti-inflammatory Activity Of PGD2 Is Mediated By Nrf2. Am J Resp Crit Care 
181(2010). 
25. Fitzgerald, G.A., Catella, F. & Oates, J.A. Eicosanoid Biosynthesis in Human Cardiovascular-Disease. 
Hum Pathol 18, 248-252 (1987). 
26. Murata, T., et al. Altered pain perception and inflammatory response in mice lacking prostacyclin 
receptor. Nature 388, 678-682 (1997). 
27. Thomas, D.W., et al. Coagulation defects and altered hemodynamic responses in mice lacking receptors 
for thromboxane A(2). Journal of Clinical Investigation 102, 1994-2001 (1998). 
28. Sheng, H.M., et al. Inhibition of human colon cancer cell growth by selective inhibition of 
cyclooxygenase-2. Journal of Clinical Investigation 99, 2254-2259 (1997). 
29. Hwang, D., Scollard, D., Byrne, J. & Levine, E. Expression of cyclooxygenase-1 and cyclooxygenase-2 
in human breast cancer. J Natl Cancer I 90, 455-460 (1998). 
30. Samad, T.A., Sapirstein, A. & Woolf, C.J. Prostanoids and pain: unraveling mechanisms and revealing 
therapeutic targets. Trends Mol Med 8, 390-396 (2002). 
31. Picot, D., Loll, P.J. & Garavito, R.M. The X-ray crystal structure of the membrane protein prostaglandin 
H2 synthase-1. Nature 367, 243-249 (1994). 
32. Kurumbail, R.G., et al. Structural basis for selective inhibition of cyclooxygenase-2 by anti-
inflammatory agents. Nature 384, 644-648 (1996). 
33. Rouzer, C.A. & Marnett, L.J. Cyclooxygenases: structural and functional insights. J Lipid Res 50, S29 - 
S34 (2009). 
34. Van der Ouderaa, F.J., Buytenhek, M., Nugteren, D.H. & Van Dorp, D.A. Purification and 
characterisation of prostaglandin endoperoxide synthetase from sheep vesicular glands. Biochim Biophys 
Acta 487, 315-331 (1977). 
35. Picot, D. & Garavito, R.M. Prostaglandin H synthase: implications for membrane structure. FEBS letters 
346, 21-25 (1994). 
36. Luong, C., et al. Flexibility of the NSAID binding site in the structure of human cyclooxygenase-2. 
Nature structural biology 3, 927-933 (1996). 
37. Shimokawa, T. & Smith, W.L. Essential histidines of prostaglandin endoperoxide synthase. His-309 is 
involved in heme binding. The Journal of biological chemistry 266, 6168-6173 (1991). 
38. Liu, J., et al. Prostaglandin endoperoxide H synthases: peroxidase hydroperoxide specificity and 
cyclooxygeanse activation. The Journal of biological chemistry 282, 18233-18244 (2007). 
39. Malkowski, M.G., Ginell, S.L., Smith, W.L. & Garavito, R.M. The productive conformation of 
arachidonic acid bound to prostaglandin synthase. Science 289, 1933-1937 (2000). 
40. Vecchio, A.J., Simmons, D.M. & Malkowski, M.G. Structural basis of fatty acid substrate binding to 
cyclooxygenase-2. The Journal of biological chemistry 285, 22152-22163 (2010). 
41. Kiefer, J.R., et al. Structural insights into the stereochemistry of the cyclooxygenase reaction. Nature 
405, 97-101 (2000). 
42. Thuresson, E.D., et al. Prostaglandin endoperoxide H synthase-1: the functions of cyclooxygenase 
active site residues in the binding, positioning, and oxygenation of arachidonic acid. The Journal of 
biological chemistry 276, 10347-10357 (2001). 
43. Harman, C.A., Rieke, C.J., Garavito, R.M. & Smith, W.L. Crystal structure of arachidonic acid bound to 
a mutant of prostaglandin endoperoxide H synthase-1 that forms predominantly 11-
hydroperoxyeicosatetraenoic acid. The Journal of biological chemistry 279, 42929-42935 (2004). 
	   34	  
44. Schneider, C., et al. Control of prostaglandin stereochemistry at the 15-carbon by cyclooxygenases-1 
and -2. A critical role for serine 530 and valine 349. The Journal of biological chemistry 277, 478-485 
(2002). 
45. Newton, R., et al. Superinduction of COX-2 mRNA by cycloheximide and interleukin-1beta involves 
increased transcription and correlates with increased NF-kappaB and JNK activation. FEBS letters 418, 
135-138 (1997). 
46. Faour, W.H., Mancini, A., He, Q.W. & Di Battista, J.A. T-cell-derived interleukin-17 regulates the level 
and stability of cyclooxygenase-2 (COX-2) mRNA through restricted activation of the p38 mitogen-
activated protein kinase cascade: role of distal sequences in the 3'-untranslated region of COX-2 mRNA. 
The Journal of biological chemistry 278, 26897-26907 (2003). 
47. Kaufmann, W.E., Worley, P.F., Pegg, J., Bremer, M. & Isakson, P. COX-2, a synaptically induced 
enzyme, is expressed by excitatory neurons at postsynaptic sites in rat cerebral cortex. Proceedings of 
the National Academy of Sciences of the United States of America 93, 2317-2321 (1996). 
48. Harris, R.C., et al. Cyclooxygenase-2 is associated with the macula densa of rat kidney and increases 
with salt restriction. The Journal of clinical investigation 94, 2504-2510 (1994). 
49. Yoshikawa, K., et al. Preferential localization of prostamide/prostaglandin F synthase in myelin sheaths 
of the central nervous system. Brain research 1367, 22-32 (2011). 
50. Mbonye, U.R., et al. The 19-amino acid cassette of cyclooxygenase-2 mediates entry of the protein into 
the endoplasmic reticulum-associated degradation system. The Journal of biological chemistry 281, 
35770-35778 (2006). 
51. Wu, G., Wei, C.H., Kulmacz, R.J., Osawa, Y. & Tsai, A.L. A mechanistic study of self-inactivation of 
the peroxidase activity in prostaglandin H synthase-1. Journal of Biological Chemistry 274, 9231-9237 
(1999). 
52. Wu, G., et al. Oxyferryl heme and not tyrosyl radical is the likely culprit in prostaglandin H synthase-1 
peroxidase inactivation. Biochemistry 46, 534-542 (2007). 
53. Markey, C.M., Alward, A., Weller, P.E. & Marnett, L.J. Quantitative studies of hydroperoxide reduction 
by prostaglandin H synthase. Reducing substrate specificity and the relationship of peroxidase to 
cyclooxygenase activities. The Journal of biological chemistry 262, 6266-6279 (1987). 
54. Siegel, M.I., McConnell, R.T., Abrahams, S.L., Porter, N.A. & Cuatrecasas, P. Regulation of 
arachidonate metabolism via lipoxygenase and cyclo-oxygenase by 12-HPETE, the product of human 
platelet lipoxygenase. Biochemical and biophysical research communications 89, 1273-1280 (1979). 
55. Yu, Y., et al. Targeted cyclooxygenase gene (ptgs) exchange reveals discriminant isoform functionality. 
The Journal of biological chemistry 282, 1498-1506 (2007). 
56. Kulmacz, R.J. Regulation of cyclooxygenase catalysis by hydroperoxides. Biochemical and biophysical 
research communications 338, 25-33 (2005). 
57. Bambai, B., Rogge, C.E., Stec, B. & Kulmacz, R.J. Role of Asn-382 and Thr-383 in activation and 
inactivation of human prostaglandin H synthase cyclooxygenase catalysis. The Journal of biological 
chemistry 279, 4084-4092 (2004). 
58. Ueno, N., Takegoshi, Y., Kamei, D., Kudo, I. & Murakami, M. Coupling between cyclooxygenases and 
terminal prostanoid synthases. Biochemical and biophysical research communications 338, 70-76 
(2005). 
59. Mechoulam, R. & Gaoni, Y. A Total Synthesis of Dl-Delta-1-Tetrahydrocannabinol, the Active 
Constituent of Hashish. Journal of the American Chemical Society 87, 3273-3275 (1965). 
60. Matsuda, L.A., Lolait, S.J., Brownstein, M.J., Young, A.C. & Bonner, T.I. Structure of a Cannabinoid 
Receptor and Functional Expression of the Cloned Cdna. Nature 346, 561-564 (1990). 
61. Herkenham, M., et al. Cannabinoid Receptor Localization in Brain. Proceedings of the National 
Academy of Sciences of the United States of America 87, 1932-1936 (1990). 
62. Munro, S., Thomas, K.L. & Abushaar, M. Molecular Characterization of a Peripheral Receptor for 
Cannabinoids. Nature 365, 61-65 (1993). 
63. Devane, W.A., et al. Isolation and Structure of a Brain Constituent That Binds to the Cannabinoid 
Receptor. Science 258, 1946-1949 (1992). 
	   35	  
64. Stella, N., Schweitzer, P. & Piomelli, D. A second endogenous cannabinoid that modulates long-term 
potentiation. Nature 388, 773-778 (1997). 
65. Clark, J.D., et al. A Novel Arachidonic Acid-Selective Cytosolic Pla2 Contains a Ca2+-Dependent 
Translocation Domain with Homology to Pkc and Gap. Cell 65, 1043-1051 (1991). 
66. Leslie, C.C., Voelker, D.R., Channon, J.Y., Wall, M.M. & Zelarney, P.T. Properties and Purification of 
an Arachidonoyl-Hydrolyzing Phospholipase-A2 from a Macrophage Cell-Line, Raw-264.7. Biochimica 
Et Biophysica Acta 963, 476-492 (1988). 
67. Lin, L.L., et al. Cpla2 Is Phosphorylated and Activated by Map Kinase. Cell 72, 269-278 (1993). 
68. Nakamura, H., Hirabayashi, T., Shimizu, M. & Murayama, T. Ceramide-1-phosphate activates cytosolic 
phospholipase A2 alpha directly and by PKC pathway. Biochem Pharmacol 71, 850-857 (2006). 
69. Mosior, M., Six, D.A. & Dennis, E.A. Group IV cytosolic phospholipase A(2) binds with high affinity 
and specificity to phosphatidylinositol 4,5-bisphosphate resulting in dramatic increases in activity. 
Journal of Biological Chemistry 273, 2184-2191 (1998). 
70. Sharp, J.D., et al. Molecular-Cloning and Expression of Human Ca2+-Sensitive Cytosolic 
Phospholipase-A2. Journal of Biological Chemistry 266, 14850-14853 (1991). 
71. Nomura, D.K., et al. Endocannabinoid Hydrolysis Generates Brain Prostaglandins That Promote 
Neuroinflammation. Science 334, 809-813 (2011). 
72. Prescott, S.M. & Majerus, P.W. Characterization of 1,2-Diacylglycerol Hydrolysis in Human-Platelets - 
Demonstration of an Arachidonoyl-Monoacylglycerol Intermediate. Journal of Biological Chemistry 
258, 764-769 (1983). 
73. Sugiura, T., Kishimoto, S., Oka, S. & Gokoh, M. Biochemistry, pharmacology and physiology of 2-
arachidonoylglycerol, an endogenous cannabinoid receptor ligand. Prog Lipid Res 45, 405-446 (2006). 
74. Ueda, N., Tsuboi, K., Uyama, T. & Ohnishi, T. Biosynthesis and degradation of the endocannabinoid 2-
arachidonoylglycerol. Biofactors 37, 1-7 (2011). 
75. Fukami, K., Inanobe, S., Kanemaru, K. & Nakamura, Y. Phospholipase C is a key enzyme regulating 
intracellular calcium and modulating the phosphoinositide balance. Prog Lipid Res 49, 429-437 (2010). 
76. Kano, M., Ohno-Shosaku, T., Hashimotodani, Y., Uchigashima, M. & Watanabe, M. Endocannabinoid-
Mediated Control of Synaptic Transmission. Physiol Rev 89, 309-380 (2009). 
77. Bisogno, T., Melck, D., De Petrocellis, L. & Di Marzo, V. Phosphatidic acid as the biosynthetic 
precursor of the endocannabinoid 2-arachidonoylglycerol in intact mouse neuroblastoma cells stimulated 
with ionomycin. J Neurochem 72, 2113-2119 (1999). 
78. Oka, S., et al. Evidence for the involvement of the cannabinoid CB2 receptor and its endogenous ligand 
2-arachidonoylglycerol in 12-O-tetradecanoylphorbol-13-acetate-induced acute inflammation in mouse 
ear. Journal of Biological Chemistry 280, 18488-18497 (2005). 
79. Ueda, H., Kobayashi, T., Kishimoto, M., Tsutsumi, T. & Okuyama, H. A Possible Pathway of 
Phosphoinositide Metabolism through Edta-Insensitive Phospholipase-a(1) Followed by 
Lysophosphoinositide-Specific Phospholipase-C in Rat-Brain. J Neurochem 61, 1874-1881 (1993). 
80. Tsutsumi, T., et al. Lysophosphoinositide-Specific Phospholipase-C in Rat-Brain Synaptic Plasma-
Membranes. Neurochem Res 19, 399-406 (1994). 
81. Nakane, S., et al. 2-arachidonoyl-sn-glycero-3-phosphate, an arachidonic acid-containing 
lysophosphatidic acid: occurrence and rapid enzymatic conversion to 2-arachidonoyl-sn-glycerol, a 
cannabinoid receptor ligand, in rat brain. Arch Biochem Biophys 402, 51-58 (2002). 
82. Okazaki, T., et al. Diacylglycerol Metabolism and Arachidonic-Acid Release in Human-Fetal 
Membranes and Decidua Vera. Journal of Biological Chemistry 256, 7316-7321 (1981). 
83. Chau, L.Y. & Tai, H.H. Release of Arachidonate from Diglyceride in Human-Platelets Requires the 
Sequential Action of a Diglyceride Lipase and a Monoglyceride Lipase. Biochemical and biophysical 
research communications 100, 1688-1695 (1981). 
84. Bisogno, T., et al. Cloning of the first sn1-DAG lipases points to the spatial and temporal regulation of 
endocannabinoid signaling in the brain. J Cell Biol 163, 463-468 (2003). 
85. Jung, K.M., et al. A key role for diacylglycerol lipase-alpha in metabotropic glutamate receptor-
dependent endocannabinoid mobilization. Mol Pharmacol 72, 612-621 (2007). 
	   36	  
86. Tanimura, A., et al. The Endocannabinoid 2-Arachidonoylglycerol Produced by Diacylglycerol Lipase 
alpha Mediates Retrograde Suppression of Synaptic Transmission. Neuron 65, 320-327 (2010). 
87. Gao, Y., et al. Loss of Retrograde Endocannabinoid Signaling and Reduced Adult Neurogenesis in 
Diacylglycerol Lipase Knock-out Mice. J Neurosci 30, 2017-2024 (2010). 
88. Hsu, K.L., et al. DAGL beta inhibition perturbs a lipid network involved in macrophage inflammatory 
responses. Nat Chem Biol 8, 999-1007 (2012). 
89. Schmid, H.H.O., Schmid, P.C. & Natarajan, V. N-Acylated Glycerophospholipids and Their 
Derivatives. Prog Lipid Res 29, 1-43 (1990). 
90. Ueda, N., Tsuboi, K. & Uyama, T. Enzymological studies on the biosynthesis of N-acylethanolamines. 
Bba-Mol Cell Biol L 1801, 1274-1285 (2010). 
91. Schmid, H.H.O. Pathways and mechanisms of N-acylethanolamine biosynthesis: can anandamide be 
generated selectively? Chem Phys Lipids 108, 71-87 (2000). 
92. Wellner, N., Diep, T.A., Janfelt, C. & Hansen, H.S. N-acylation of phosphatidylethanolamine and its 
biological functions in mammals. Bba-Mol Cell Biol L 1831, 652-662 (2013). 
93. Cadas, H., diTomaso, E. & Piomelli, D. Occurrence and biosynthesis of endogenous cannabinoid 
precursor, N-arachidonoyl phosphatidylethanolamine, in rat brain. J Neurosci 17, 1226-1242 (1997). 
94. Jin, X.H., et al. cDNA cloning and characterization of human and mouse Ca2+-independent 
phosphatidylethanolamine N-acyltransferases. Bba-Mol Cell Biol L 1791, 32-38 (2009). 
95. Jin, X.H., et al. Discovery and characterization of Ca2+-independent phosphatidylethanolarnine N-
acyltransferase generating the anandarnide precursor and its congeners. Journal of Biological Chemistry 
282, 3614-3623 (2007). 
96. Okamoto, Y., Wang, J., Morishita, J. & Ueda, N. Biosynthetic pathways of the endocannabinoid 
anandamide. Chem Biodivers 4, 1842-1857 (2007). 
97. Okamoto, Y., Morishita, J., Tsuboi, K., Tonai, T. & Ueda, N. Molecular characterization of a 
phospholipase D generating anandamide and its congeners. Journal of Biological Chemistry 279, 5298-
5305 (2004). 
98. Wang, J., et al. Functional analysis of the purified anandamide-generating phospholipase D as a member 
of the metallo-beta-lactamase family. Journal of Biological Chemistry 281, 12325-12335 (2006). 
99. Wang, J., Okamoto, Y., Tsuboi, K. & Ueda, N. The stimulatory effect of phosphatidylethanolamine on 
N-acylphosphatidylethanolamine-hydrolyzing phospholipase D (NAPE-PLD). Neuropharmacology 54, 
8-15 (2008). 
100. Sun, Y.X., et al. Biosynthesis of anandamide and N-palmitoylethanolamine by sequential actions of 
phospholipase A(2) and lysophospholipase D. Biochem J 380, 749-756 (2004). 
101. Simon, G.M. & Cravatt, B.F. Endocannabinoid biosynthesis proceeding through glycerophospho-N-acyl 
ethanolamine and a role for alpha/beta-hydrolase 4 in this pathway. Journal of Biological Chemistry 
281, 26465-26472 (2006). 
102. Simon, G.M. & Cravatt, B.F. Anandamide biosynthesis catalyzed by the phosphodiesterase GDE1 and 
detection of glycerophospho-n-acyl ethanolamine precursors in mouse brain. Journal of Biological 
Chemistry 283, 9341-9349 (2008). 
103. Simon, G.M. & Cravatt, B.F. Characterization of mice lacking candidate N-acyl ethanolamine 
biosynthetic enzymes provides evidence for multiple pathways that contribute to endocannabinoid 
production in vivo. Mol Biosyst 6, 1411-1418 (2010). 
104. Liu, J., et al. A biosynthetic pathway for anandamide. Proceedings of the National Academy of Sciences 
of the United States of America 103, 13345-13350 (2006). 
105. Liu, J., et al. Lipopolysaccharide induces anandamide synthesis in macrophages via 
CD14/MAPK/phosphoinositide 3-kinase/NF-kappa B independently of platelet-activating factor. 
Journal of Biological Chemistry 278, 45034-45039 (2003). 
106. Liu, J., et al. Multiple pathways involved in the biosynthesis of anandamide. Neuropharmacology 54, 1-
7 (2008). 
107. Howlett, A.C., et al. International Union of Pharmacology. XXVII. Classification of cannabinoid 
receptors. Pharmacol Rev 54, 161-202 (2002). 
	   37	  
108. Tsou, K., Brown, S., Sanudo-Pena, M.C., Mackie, K. & Walker, J.M. Immunohistochemical distribution 
of cannabinoid CB1 receptors in the rat central nervous system. Neuroscience 83, 393-411 (1998). 
109. Hohmann, A.G. & Herkenham, M. Localization of central cannabinoid CB1 receptor messenger RNA in 
neuronal subpopulations of rat dorsal root ganglia: A double-label in situ hybridization study. 
Neuroscience 90, 923-931 (1999). 
110. Bouaboula, M., et al. Cannabinoid-Receptor Expression in Human-Leukocytes. European Journal of 
Biochemistry 214, 173-180 (1993). 
111. Hoffman, A.F. & Lupica, C.R. Mechanisms of cannabinoid inhibition of GABA(A) synaptic 
transmission in the hippocampus. J Neurosci 20, 2470-2479 (2000). 
112. Robbe, D., Alonso, G., Duchamp, F., Bockaert, J. & Manzoni, O.J. Localization and mechanisms of 
action of cannabinoid receptors at the glutamatergic synapses of the mouse nucleus accumbens. J 
Neurosci 21, 109-116 (2001). 
113. Misner, D.L. & Sullivan, J.M. Mechanism of cannabinoid effects on long-term potentiation and 
depression in hippocampal CA1 neurons. J Neurosci 19, 6795-6805 (1999). 
114. Sullivan, J.M. Mechanisms of cannabinoid-receptor-mediated inhibition of synaptic transmission in 
cultured hippocampal pyramidal neurons. J Neurophysiol 82, 1286-1294 (1999). 
115. Mackie, K. & Hille, B. Cannabinoids Inhibit N-Type Calcium Channels in Neuroblastoma Glioma-
Cells. Proceedings of the National Academy of Sciences of the United States of America 89, 3825-3829 
(1992). 
116. Mu, J., Zhuang, S.Y., Kirby, M.T., Hampson, R.E. & Deadwyler, S.A. Cannabinoid receptors 
differentially modulate potassium A and D currents in hippocampal neurons in culture. J Pharmacol Exp 
Ther 291, 893-902 (1999). 
117. Schweitzer, P. Cannabinoids decrease the K+ M-current in hippocampal CA1 neurons. J Neurosci 20, 
51-58 (2000). 
118. Alger, B.E. Retrograde signaling in the regulation of synaptic transmission: focus on endocannabinoids. 
Prog Neurobiol 68, 247-286 (2002). 
119. Melis, M., et al. Prefrontal cortex stimulation induces 2-arachidonoyl-glycerol-mediated suppression of 
excitation in dopamine neurons. J Neurosci 24, 10707-10715 (2004). 
120. Riegel, A.C. & Lupica, C.R. Independent presynaptic and postsynaptic mechanisms regulate 
endocannabinoid signaling at multiple synapses in the ventral tegmental area. J Neurosci 24, 11070-
11078 (2004). 
121. Carlson, G., Wang, Y. & Alger, B.E. Endocannabinoids facilitate the induction of LTP in the 
hippocampus. Nat Neurosci 5, 723-724 (2002). 
122. Kortleven, C., Fasano, C., Thibault, D., Lacaille, J.C. & Trudeau, L.E. The endocannabinoid 2-
arachidonoylglycerol inhibits long-term potentiation of glutamatergic synapses onto ventral tegmental 
area dopamine neurons in mice. Eur J Neurosci 33, 1751-1760 (2011). 
123. Sudhof, T.C. A molecular machine for neurotransmitter release: synaptotagmin and beyond. Nature 
medicine 19, 1227-1231 (2013). 
124. Byerley, W.F., Reimherr, F.W., Wood, D.R. & Grosser, B.I. Fluoxetine, a selective serotonin uptake 
inhibitor, for the treatment of outpatients with major depression. Journal of clinical 
psychopharmacology 8, 112-115 (1988). 
125. Barar, F.S., et al. Interactions between catecholamines and tricyclic and monoamine oxidase inhibitor 
antidepressive agents in man. British journal of pharmacology 43, 472P-473P (1971). 
126. Cravatt, B.F., et al. Molecular characterization of an enzyme that degrades neuromodulatory fatty-acid 
amides. Nature 384, 83-87 (1996). 
127. Kurahashi, Y., Ueda, N., Suzuki, H., Suzuki, M. & Yamamoto, S. Reversible hydrolysis and synthesis of 
anandamide demonstrated by recombinant rat fatty-acid amide hydrolase. Biochemical and biophysical 
research communications 237, 512-515 (1997). 
128. Thomas, E.A., Cravatt, B.F., Danielson, P.E., Gilula, N.B. & Sutcliffe, J.G. Fatty acid amide hydrolase, 
the degradative enzyme for anandamide and oleamide, has selective distribution in neurons within the 
rat central nervous system. J Neurosci Res 50, 1047-1052 (1997). 
	   38	  
129. Marrs, W.R., et al. The serine hydrolase ABHD6 controls the accumulation and efficacy of 2-AG at 
cannabinoid receptors. Nat Neurosci 13, 951-957 (2010). 
130. Savinainen, J.R., Saario, S.M. & Laitinen, J.T. The serine hydrolases MAGL, ABHD6 and ABHD12 as 
guardians of 2-arachidonoylglycerol signalling through cannabinoid receptors. Acta physiologica 204, 
267-276 (2012). 
131. Xie, S., et al. Inactivation of lipid glyceryl ester metabolism in human THP1 monocytes/macrophages 
by activated organophosphorus insecticides: role of carboxylesterases 1 and 2. Chemical research in 
toxicology 23, 1890-1904 (2010). 
132. Wang, R., et al. Identification of Palmitoyl Protein Thioesterase 1 in Human THP1 Monocytes and 
Macrophages and Characterization of Unique Biochemical Activities for This Enzyme. Biochemistry 52, 
7559-7574 (2013). 
133. Gulyas, A.I., et al. Segregation of two endocannabinoid-hydrolyzing enzymes into pre- and postsynaptic 
compartments in the rat hippocampus, cerebellum and amygdala. Eur J Neurosci 20, 441-458 (2004). 
134. Egertova, M., Giang, D.K., Cravatt, B.F. & Elphick, M.R. A new perspective on cannabinoid signalling: 
complementary localization of fatty acid amide hydrolase and the CB1 receptor in rat brain. P Roy Soc 
B-Biol Sci 265, 2081-2085 (1998). 
135. Patricelli, M.P. & Cravatt, B.F. Fatty acid amide hydrolase competitively degrades bioactive amides and 
esters through a nonconventional catalytic mechanism. Biochemistry 38, 14125-14130 (1999). 
136. Cravatt, B.F., et al. Supersensitivity to anandamide and enhanced endogenous cannabinoid signaling in 
mice lacking fatty acid amide hydrolase. Proceedings of the National Academy of Sciences of the United 
States of America 98, 9371-9376 (2001). 
137. Kathuria, S., et al. Modulation of anxiety through blockade of anandamide hydrolysis. Nature medicine 
9, 76-81 (2003). 
138. Alexander, J.P. & Cravatt, B.F. Mechanism of carbamate inactivation of FAAH: Implications for the 
design of covalent inhibitors and in vivo functional probes for enzymes. Chem Biol 12, 1179-1187 
(2005). 
139. Ahn, K., McKinney, M.K. & Cravatt, B.F. Enzymatic pathways that regulate endocannabinoid signaling 
in the nervous system. Chem Rev 108, 1687-1707 (2008). 
140. Jayamanne, A., et al. Actions of the FAAH inhibitor URB597 in neuropathic and inflammatory chronic 
pain models. British journal of pharmacology 147, 281-288 (2006). 
141. Cross-Mellor, S.K., Ossenkopp, K.P., Piomelli, D. & Parker, L.A. Effects of the FAAH inhibitor, 
URB597, and anandamide on lithium-induced taste reactivity responses: a measure of nausea in the rat. 
Psychopharmacology 190, 135-143 (2007). 
142. Lichtman, A.H., et al. Reversible inhibitors of fatty acid amide hydrolase that promote analgesia: 
Evidence for an unprecedented combination of potency and selectivity. J Pharmacol Exp Ther 311, 441-
448 (2004). 
143. Zhang, D., et al. Fatty acid amide hydrolase inhibitors display broad selectivity and inhibit multiple 
carboxylesterases as off-targets. Neuropharmacology 52, 1095-1105 (2007). 
144. Clapper, J.R., et al. A Second Generation of Carbamate-Based Fatty Acid Amide Hydrolase Inhibitors 
with Improved Activity in vivo. Chemmedchem 4, 1505-1513 (2009). 
145. Ahn, K., et al. Novel mechanistic class of fatty acid amide hydrolase inhibitors with remarkable 
selectivity. Biochemistry 46, 13019-13030 (2007). 
146. Ahn, K., et al. Discovery and Characterization of a Highly Selective FAAH Inhibitor that Reduces 
Inflammatory Pain. Chem Biol 16, 411-420 (2009). 
147. Meyers, M.J., et al. Discovery of novel spirocyclic inhibitors of fatty acid amide hydrolase (FAAH). 
Part 2. Discovery of 7-azaspiro[3.5]nonane urea PF-04862853, an orally efficacious inhibitor of fatty 
acid amide hydrolase (FAAH) for pain. Bioorg Med Chem Lett 21, 6545-6553 (2011). 
148. Ahn, K., et al. Mechanistic and Pharmacological Characterization of PF-04457845: A Highly Potent and 
Selective Fatty Acid Amide Hydrolase Inhibitor That Reduces Inflammatory and Noninflammatory 
Pain. J Pharmacol Exp Ther 338, 114-124 (2011). 
	   39	  
149. Johnson, D.S., et al. Discovery of PF-04457845: A Highly Potent, Orally Bioavailable, and Selective 
Urea FAAH Inhibitor. Acs Med Chem Lett 2, 91-96 (2011). 
150. Li, G.L., et al. Assessment of the pharmacology and tolerability of PF-04457845, an irreversible 
inhibitor of fatty acid amide hydrolase-1, in healthy subjects. Brit J Clin Pharmaco 73, 706-716 (2012). 
151. Huggins, J.P., Smart, T.S., Langman, S., Taylor, L. & Young, T. An efficient randomised, placebo-
controlled clinical trial with the irreversible fatty acid amide hydrolase-1 inhibitor PF-04457845, which 
modulates endocannabinoids but fails to induce effective analgesia in patients with pain due to 
osteoarthritis of the knee. Pain 153, 1837-1846 (2012). 
152. Blankman, J.L., Simon, G.M. & Cravatt, B.F. A comprehensive profile of brain enzymes that hydrolyze 
the endocannabinoid 2-arachidonoylglycerol. Chem Biol 14, 1347-1356 (2007). 
153. Karlsson, M., Contreras, J.A., Hellman, U., Tornqvist, H. & Holm, C. cDNA cloning, tissue distribution, 
and identification of the catalytic triad of monoglyceride lipase. Evolutionary relationship to esterases, 
lysophospholipases, and haloperoxidases. The Journal of biological chemistry 272, 27218-27223 (1997). 
154. Dinh, T.P., et al. Brain monoglyceride lipase participating in endocannabinoid inactivation. Proceedings 
of the National Academy of Sciences of the United States of America 99, 10819-10824 (2002). 
155. Dinh, T.P., Freund, T.F. & Piomelli, D. A role for monoglyceride lipase in 2-arachidonoylglycerol 
inactivation. Chem Phys Lipids 121, 149-158 (2002). 
156. Tornqvist, H. & Belfrage, P. Purification and some properties of a monoacylglycerol-hydrolyzing 
enzyme of rat adipose tissue. The Journal of biological chemistry 251, 813-819 (1976). 
157. Long, J.Z., et al. Selective blockade of 2-arachidonoylglycerol hydrolysis produces cannabinoid 
behavioral effects. Nat Chem Biol 5, 37-44 (2009). 
158. Long, J.Z., Nomura, D.K. & Cravatt, B.F. Characterization of monoacylglycerol lipase inhibition reveals 
differences in central and peripheral endocannabinoid metabolism. Chem Biol 16, 744-753 (2009). 
159. Kinsey, S.G., et al. Blockade of endocannabinoid-degrading enzymes attenuates neuropathic pain. J 
Pharmacol Exp Ther 330, 902-910 (2009). 
160. Pan, B., et al. Blockade of 2-arachidonoylglycerol hydrolysis by selective monoacylglycerol lipase 
inhibitor 4-nitrophenyl 4-(dibenzo[d][1,3]dioxol-5-yl(hydroxy)methyl)piperidine-1-carboxylate 
(JZL184) Enhances retrograde endocannabinoid signaling. J Pharmacol Exp Ther 331, 591-597 (2009). 
161. Sciolino, N.R., Zhou, W. & Hohmann, A.G. Enhancement of endocannabinoid signaling with JZL184, 
an inhibitor of the 2-arachidonoylglycerol hydrolyzing enzyme monoacylglycerol lipase, produces 
anxiolytic effects under conditions of high environmental aversiveness in rats. Pharmacological 
research : the official journal of the Italian Pharmacological Society 64, 226-234 (2011). 
162. Crow, J.A., Bittles, V., Borazjani, A., Potter, P.M. & Ross, M.K. Covalent inhibition of recombinant 
human carboxylesterase 1 and 2 and monoacylglycerol lipase by the carbamates JZL184 and URB597. 
Biochem Pharmacol 84, 1215-1222 (2012). 
163. Chang, J.W., et al. Highly selective inhibitors of monoacylglycerol lipase bearing a reactive group that 
is bioisosteric with endocannabinoid substrates. Chem Biol 19, 579-588 (2012). 
164. Muccioli, G.G., et al. Identification of a novel endocannabinoid-hydrolyzing enzyme expressed by 
microglial cells. J Neurosci 27, 2883-2889 (2007). 
165. Su, A.I., et al. Large-scale analysis of the human and mouse transcriptomes. Proceedings of the National 
Academy of Sciences of the United States of America 99, 4465-4470 (2002). 
166. Bachovchin, D.A., et al. Superfamily-wide portrait of serine hydrolase inhibition achieved by library-
versus-library screening. Proceedings of the National Academy of Sciences of the United States of 
America 107, 20941-20946 (2010). 
167. Tchantchou, F. & Zhang, Y. Selective inhibition of alpha/beta-hydrolase domain 6 attenuates 
neurodegeneration, alleviates blood brain barrier breakdown, and improves functional recovery in a 
mouse model of traumatic brain injury. Journal of neurotrauma 30, 565-579 (2013). 
168. Hsu, K.L., et al. Discovery and optimization of piperidyl-1,2,3-triazole ureas as potent, selective, and in 
vivo-active inhibitors of alpha/beta-hydrolase domain containing 6 (ABHD6). Journal of medicinal 
chemistry 56, 8270-8279 (2013). 
	   40	  
169. Schlosburg, J.E., Kinsey, S.G. & Lichtman, A.H. Targeting fatty acid amide hydrolase (FAAH) to treat 
pain and inflammation. The AAPS journal 11, 39-44 (2009). 
170. Kinsey, S.G., Long, J.Z., Cravatt, B.F. & Lichtman, A.H. Fatty acid amide hydrolase and 
monoacylglycerol lipase inhibitors produce anti-allodynic effects in mice through distinct cannabinoid 
receptor mechanisms. The journal of pain : official journal of the American Pain Society 11, 1420-1428 
(2010). 
171. Hohmann, A.G., et al. An endocannabinoid mechanism for stress-induced analgesia. Nature 435, 1108-
1112 (2005). 
172. Guindon, J., Guijarro, A., Piomelli, D. & Hohmann, A.G. Peripheral antinociceptive effects of inhibitors 
of monoacylglycerol lipase in a rat model of inflammatory pain. British journal of pharmacology 163, 
1464-1478 (2011). 
173. Guindon, J., Lai, Y., Takacs, S.M., Bradshaw, H.B. & Hohmann, A.G. Alterations in endocannabinoid 
tone following chemotherapy-induced peripheral neuropathy: effects of endocannabinoid deactivation 
inhibitors targeting fatty-acid amide hydrolase and monoacylglycerol lipase in comparison to reference 
analgesics following cisplatin treatment. Pharmacological research : the official journal of the Italian 
Pharmacological Society 67, 94-109 (2013). 
174. Khasabova, I.A., Chandiramani, A., Harding-Rose, C., Simone, D.A. & Seybold, V.S. Increasing 2-
arachidonoyl glycerol signaling in the periphery attenuates mechanical hyperalgesia in a model of bone 
cancer pain. Pharmacological research : the official journal of the Italian Pharmacological Society 64, 
60-67 (2011). 
175. Ghosh, S., et al. The monoacylglycerol lipase inhibitor JZL184 suppresses inflammatory pain in the 
mouse carrageenan model. Life sciences 92, 498-505 (2013). 
176. Gaetani, S., et al. The endocannabinoid system as a target for novel anxiolytic and antidepressant drugs. 
International review of neurobiology 85, 57-72 (2009). 
177. Moreira, F.A., Kaiser, N., Monory, K. & Lutz, B. Reduced anxiety-like behaviour induced by genetic 
and pharmacological inhibition of the endocannabinoid-degrading enzyme fatty acid amide hydrolase 
(FAAH) is mediated by CB1 receptors. Neuropharmacology 54, 141-150 (2008). 
178. Busquets-Garcia, A., et al. Differential role of anandamide and 2-arachidonoylglycerol in memory and 
anxiety-like responses. Biological psychiatry 70, 479-486 (2011). 
179. Gomes, F.V., Casarotto, P.C., Resstel, L.B. & Guimaraes, F.S. Facilitation of CB1 receptor-mediated 
neurotransmission decreases marble burying behavior in mice. Progress in neuro-psychopharmacology 
& biological psychiatry 35, 434-438 (2011). 
180. Kinsey, S.G., O'Neal, S.T., Long, J.Z., Cravatt, B.F. & Lichtman, A.H. Inhibition of endocannabinoid 
catabolic enzymes elicits anxiolytic-like effects in the marble burying assay. Pharmacology, 
biochemistry, and behavior 98, 21-27 (2011). 
181. Yu, M., Ives, D. & Ramesha, C.S. Synthesis of prostaglandin E-2 ethanolamide from anandamide by 
cyclooxygenase-2. Journal of Biological Chemistry 272, 21181-21186 (1997). 
182. Kozak, K.R., Rowlinson, S.W. & Marnett, L.J. Oxygenation of the endocannabinoid, 2-
arachidonylglycerol, to glyceryl prostaglandins by cyclooxygenase-2. Journal of Biological Chemistry 
275, 33744-33749 (2000). 
183. So, O.Y., Scarafia, L.E., Mak, A.Y., Callan, O.H. & Swinney, D.C. The dynamics of prostaglandin H 
synthases. Studies with prostaglandin h synthase 2 Y355F unmask mechanisms of time-dependent 
inhibition and allosteric activation. The Journal of biological chemistry 273, 5801-5807 (1998). 
184. Kozak, K.R., Prusakiewicz, J.J., Rowlinson, S.W., Prudhomme, D.R. & Marnett, L.J. Amino acid 
determinants in cyclooxygenase-2 oxygenation of the endocannabinoid anandamide. Biochemistry 42, 
9041-9049 (2003). 
185. Kozak, K.R., Prusakiewicz, J.J., Rowlinson, S.W., Schneider, C. & Marnett, L.J. Amino acid 
determinants in cyclooxygenase-2 oxygenation of the endocannabinoid 2-arachidonylglycerol. The 
Journal of biological chemistry 276, 30072-30077 (2001). 
186. Vecchio, A.J. & Malkowski, M.G. The structural basis of endocannabinoid oxygenation by 
cyclooxygenase-2. The Journal of biological chemistry 286, 20736-20745 (2011). 
	   41	  
187. Kozak, K.R., et al. Metabolism of the endocannabinoids, 2-arachidonylglycerol and anandamide, into 
prostaglandin, thromboxane, and prostacyclin glycerol esters and ethanolamides. The Journal of 
biological chemistry 277, 44877-44885 (2002). 
188. Weber, A., et al. Formation of prostamides from anandamide in FAAH knockout mice analyzed by 
HPLC with tandem mass spectrometry. J Lipid Res 45, 757-763 (2004). 
189. Duggan, K.C., et al. (R)-Profens are substrate-selective inhibitors of endocannabinoid oxygenation by 
COX-2. Nat Chem Biol 7, 803-809 (2011). 
190. Ritter, J.K., et al. Production and actions of the anandamide metabolite prostamide E2 in the renal 
medulla. J Pharmacol Exp Ther 342, 770-779 (2012). 
191. Gatta, L., et al. Discovery of prostamide F2alpha and its role in inflammatory pain and dorsal horn 
nociceptive neuron hyperexcitability. PloS one 7, e31111 (2012). 
192. Silvestri, C., et al. Anandamide-derived prostamide F2alpha negatively regulates adipogenesis. The 
Journal of biological chemistry 288, 23307-23321 (2013). 
193. Hu, S.S., Bradshaw, H.B., Chen, J.S., Tan, B. & Walker, J.M. Prostaglandin E2 glycerol ester, an 
endogenous COX-2 metabolite of 2-arachidonoylglycerol, induces hyperalgesia and modulates 
NFkappaB activity. British journal of pharmacology 153, 1538-1549 (2008). 
194. Kingsley, P.J., Rouzer, C.A., Saleh, S. & Marnett, L.J. Simultaneous analysis of prostaglandin glyceryl 
esters and prostaglandins by electrospray tandem mass spectrometry. Analytical biochemistry 343, 203-
211 (2005). 
195. Rouzer, C.A., et al. Zymosan-induced glycerylprostaglandin and prostaglandin synthesis in resident 
peritoneal macrophages: roles of cyclo-oxygenase-1 and -2. Biochem J 399, 91-99 (2006). 
196. Rouzer, C.A. & Marnett, L.J. Glycerylprostaglandin synthesis by resident peritoneal macrophages in 
response to a zymosan stimulus. The Journal of biological chemistry 280, 26690-26700 (2005). 
197. Alhouayek, M., Masquelier, J., Cani, P.D., Lambert, D.M. & Muccioli, G.G. Implication of the anti-
inflammatory bioactive lipid prostaglandin D2-glycerol ester in the control of macrophage activation 
and inflammation by ABHD6. Proceedings of the National Academy of Sciences of the United States of 
America 110, 17558-17563 (2013). 
198. Kozak, K.R., et al. Metabolism of prostaglandin glycerol esters and prostaglandin ethanolamides in vitro 
and in vivo. The Journal of biological chemistry 276, 36993-36998 (2001). 
199. Correa, F., et al. Anandamide inhibits IL-12p40 production by acting on the promoter repressor element 
GA-12: possible involvement of the COX-2 metabolite prostamide E(2). Biochem J 409, 761-770 
(2008). 
200. Woodward, D.F., et al. Bimatoprost: a novel antiglaucoma agent. Cardiovascular drug reviews 22, 103-
120 (2004). 
201. Krauss, A.H. & Woodward, D.F. Update on the mechanism of action of bimatoprost: a review and 
discussion of new evidence. Surv Ophthalmol 49 Suppl 1, S5-11 (2004). 
202. Liang, Y., et al. Identification and pharmacological characterization of the prostaglandin FP receptor 
and FP receptor variant complexes. British journal of pharmacology 154, 1079-1093 (2008). 
203. Nirodi, C.S., Crews, B.C., Kozak, K.R., Morrow, J.D. & Marnett, L.J. The glyceryl ester of 
prostaglandin E2 mobilizes calcium and activates signal transduction in RAW264.7 cells. Proceedings 
of the National Academy of Sciences of the United States of America 101, 1840-1845 (2004). 
204. Sang, N., Zhang, J. & Chen, C. PGE2 glycerol ester, a COX-2 oxidative metabolite of 2-arachidonoyl 
glycerol, modulates inhibitory synaptic transmission in mouse hippocampal neurons. J Physiol 572, 735-
745 (2006). 
205. Sang, N., Zhang, J. & Chen, C. COX-2 oxidative metabolite of endocannabinoid 2-AG enhances 
excitatory glutamatergic synaptic transmission and induces neurotoxicity. J Neurochem 102, 1966-1977 
(2007). 
206. Ghosh, M., et al. COX-2 suppresses tissue factor expression via endocannabinoid-directed PPARdelta 
activation. J Exp Med 204, 2053-2061 (2007). 
207. Jack, D.B. One hundred years of aspirin. Lancet 350, 437-439 (1997). 
	   42	  
208. Vane, J.R. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nat 
New Biol 231, 232-235 (1971). 
209. Smith, J.B. & Willis, A.L. Aspirin selectively inhibits prostaglandin production in human platelets. Nat 
New Biol 231, 235-237 (1971). 
210. Rome, L.H. & Lands, W.E. Structural requirements for time-dependent inhibition of prostaglandin 
biosynthesis by anti-inflammatory drugs. Proceedings of the National Academy of Sciences of the 
United States of America 72, 4863-4865 (1975). 
211. Van Der Ouderaa, F.J., Buytenhek, M., Nugteren, D.H. & Van Dorp, D.A. Acetylation of prostaglandin 
endoperoxide synthetase with acetylsalicylic acid. European journal of biochemistry / FEBS 109, 1-8 
(1980). 
212. Roth, G.J., Machuga, E.T. & Ozols, J. Isolation and covalent structure of the aspirin-modified, active-
site region of prostaglandin synthetase. Biochemistry 22, 4672-4675 (1983). 
213. Rome, L.H., Lands, W.E., Roth, G.J. & Majerus, P.W. Aspirin as a quantitative acetylating reagent for 
the fatty acid oxygenase that forms prostaglandins. Prostaglandins 11, 23-30 (1976). 
214. Loll, P.J., Picot, D. & Garavito, R.M. The structural basis of aspirin activity inferred from the crystal 
structure of inactivated prostaglandin H2 synthase. Nature structural biology 2, 637-643 (1995). 
215. FitzGerald, G.A., et al. Endogenous biosynthesis of prostacyclin and thromboxane and platelet function 
during chronic administration of aspirin in man. The Journal of clinical investigation 71, 676-688 
(1983). 
216. Selinsky, B.S., Gupta, K., Sharkey, C.T. & Loll, P.J. Structural analysis of NSAID binding by 
prostaglandin H2 synthase: time-dependent and time-independent inhibitors elicit identical enzyme 
conformations. Biochemistry 40, 5172-5180 (2001). 
217. Bhattacharyya, D.K., Lecomte, M., Rieke, C.J., Garavito, M. & Smith, W.L. Involvement of arginine 
120, glutamate 524, and tyrosine 355 in the binding of arachidonate and 2-phenylpropionic acid 
inhibitors to the cyclooxygenase active site of ovine prostaglandin endoperoxide H synthase-1. The 
Journal of biological chemistry 271, 2179-2184 (1996). 
218. Rieke, C.J., Mulichak, A.M., Garavito, R.M. & Smith, W.L. The role of arginine 120 of human 
prostaglandin endoperoxide H synthase-2 in the interaction with fatty acid substrates and inhibitors. The 
Journal of biological chemistry 274, 17109-17114 (1999). 
219. Kulmacz, R.J. & Lands, W.E. Stoichiometry and kinetics of the interaction of prostaglandin H synthase 
with anti-inflammatory agents. The Journal of biological chemistry 260, 12572-12578 (1985). 
220. Mancini, J.A., Riendeau, D., Falgueyret, J.P., Vickers, P.J. & O'Neill, G.P. Arginine 120 of 
prostaglandin G/H synthase-1 is required for the inhibition by nonsteroidal anti-inflammatory drugs 
containing a carboxylic acid moiety. The Journal of biological chemistry 270, 29372-29377 (1995). 
221. Kalgutkar, A.S., et al. Biochemically based design of cyclooxygenase-2 (COX-2) inhibitors: facile 
conversion of nonsteroidal antiinflammatory drugs to potent and highly selective COX-2 inhibitors. 
Proceedings of the National Academy of Sciences of the United States of America 97, 925-930 (2000). 
222. Kalgutkar, A.S., Marnett, A.B., Crews, B.C., Remmel, R.P. & Marnett, L.J. Ester and amide derivatives 
of the nonsteroidal antiinflammatory drug, indomethacin, as selective cyclooxygenase-2 inhibitors. 
Journal of medicinal chemistry 43, 2860-2870 (2000). 
223. Prusakiewicz, J.J., Felts, A.S., Mackenzie, B.S. & Marnett, L.J. Molecular basis of the time-dependent 
inhibition of cyclooxygenases by indomethacin. Biochemistry 43, 15439-15445 (2004). 
224. Felts, A.S., et al. Desmethyl derivatives of indomethacin and sulindac as probes for cyclooxygenase-
dependent biology. Acs Chem Biol 2, 479-483 (2007). 
225. Rowlinson, S.W., et al. A novel mechanism of cyclooxygenase-2 inhibition involving interactions with 
Ser-530 and Tyr-385. The Journal of biological chemistry 278, 45763-45769 (2003). 
226. Mancini, J.A., et al. Altered sensitivity of aspirin-acetylated prostaglandin G/H synthase-2 to inhibition 
by nonsteroidal anti-inflammatory drugs. Mol Pharmacol 51, 52-60 (1997). 
227. Masferrer, J.L., et al. Selective inhibition of inducible cyclooxygenase 2 in vivo is antiinflammatory and 
nonulcerogenic. Proceedings of the National Academy of Sciences of the United States of America 91, 
3228-3232 (1994). 
	   43	  
228. Bombardier, C., et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in 
patients with rheumatoid arthritis. VIGOR Study Group. The New England journal of medicine 343, 
1520-1528, 1522 p following 1528 (2000). 
229. Silverstein, F.E., et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs 
for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib 
Long-term Arthritis Safety Study. Jama 284, 1247-1255 (2000). 
230. Gans, K.R., et al. Anti-inflammatory and safety profile of DuP 697, a novel orally effective 
prostaglandin synthesis inhibitor. J Pharmacol Exp Ther 254, 180-187 (1990). 
231. Lee, S.H., et al. Selective expression of mitogen-inducible cyclooxygenase in macrophages stimulated 
with lipopolysaccharide. The Journal of biological chemistry 267, 25934-25938 (1992). 
232. Copeland, R.A., et al. Mechanism of selective inhibition of the inducible isoform of prostaglandin G/H 
synthase. Proceedings of the National Academy of Sciences of the United States of America 91, 11202-
11206 (1994). 
233. Lanzo, C.A., Beechem, J.M., Talley, J. & Marnett, L.J. Investigation of the binding of isoform-selective 
inhibitors to prostaglandin endoperoxide synthases using fluorescence spectroscopy. Biochemistry 37, 
217-226 (1998). 
234. Lanzo, C.A., Sutin, J., Rowlinson, S., Talley, J. & Marnett, L.J. Fluorescence quenching analysis of the 
association and dissociation of a diarylheterocycle to cyclooxygenase-1 and cyclooxygenase-2: dynamic 
basis of cyclooxygenase-2 selectivity. Biochemistry 39, 6228-6234 (2000). 
235. Walker, M.C., et al. A three-step kinetic mechanism for selective inhibition of cyclo-oxygenase-2 by 
diarylheterocyclic inhibitors. Biochem J 357, 709-718 (2001). 
236. Leblanc, Y., et al. Synthesis and biological evaluation of 2,3-diarylthiophenenes as selective Cox-2 and 
Cox-1 inhibitors. Biorganic & Medicinal Chemistry Letters 5, 2123-2128 (1995). 
237. Guo, Q., Wang, L.H., Ruan, K.H. & Kulmacz, R.J. Role of Val509 in time-dependent inhibition of 
human prostaglandin H synthase-2 cyclooxygenase activity by isoform-selective agents. The Journal of 
biological chemistry 271, 19134-19139 (1996). 
238. Gierse, J.K., et al. A single amino acid difference between cyclooxygenase-1 (COX-1) and -2 (COX-2) 
reverses the selectivity of COX-2 specific inhibitors. The Journal of biological chemistry 271, 15810-
15814 (1996). 
239. Wong, E., Bayly, C., Waterman, H.L., Riendeau, D. & Mancini, J.A. Conversion of prostaglandin G/H 
synthase-1 into an enzyme sensitive to PGHS-2-selective inhibitors by a double His513 --> Arg and 
Ile523 --> val mutation. The Journal of biological chemistry 272, 9280-9286 (1997). 
240. Windsor, M.A., Valk, P.L., Xu, S., Banerjee, S. & Marnett, L.J. Exploring the molecular determinants of 
substrate-selective inhibition of cyclooxygenase-2 by lumiracoxib. Bioorg Med Chem Lett 23, 5860-
5864 (2013). 
241. Blobaum, A.L. & Marnett, L.J. Molecular determinants for the selective inhibition of cyclooxygenase-2 
by lumiracoxib. The Journal of biological chemistry 282, 16379-16390 (2007). 
242. Capone, M.L., et al. Human pharmacology of naproxen sodium. J Pharmacol Exp Ther 322, 453-460 
(2007). 
243. Juni, P., Rutjes, A.W. & Dieppe, P.A. Are selective COX 2 inhibitors superior to traditional non 
steroidal anti-inflammatory drugs? BMJ 324, 1287-1288 (2002). 
244. Warner, T.D., et al. Nonsteroid drug selectivities for cyclo-oxygenase-1 rather than cyclo-oxygenase-2 
are associated with human gastrointestinal toxicity: a full in vitro analysis. Proceedings of the National 
Academy of Sciences of the United States of America 96, 7563-7568 (1999). 
245. Bresalier, R.S., et al. Cardiovascular events associated with rofecoxib in a colorectal adenoma 
chemoprevention trial. The New England journal of medicine 352, 1092-1102 (2005). 
246. Solomon, S.D., et al. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal 
adenoma prevention. The New England journal of medicine 352, 1071-1080 (2005). 
247. McAdam, B.F., et al. Systemic biosynthesis of prostacyclin by cyclooxygenase (COX)-2: the human 
pharmacology of a selective inhibitor of COX-2. Proceedings of the National Academy of Sciences of 
the United States of America 96, 272-277 (1999). 
	   44	  
248. Graham, D.J., et al. Risk of acute myocardial infarction and sudden cardiac death in patients treated with 
cyclo-oxygenase 2 selective and non-selective non-steroidal anti-inflammatory drugs: nested case-
control study. Lancet 365, 475-481 (2005). 
249. Kearney, P.M., et al. Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-
inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials. BMJ 332, 
1302-1308 (2006). 
250. McGettigan, P. & Henry, D. Cardiovascular risk and inhibition of cyclooxygenase: a systematic review 
of the observational studies of selective and nonselective inhibitors of cyclooxygenase 2. JAMA 296, 
1633-1644 (2006). 
251. Grosser, T., Fries, S. & FitzGerald, G.A. Biological basis for the cardiovascular consequences of COX-2 
inhibition: therapeutic challenges and opportunities. The Journal of clinical investigation 116, 4-15 
(2006). 
252. Yuan, C., Rieke, C.J., Rimon, G., Wingerd, B.A. & Smith, W.L. Partnering between monomers of 
cyclooxygenase-2 homodimers. Proceedings of the National Academy of Sciences of the United States of 
America 103, 6142-6147 (2006). 
253. Rowlinson, S.W., Crews, B.C., Lanzo, C.A. & Marnett, L.J. The binding of arachidonic acid in the 
cyclooxygenase active site of mouse prostaglandin endoperoxide synthase-2 (COX-2). A putative L-
shaped binding conformation utilizing the top channel region. The Journal of biological chemistry 274, 
23305-23310 (1999). 
254. Kulmacz, R.J. & Lands, W.E. Prostaglandin H synthase. Stoichiometry of heme cofactor. The Journal of 
biological chemistry 259, 6358-6363 (1984). 
255. Dong, L., et al. Human Cyclooxygenase-2 Is a Sequence Homodimer That Functions as a 
Conformational Heterodimer. Journal of Biological Chemistry 286, 19035-19046 (2011). 
256. Kulmacz, R.J. & Lands, W.E.M. Prostaglandin-H Synthase - Stoichiometry of Heme Cofactor. Journal 
of Biological Chemistry 259, 6358-6363 (1984). 
257. Yuan, C., et al. Cyclooxygenase Allosterism, Fatty Acid-mediated Cross-talk between Monomers of 
Cyclooxygenase Homodimers. The Journal of biological chemistry 284, 10046-10055 (2009). 
258. Rimon, G., et al. Coxibs interfere with the action of aspirin by binding tightly to one monomer of 
cyclooxygenase-1. Proceedings of the National Academy of Sciences of the United States of America 
107, 28-33 (2010). 
259. Sidhu, R.S., Lee, J.Y., Yuan, C. & Smith, W.L. Comparison of cyclooxygenase-1 crystal structures: 
cross-talk between monomers comprising cyclooxygenase-1 homodimers. Biochemistry 49, 7069-7079 
(2010). 
260. Kozak, K.R., Rowlinson, S.W. & Marnett, L.J. Oxygenation of the endocannabinoid, 2-
arachidonylglycerol, to glyceryl prostaglandins by cyclooxygenase-2. The Journal of biological 
chemistry 275, 33744-33749 (2000). 
261. Prusakiewicz, J.J., Duggan, K.C., Rouzer, C.A. & Marnett, L.J. Differential sensitivity and mechanism 
of inhibition of COX-2 oxygenation of arachidonic acid and 2-arachidonoylglycerol by ibuprofen and 
mefenamic acid. Biochemistry 48, 7353-7355 (2009). 
 
 
 45 
CHAPTER II 
THE BASIS OF SUBSTRATE-SELECTIVE CYCLOOXYGENASE-2 INHIBITION 
Introduction 
Cyclooxygenase-2 (COX-2) catalyzes the committed step in the production of prostaglandins (PGs). In 
addition to oxygenating arachidonic acid (AA), it can also oxygenate 2-arachidonoylglycerol (2-AG) and 
arachidonoylethanolamide (AEA) to form prostaglandin glycerols (PG-Gs) and prostaglandin ethanolamides 
(PG-EAs), respectively.1,2 While 2-AG and AA are oxygenated by human COX-2 at comparable kcat/KM’s, AEA 
is oxygenated at approximately 30% of the rate of 2-AG and AA.  
Investigations into the inhibition of COX-2 revealed that 2-AG oxygenation is inhibited at much lower 
concentrations of (S)-ibuprofen or mefenamic acid than AA oxygenation.3 The finding that (S)-ibuprofen and 
mefenamic acid are non-competitive inhibitors of 2-AG oxygenation, but competitive inhibitors of AA 
oxygenation lead to a mechanistic hypothesis. Binding of one molecule of (S)-ibuprofen or mefenamic acid to 
the first monomer of COX-2 results in inhibition of 2-AG oxygenation in the second monomer, but does not 
block AA oxygenation. Inhibition of AA oxygenation requires a second molecule of (S)-ibuprofen or 
mefenamic acid to bind to the second monomer (Figure 1). These studies reveal that (S)-ibuprofen and 
mefenamic acid inhibit the oxygenation of AA and 2-AG by different mechanisms and with different potencies, 
a phenomenon that has been termed “substrate-selective” inhibition. 
 
Figure 1: Model for differential inhibition of 2-AG and AA oxygenation by COX-2. The uninhibited COX-
2 homodimer (blue) is able to oxygenate both AA and 2-AG. Binding of an inhibitor (red) to a single monomer 
(teal) precludes the productive binding of 2-AG in the partner monomer (green) but still allows for AA 
oxygenation. Metabolism of AA is inhibited only when an inhibitor occupies both active sites of COX-2. 
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 A growing body of evidence that the COX-2 monomers are sequence homodimers but functional 
heterodimers suggests that binding of a substrate, an inhibitor, or an activator to one monomer causes a change 
in the second monomer.4 In the case of substrate-selective inhibition, binding of a single molecule of (S)-
ibuprofen or mefenamic acid to one monomer causes a change in the second monomer of COX-2 such that 2-
AG cannot be oxygenated, but AA can still be utilized as a substrate. While multiple reports have identified 
some residues that mediate monomer cross talk, the basis of substrate-selective inhibition has not been studied. 
In addition, the scope of compounds that exhibit substrate-selective inhibition has not been established. 
 We sought to determine the generalizability of substrate-selective inhibition by studying the inhibition 
of COX-2 mediated oxygenation of 2-AG and AA by several different classes of non-steroidal anti-
inflammatory drugs (NSAIDs). These studies identified that compounds that are weak, reversible inhibitors of 
AA oxygenation are potent, substrate-selective inhibitors of 2-AG oxygenation. In contrast, COX-2 inhibitors 
that are slow, tight-binding inhibitors potently inhibit 2-AG and AA oxygenation with comparable IC50 values 
for the two substrates. Additionally, we identified and characterized substrate-selective inhibition by (R)-
arylpropionic acids. Further studies were undertaken to determine the structural basis and enzymatic mechanism 
of substrate-selective inhibition utilizing a combination of site-directed mutagenesis and X-ray crystallography. 
These studies identified rotation of Leu-351, which lies adjacent to the binding pocket of the glycerol moiety of 
2-AG, as a critical mediator of substrate-selective inhibition.   
 
Experimental Procedures 
Materials 
Wild-type and mutant murine COX-2s were expressed and purified as previously described.5 AA was purchased 
from Nu-Check Prep, Inc. (Elysian, MN). Diclofenac, (S)-ibuprofen, (S)-flurbiprofen, (S)-naproxen, 
indomethacin, mefenamic acid, (R)-naproxen, PGE2, and glycerol-d5 were purchased from Sigma-Aldrich 
(Milwaukee, WI). (R)-ibuprofen was purchased from Santa Cruz Biotechnology (Santa Cruz, CA). (R)-
flurbiprofen, 2-AG, AEA, PGE2-d4, and 5-phenyl-4-pentenyl hydroperoxide (PPHP) were purchased from 
Cayman Chemical Company (Ann Arbor, MI). Lumiracoxib was purchased from LKT Laboratories, Inc. (St. 
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Paul, MN). 2′-des-methylindomethacin (DM-indomethacin), celecoxib, and rofecoxib were synthesized 
according to published methods.6-8 All substrates and inhibitors were dissolved in dimethyl sulfoxide (DMSO) 
for use. Reagents used in the crystallization of murine COX-2 were purchased from Hampton Research (Aliso 
Viejo, CA). 
 
Inhibition of AA and 2-AG oxygenation as measured by oxygen uptake 
For AA experiments, 440 nM mCOX-2 was pre-incubated with inhibitor for 2 minutes at 37°C prior to the 
addition of 50 µM AA. For experiments in which 2-AG was used as the substrate, the concentration of mCOX-2 
was increased to 890 nM to allow for a similar extent of oxygenation of 2-AG compared to AA. Initial reaction 
velocity was determined from the linear portion of the oxygen uptake curves as measured by an Instech 210 
Fiber Optic oxygen monitor (Plymouth Meeting, PA) and normalized to the DMSO control. Each condition was 
performed in triplicate. 
 
Inhibition of AA, 2-AG, and AEA oxygenation by murine COX-2 by mass spectrometry 
A fixed concentration of murine COX-2 (50 nM for 5 µM substrate or 250 nM for 50 µM substrate) was 
suspended in a 100 mM Tris-HCl, pH = 8, 500 µM phenol buffer. 2 equivalents of heme were added, the 
solution was vigorously mixed, and then aliquoted out at 190 µl per tube. To each tube 5 µl of DMSO or 
inhibitor solution was added and the tube was vigorously mixed and capped for pre-incubation for five or 
fifteen minutes at 37 °C before the addition of substrate; pre-incubation times were determined based on 
previous reports of the time necessary to achieve maximal inhibition. After pre-incubation, 5 µM or 50 µM of 
AA or 2-AG was added in 5 µl of DMSO to the tube, vigorously mixed, and allowed to react for 30 seconds. 
After 30 seconds the reaction was quenched by adding 200 µl of ethyl acetate containing 0.1% glacial acetic 
acid, 300 pmol of PGE2-d4, and 300 pmol of PGE2-G-d5. Tubes were then frozen and the organic layer was 
separated and evaporated to dryness under nitrogen gas. The samples were then reconstituted in 200 µl of 1:1 
MeOH:water and analyzed using liquid chromatography-tandem mass spectrometry (LC-MS/MS) analysis. For 
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kinetic inhibition assays, 100 nM of murine COX-2 was incubated with different concentrations of substrate 
from 2.5 to 40 µM. LC-MS/MS analysis was performed using mobile phases consisting of 5 mM ammonium 
acetate in water at pH 3.5 with glacial acetic acid (buffer A) and acetonitrile with 6% buffer A (Buffer B). 
Samples were separated on an Ascentis® C18 column (5 cm x 2.1 mm, 3 µm pore size) using a gradient starting 
at 20% buffer B for 1 minute, then to 95% buffer B over 4 minutes, then 1 minute at 95% buffer B, and re-
equilibration to 20% buffer B over 30 seconds for a total time of 6.5 minutes. The PGs and PG-Gs were 
monitored using selected reaction monitoring (SRM) with the transitions m/z 370 ! 317 (PGE2/D2), m/z 374 ! 
321 (PGE2-d4), m/z 444 ! 391 (PGE2-G/D2-G), m/z 449! 396 (PGE2-G-d5). Analytes were quantitated using 
the ratio of the area of the analyte peak to its corresponding internal standard peak area. Percent activity was 
calculated by normalizing samples to the average of the DMSO control samples. 
 
Peroxidase activity assay  
Assays were performed as described with slight modifications.9 Hematin-reconstituted murine COX-2 (100 nM) 
in 100 mM Tris-HCl buffer was incubated with inhibitor (100 µM – 5 µM) in the presence of 200 µM phenol at 
37°C for 5 min. The reaction was initiated by the addition of PPHP (100 µM) and terminated after 5 min by the 
addition of ice cold quench solution (ethyl acetate + 0.5% acetic acid) followed by vigorous mixing and 
centrifugation at 4°C. The organic layer was removed, evaporated to dryness under nitrogen gas, and 
reconstituted in 300 µL of a 1:1 solution of methanol and water. Samples were separated by reverse phase high-
performance liquid chromatography (HPLC) using a UV detector set at 254 nm. Samples were 
chromatographed with a C8 reverse-phase column (150 x 2.00 mm Luna C8 HPLC column, 3 µm particle size) 
with a gradient beginning at 50% (v/v) methanol/water, increasing to 90% methanol over 9 minutes, and held at 
90% methanol for 10 additional minutes at a flow rate of 0.20 mL/min. The area of the peak was used to 
determine the concentrations of the analytes. Peroxidase activity was measured by the percent conversion of 
PPHP to 5-phenyl-4-pentenyl alcohol (PPA) using the equation: [PPA]/([PPA]+[PPHP]).  
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Crystallography  
COX-2 was expressed and purified as previously described.10 Purified protein was prepared for crystallization 
and hanging-drop crystallization experiments were set up according to published methods.11 All diffraction data 
were collected at 100 K at beamline 24ID-E located at the Advanced Photon Source using an ADSC Quantum 
315 charge-coupled-device-based detector. Diffraction data were processed with HKL2000.12 Initial phases 
were determined by molecular replacement using a search model (PDB 3NT1) with MOLREP.13 A solution 
having two molecules in the asymmetric unit was obtained. The model was improved with iterative rounds of 
model building in Coot and refinement in PHENIX.14,15 Molecular graphics were generated using PyMOL.16 
Results 
Differential inhibition of COX-2  
 To determine the generalizability of substrate-selective inhibition we assayed a series of inhibitors from 
multiple structural classes against both AA and 2-AG. We first analyzed several arylcarboxylic acids and 
diarylheterocycles, which are classified as slow, tight-binding inhibitors of COX-2 (Table 1).17 These 
compounds have low Kd values for binding and exhibit time-dependent inhibition of COX-1 and COX-2. For 
example, indomethacin, an indole acetic acid derivative, is a potent inhibitor of both COX-1 and COX-2, but 
requires up to 15 minutes of preincubation with the enzymes for full inhibition.18 Indomethacin acted as a potent 
inhibitor of both substrates with IC50 values of 180 nM for AA and of 10 nM for 2-AG. As discussed 
previously, it has been shown that binding of a single molecule of indomethacin to the COX homodimer is 
sufficient to achieve full inhibition of AA oxygenation by the enzyme.19 Additional studies found that the COX-
2 selective inhibitors rofecoxib and celecoxib are also potent inhibitors of both AA and 2-AG oxygenation. 
These studies suggest that a single binding event of indomethacin or a diarylheterocycle to one monomer 
inhibits the oxygenation of both AA and 2-AG in the second monomer.  
 Previous studies have determined that the primary determinant of the slow, tight binding of 
indomethacin to COX-2 is the insertion of the 2’-methyl group of the indole ring into a hydrophobic pocket in 
the COX active site.7 Removal of the 2’-methyl group to generate 2′-desmethyl indomethacin (DM-indo) results 
in a rapid reversible inhibitor of AA oxygenation with a significantly increased IC50.20 To probe the importance 
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of this methyl group for inhibition of 2-AG, DM-indo was assayed for inhibition of both AA and 2-AG. DM-
indo did not display potent inhibition of AA oxygenation, with maximal inhibition of 30% at 25 µM inhibitor 
concentration. In sharp contrast, DM-indo was a potent inhibitor of 2-AG oxygenation by COX-2, with an IC50 
of 110 nM. Thus, as with the rapid-reversible inhibitors (S)-ibuprofen and mefenamic acid, DM-indo exhibits 
little inhibition of AA oxygenation by COX-2, but acts as an extremely potent inhibitor of 2-AG oxygenation.3  
 As both (S)-ibuprofen and DM-indo bind to the constriction site of COX-2, we sought to determine if 
different binding poses could also display substrate-selectivity. Thus, we also compared the inhibition of AA 
and 2-AG by diclofenac and its analog lumiracoxib. Diclofenac is a slow-tight binding inhibitor that binds in an 
inverted pose relative to (S)-ibuprofen and DM-indo, with its carboxylate hydrogen bonded to Tyr-385 and Ser-
530.5 Lumiracoxib is a diclofenac analog that contains a single substitution of fluorine for chlorine on its lower 
ring and a meta-methyl group on its upper ring. Notably, lumiracoxib is the most selective COX-2-selective 
inhibitor in the ex vivo human whole blood assay.21 Despite its clinical use as a selective COX-2 inhibitor, 
lumiracoxib is a poor inhibitor of AA oxygenation and acts as a rapid-reversible inhibitor.22 Diclofenac inhibits 
AA with an IC50 of 60 nM and 2-AG with an IC50 of 50 nM. In sharp contrast, lumiracoxib exhibits little to no 
inhibition of AA, but inhibits 2-AG with an IC50 of 40 nM.     
 Thus, compounds classified as rapid, reversible inhibitors are potent inhibitors of 2-AG oxidation, but 
weak inhibitors of AA oxidation. In contrast, compounds that are classified as slow, tight-binding inhibitors 
exhibit potent inhibition of both 2-AG and AA oxidation by COX-2, with similar IC50 values for both 
substrates. Multiple inhibitor classes and binding modes exhibit these distinct kinetic inhibition modes and 
within the inhibitor classes no differences are apparent, including between COX-2-selective inhibitors or non-
selective inhibitors of COX-1 and COX-2. 
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Table 1: IC50 values for various COX inhibitors against AA and 2-AG oxygenation by COX-2. Enzyme 
and inhibitor were pre-incubated for 15 minutes prior to the addition of 50 µM substrate for 30 seconds. 
Reactions were quenched with organic solvent containing deuterated internal standards. Product formation was 
analyzed by LC-MS/MS using SRM and normalized to DMSO control. *AA oxygenation was measured using 
an oxygen electrode. Values for ibuprofen and mefenamic acid reproduced from.3 
 Inhibitor 50 µM AA IC50 50 µM 2-AG IC50 
Rapid, reversible 
inhibitors 
(S)-Ibuprofen* 7 µM 20 nM 
Mefenamic acid* 180 µM 210 nM 
DM-Indo > 25 µM 110 nM 
Lumiracoxib No inhibition 40 nM 
    
Slow, tight inhibitors 
Diclofenac 60 nM 50 nM 
(S)-Flurbiprofen 130 nM 30 nM 
Indomethacin 180 nM 10 nM 
Celecoxib 80 nM 95 nM 
Rofecoxib 520 nM 85 nM 
 
Substrate-selective inhibition by (R)-profens  
 The arylpropionic acid class of NSAIDs, also known as the profens, contains a methyl group α to their 
carboxylic acid moieties. The stereochemistry of this methyl group has an enormous impact of the ability of 
arylpropionic acid inhibitors to inhibit the oxygenation of AA by COX enzymes, with the (S)-enantiomers being 
inhibitors and the (R)-enantiomers displaying no inhibition (Figure 2).23 As discussed above, the rapid, 
reversible inhibitor (S)-ibuprofen acts as a substrate-selective inhibitor with potent inhibition of 2-AG, but weak 
inhibition of AA oxygenation by COX-2. In contrast, (S)-flurbiprofen is a slow, tight binding inhibitor and 
inhibits AA and 2-AG with similar IC50 values. 
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Figure 2: Chemical structures of (S)- and (R)-arylpropionic acid NSAIDs. 
 A third widely used member of the arylpropionic acid class of inhibitors is (S)-naproxen, which is a non-
selective COX-1 and COX-2 inhibitor and is the only arylpropionic acid marketed exclusively as the (S)-
enantiomer. (S)-naproxen exhibits a “mixed” inhibition mode, as it does not associate with COX in a single-step 
mechanism as a rapid-reversible inhibitor does, but also does not form an irreversible enzyme-inhibitor complex 
as a slow, tight binder does.24 With substrate concentrations of 5 µM, (S)-naproxen inhibits AA oxygenation 
with an IC50 of 340 nM and 2-AG oxygenation with an IC50 of 30 nM. Thus, it acts as a slightly substrate-
selective inhibitor under these conditions.  
 Given our findings with other weak inhibitors of AA oxygenation by COX-2, we hypothesized that the 
(R)-enantiomers of flurbiprofen, ibuprofen, and naproxen may inhibit 2-AG oxygenation despite the fact that 
they had previously been shown to not inhibit AA oxygenation. As previously demonstrated, (R)-flurbiprofen, 
(R)-ibuprofen, and (R)-naproxen did not inhibit AA oxygenation by COX-2 (Figure 3). However, all three 
inhibitors blocked the oxygenation of 2-AG by COX-2 with IC50 values of 80 nM for (R)-flurbiprofen, 10 µM 
for (R)-ibuprofen, and 3 µM for (R)-naproxen when 5 µM substrate was used. The ability of the (R)-profens to 
inhibit 2-AG is quite striking as previous reports suggested that (R)-profens do not bind in the COX active site 
due to steric clashes with the constriction site.25 
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Figure 3: Inhibition of COX-2-mediated AA and 2-AG oxygenation by (R)-profens. COX-2 was pre-
incubated with 62.5 nM–25 µM (R)-ibuprofen, (R)-naproxen, or (R)-flurbiprofen for 15 minutes followed by the 
addition of 50 µM AA (!) or 2-AG (!) for 30 seconds. PG and PG-G production were measured by LC-
MS/MS as described under Experimental Procedures. 
 
 Previous reports have demonstrated that COX-2-mediated oxygenation of 2-AG is much more sensitive 
to peroxide tone than the oxygenation of AA.26 To determine if the (R)-profens inhibit 2-AG oxygenation by 
either binding to the peroxidase active site or interfering with the peroxide tone of the enzyme mixture, Kelsey 
Duggan analyzed the ability of (R)-flurbiprofen and (R)-naproxen to inhibit the peroxidase (POX) activity of 
COX-2. POX activity was determined by HPLC monitoring of the conversion of PPHP to its corresponding 
alcohol, PPA. No significant inhibition of POX activity was evident with concentrations of either (R)-
flurbiprofen or (R)-naproxen up to 500 µM (Figure 4). 
 
Figure 4: Lack of inhibition of POX activity by (R)-flurbiprofen and (R)-naproxen. (R)-flurbiprofen or (R)-
naproxen (100-500 µM) were pre-incubated with murine COX-2 for 5 minutes at 37 °C prior to the addition of 
100 µM PPHP.  The reaction was quenched after 5 minutes by the addition of ethyl acetate with 0.5% acetic 
acid. Conversion of PPHP to PPA was monitored by HPLC as described under experimental procedures.  
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Structural basis of (R)-profen substrate-selective inhibition 
 To determine the basis of (R)-profen substrate-selective inhibition of 2-AG we utilized a combination of 
site-directed mutagenesis and X-ray crystallography. Previous reports have identified residues that mediate the 
ability of NSAIDs to inhibit AA oxygenation by using site-directed mutagenesis to modulate the ability of 
residues to interact with inhibitors. We employed this strategy to identify the residues critical for (R)-
flurbiprofen inhibition of 2-AG. Mutation of Tyr-355 to Phe, Glu-524 to Leu, or Ser-530 to Ala did not have 
significant effects on the IC50 value of (R)-flurbiprofen inhibition of 2-AG oxygenation relative to wild-type 
murine COX-2 (Figure 5). In contrast, mutation of Arg-120 to Gln resulted in no inhibition of 2-AG 
oxygenation by (R)-flurbiprofen, revealing that the ion-pairing interaction between (R)-flurbiprofen and the 
constriction site is a critical mediator of substrate-selective inhibition. These studies suggest that (R)-profens 
bind to the COX active site in a similar manner to the (S)-profens, with their carboxylate moieties ion-paired to 
Arg-120. 
 
Figure 5: Inhibition of wild-type and mutant murine COX-2 oxygenation of 2-AG by (R)-flurbiprofen. 
While (R)-flurbiprofen inhibited the oxygenation of 2-AG by wild-type, Y355F, E524L, and S530A COX-2 
with similar IC50 values. In contrast, mutation of Arg-120 to Gln resulted in no inhibition of 2-AG oxygenation 
by (R)-flurbiprofen. 
 
 In agreement with the site-directed mutagenesis studies, crystal structures of (R)-flurbiprofen and (R)-
naproxen bound to murine COX-2 generated by Kelsey Duggan, Joel Musee, and Surajit Banerjee revealed that 
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they bind in a nearly identical fashion to the COX active site as previously determined for (S)-ibuprofen bound 
to COX-1, (S)-naproxen bound to COX-2, and (S)-flurbiprofen bound to COX-1 and COX-2.11,27-29 Both (R)-
flurbiprofen and (R)-naproxen bind with their carboxylates coordinated to Arg-120 at the constriction site and 
their aryl rings projecting up into the COX active site (Figure 6). This is in sharp contrast to a previous report 
that the α-methyl groups of (R)-profens abrogate binding to the COX active site through a steric clash with Tyr-
355.25 In fact, the α-methyl groups of both (R)-flurbiprofen and (R)-naproxen bind adjacent to Tyr-355.   
 
Figure 6: Crystal structures of (R)-flurbiprofen and (R)-naproxen bound to murine COX-2. Both (R)-
flurbiprofen (left, blue, PDB ID: 3RR3) and (R)-naproxen (right, teal, PDB ID: 3Q7D) bind with their 
carboxylates coordinated to Arg-120 at the constriction site and their aryl rings projecting up into the COX 
active site. 
 
 Overlaying the 1.7 Å resolution crystal structure of (S)-naproxen with the (R)-naproxen structure allows 
for direct comparison of the binding of (S)-naproxen to (R)-naproxen.30 This overlay reveals the near 
superimposition of the two naphthyl rings and the difference in chirality of the two α-methyl groups (Figure 7). 
Both (S)-naproxen and (R)-naproxen ion-pair and hydrogen bond with Arg-120 and Tyr-355 and form 
hydrophobic interactions with Ala-527, Val-349, Gly-526, Trp-387, Tyr-385, and Leu-352. However, there is a 
repositioning of Arg-120 and Tyr-355 (r.m.s. deviations of 0.47 Å and 0.45 Å, respectively) to accommodate 
the α-methyl group of (R)-naproxen, which increases the hydrogen bond distance between Tyr-355 and the 
carboxylate of (R)-naproxen to 3.05 Å compared to 2.44 Å for the same interaction in the (S)-naproxen 
complex. 
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Figure 7: Overlay of (S)- and (R)-naproxen crystal structures. (S)-naproxen (blue, PDB ID: 3NT1) and (R)-
naproxen (grey, PDB ID: 3Q7D) display nearly identical binding modes to the COX active site. The primary 
difference in binding is a repositioning of Arg-120 and Tyr-355 to accommodate the (R)-methyl group of (R)-
naproxen. 
 
 As with the naproxen enantiomers, (R)-flurbiprofen and (S)-flurbiprofen bind in a similar fashion within 
the COX-2 active site (Figure 8). Both form an ion-pair and hydrogen bonds with Arg-120 and Tyr-355 at the 
base of the active site and hydrophobic interactions with Ala-527, Val-349, Gly-526, Tyr-385, Leu-359, and 
Ser-530. The comparison of the crystal structures of the flurbiprofen and naproxen enantiomers identifies 
substrate-selective inhibition is imparted through very subtle differences in binding and not overt changes in 
either binding mode or inhibitor-enzyme interactions. Thus, the primary determinant of substrate-selective 
inhibition appears to be the kinetic mode of inhibition.  
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Figure 8: Overlay of (S)- and (R)-flurbiprofen crystal structures. (S)-naproxen (blue, PDB ID: 3PGH) and 
(R)-naproxen (grey, PDB ID: 3RR3) display nearly identical binding modes to the COX active site. As with 
naproxen, the primary difference in binding is a repositioning of Arg-120 and Tyr-355 to accommodate the (R)-
methyl group of (R)-flurbiprofen. 
 
Investigations into the mechanism of substrate-selective inhibition 
Although multiple substrate-selective inhibitors from multiple NSAID classes had been identified, the 
mechanism by which substrate-selective inhibition occurs remained elusive. The elucidation of the binding 
mode of 1-AG to COX-2 and novel insights into COX dimer crosstalk assisted in the identification of the 
residues that mediate substrate-selective inhibition. The crystal structure of 1-AG bound to the active site of 
COX-2 identified that the 2,3-dihydroxypropyl moiety binds above the side chain of Arg-120 in a pocket 
formed by rotation of Leu-531 (Figure 9).31 This movement of Leu-531 is identical to that observed when AA 
binds to COX-2 in the non-productive conformation.32 However, when AA binds in the productive 
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conformation, Leu-531 is rotated in toward the active site. Thus, rotation of Leu-531 prevents the oxygenation 
of 2-AG but not AA. 
 
 
Figure 9: Comparison of the productive binding modes of 1-AG and AA with murine COX-2. 1-AG 
(yellow) bound in the productive mode positions C-13 (orange) adjacent to Tyr-385 for abstraction of the 13-
pro-(S)-hydrogen. This binding requires the rotation of Leu-531 (green) to accommodate the binding of the 2,3-
dihydroxypropyl moiety of 1-AG (left, PDB ID: 3MDL).  Similarly, the productive conformation of AA (teal) 
positions its C-13 (orange) adjacent to Tyr-385 for abstraction of the 13-pro-(S)-hydrogen. However, the 
binding of AA does not require the rotation of Leu-531 (green) out of the active site (right, PDB ID: 3HS5). 
 
 In depth studies on communication between the two COX monomers have identified that the two 
monomers are functionally interdependent and that binding of a substrate, inhibitor, or activator at one active 
site alters the properties of the active site of the second monomer.4 This subunit communication occurs through 
the repositioning of residues and translation through the dimer interface.33 A crystal structure of the COX-2-
selective inhibitor celecoxib bound to one monomer of COX-1 identified a conformational change in the loop 
consisting of residues 121 to 127 that may be the basis for dimer communication.34  
 We hypothesized that substrate-selective inhibition could arise from binding of an inhibitor to the first 
monomer and a subsequent conformational change in the second monomer such that 2-AG could not be 
oxygenated but AA could still be utilized as a substrate. The identification of the rotation of Leu-531 as a 
critical mediator of 1-AG binding suggested that this rotation could be a key determinant of substrate-selective 
inhibition, as Leu-531 rotation into the COX active site would not impair AA oxygenation but would prevent 2-
AG oxygenation due to a steric clash with the glycerol moiety. 
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 Previous studies have identified that mutation of Leu-531 has minor effects on the oxygenation of AA, 
2-AG, and 1-AG by COX-2.31,32 While mutation of Leu-531 has some impact on the oxygenation of substrates 
by COX-2, we hypothesized that decreasing the steric bulk of Leu-531 could reduce substrate-selective 
inhibition by reducing the steric impact of the rotation of residue 531 on the ability of 2-AG to bind and be 
oxygenated in the catalytic monomer. To determine the impact of Leu-531 on substrate-selective inhibition we 
screened the ability of (R)-flurbiprofen to inhibit a series of Leu-531 mutants with decreased steric bulk.  
Mutation of Leu-531 to Ile had no impact on (R)-flurbiprofen inhibition of 2-AG, however, mutation of Leu-
531 to Val increased the IC50 and mutation of Leu-531 to Ala resulted in an abrogation of 2-AG inhibition 
altogether (Figure 10). To further assess this finding we also analyzed the ability of lumiracoxib, which binds in 
an inverted mode compared to (R)-flurbiprofen, to inhibit 2-AG oxygenation by COX-2. As with (R)-
flurbiprofen, lumiracoxib exhibited a loss of potency with substitution of Leu-531 for either valine or alanine. 
Thus, decreasing the steric bulk of residue 531 results in decreased inhibition of 2-AG oxygenation by multiple 
substrate-selective inhibitors. 
 
Figure 10: Impact of mutation of Leu-531 on inhibition of 2-AG oxygenation by (R)-flurbiprofen and 
lumiracoxib. Both (R)-flurbiprofen (left) and lumiracoxib (right) have decreased inhibition of 2-AG 
oxygenation against L531V and L531A mutants compared to wild-type or L531I murine COX-2.  
 
 To further explore the impact of Leu-531 mutation to Ala we performed kinetic experiments to 
determine the kinetic mode of inhibition of (R)-flurbiprofen against wild-type and L531A murine COX-2. 
Previous studies demonstrated that the substrate-selective inhibitors (S)-ibuprofen and mefenamic acid acted as 
competitive inhibitors of AA oxygenation but non-competitive inhibitors of 2-AG oxygenation.3 Consistent 
with these data, (R)-flurbiprofen acted as a non-competitive inhibitor of 2-AG oxygenation in wild type COX-2 
(Figure 11). However, mutation of Leu-531 to Ala converted (R)-flurbiprofen into a competitive inhibitor of 2-
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AG oxygenation. Thus, mutation of Leu-531 to Ala abolishes the ability of a substrate-selective inhibitor to act 
as a non-competitive inhibitor of 2-AG oxygenation. 
 
Figure 11: Inhibition kinetics of (R)-flurbiprofen against wild-type and L531A COX-2. While (R)-
flurbiprofen acts as a non-competitive inhibitor of 2-AG oxygenation with wild-type COX-2 (left), it acts as a 
competitive inhibitor of 2-AG oxygenation with L531A COX-2 (right). 
 
 To determine if mutation of Leu-531 to Ala modifies the binding of substrate-selective inhibitors we 
attempted to crystalize (R)-flurbiprofen and lumiracoxib with L531A COX-2. A crystal structure solved by Shu 
Xu revealed that lumiracoxib binds in a nearly identical fashion to L531A COX-2 as wild type COX-2 (Figure 
12).35 Lumiracoxib forms hydrogen bonds between its carboxylate and Tyr-385 and Ser-530 in both wild-type 
and L531A COX-2. In addition, the ortho-chlorine atom lies adjacent to Ser-530 and inserts into a hydrophobic 
pocket comprised of Val-349, Ala-527, and Leu-531 (or Ala-531 in L531A). Thus, the binding of substrate-
selective inhibitors to wild type and L531A COX-2 appears to be analogous. 
 
Figure 12: Comparison of the binding of lumiracoxib to wild-type and L531A COX-2. Lumiracoxib (blue) 
exhibits nearly identical binding in wild-type (left, PDB ID: 4OTY) and L531A COX-2 (right). Mutation of 
L531A results in a larger pocket between Ser-530 and Arg-120 relative to wild-type enzyme. 
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Discussion 
 COX inhibitors exhibit multiple kinetic modes of inhibition. The two primary modes are rapid, 
reversible inhibition and slow, tight-binding inhibition.18 Previous reports have identified that rapid, reversible 
inhibitors are weak inhibitors of AA oxygenation and slow, tight-binders are potent inhibitors of AA 
oxygenation.3 Consistent with previous studies in our laboratory, we have found that rapid, reversible inhibitors 
are potent inhibitors of 2-AG oxygenation while slow, tight-binders are potent inhibitors of AA oxygenation 
and 2-AG oxygenation.3 Taken together, these studies identify that rapid, reversible inhibitors of COX-2 exhibit 
substrate-selective inhibition while slow, tight binding inhibitors inhibit AA and 2-AG oxygenation with 
comparable IC50 values.  
 Slow, tight-binding inhibitors have very low dissociation rates due to a two-step mechanism of 
inhibition. After binding to the enzyme they exhibit a slow, time-dependent second step that leads to a 
functionally irreversible interaction with the enzyme.36-38 Inhibition of both AA and 2-AG can occur with the 
binding of a single slow, tight-binding inhibitor to one subunit in the case of indomethacin and (S)-flurbiprofen 
(Figure 13).19 Thus, slow, tight-binding inhibitors have similar IC50 values toward both AA and 2-AG. 
 
Figure 13: Mechanism of inhibition of AA and 2-AG by slow, tight-binding inhibitors. Binding of one 
molecule of a slow, tight-binding inhibitor to the first monomer results in a time-dependent conformational 
change in the second monomer such that the oxygenation of both AA and 2-AG by COX-2 is inhibited.  
 
 In contrast, rapid, reversible inhibitors have different kinetic modes of inhibition for AA and 2-AG. 
While they are competitive inhibitors of AA oxygenation, they exhibit non-competitive inhibition of 2-AG 
oxygenation.3 Studies on the communication between the two subunits of COX-2 suggest that this non-
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competitive inhibition occurs through the dimer interface.4 Our data are consistent with the hypothesis that 
binding of a single molecule of a rapid, reversible inhibitor to the first monomer is sufficient to inhibit 2-AG 
oxygenation, but not AA oxygenation, in the second monomer. Thus, although both slow, tight-binding 
inhibitors and rapid, reversible inhibitors induce conformational changes in the second subunit after binding to 
the first subunit, the changes are not identical given the lack of AA inhibition by rapid, reversible inhibitors.   
 In addition to previously characterized rapid, reversible inhibitors, we have identified the (R)-profens, 
which were previously classified as inactive with respect to inhibition of AA oxygenation by COX-2, as 
substrate-selective inhibitors. The (R)-profens display a remarkable selectivity for 2-AG inhibition as they do 
not have any observable inhibition of AA oxygenation in vitro. This discovery suggests that molecules 
previously classified as non-inhibitors of AA oxygenation by COX-2 could be exceptional substrate-selective 
inhibitors. Understanding the scope of scaffolds that exhibit substrate-selective inhibition will assist in the 
design and development of novel substrate-selective inhibitors. 
 Investigations into the binding mode of 1-AG to COX-2 suggested that substrate-selective inhibition 
could be mediated by the rotation of Leu-531 into the COX channel. While the 2,3-dihydroxypropyl moiety of 
1-AG requires rotation of Leu-531 out of the channel for productive binding, the productive binding of AA does 
not.31,32 Consistent with the hypothesis that substrate-selective inhibition is imparted by binding of an inhibitor 
to the first subunit causing a rotation of Leu-531 in the second subunit, mutation of Leu-531 to Ala abrogates 
substrate-selective inhibition by both (R)-flurbiprofen and lumiracoxib. This is notable because (R)-flurbiprofen 
and lumiracoxib bind in a complimentary fashion to the COX active site, suggesting that regardless of binding 
pose Leu-531 mediates substrate-selective inhibition. In addition, a crystal structure of lumiracoxib bound to 
L531A COX-2 revealed that it has the same binding interactions with L531A COX-2 as it does with wild-type 
COX-2. Notably, lumiracoxib did inhibit the oxygenation of 2-AG by L531A COX-2, however it was at a 
significantly increased IC50 value relative to WT COX-2. This suggests that mutation of L531A does not 
necessarily completely abolish inhibition of 2-AG oxygenation by some substrate-selective inhibitors.   
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CHAPTER III 
SUBSTRATE-SELECTIVE INHIBITION IN CELLULAR SYSTEMS 
Introduction 
 The endocannabinoids anandamide (AEA) and 2-arachidonoyl glycerol (2-AG) are the endogenous 
ligands of the G-protein coupled cannabinoid 1 and 2 receptors (CB1 and CB2).1,2 Both AEA and 2-AG activate 
the CB receptors to produce some of their manifold biological effects.3 The CB receptors inhibit adenylyl 
cyclase through their Gi/o subunits and couple to the mitogen-activated protein kinase-extracellular-signal-
regulated kinase pathway through their Gβγ subunits.4-6 The CB1 receptor is highly expressed through the central 
nervous system including in the hippocampus, basal ganglia, cerebellum, brain stem, spinal cord, and dorsal 
root ganglia.7,8 In contrast, the CB2 receptor is highly expressed in the spleen and on immune cells including 
monocytes, macrophages, B-cells, and T-cells.9,10  
 A primary therapeutic effect of endocannabinoids is analgesia. Activation of CB1 receptors by 
endocannabinoids regulates analgesia through the modulation of neuronal transmission in the rostral ventral 
medulla, the periaqueductal grey, and the spinal trigeminal nucleus.11-13 Treatment of these areas with CB1 
antagonists leads to hyperalgesia in an opiod receptor-independent manner.14,15 Pain is generated by noxious 
stimuli from peripheral insults, which activate glutamatergic signaling and cause neuronal hyperexcitability in 
the dorsal horn of the spinal cord. Glutamatergic activation in the dorsal horn can further induce excitotoxicity 
and the production of inflammatory cytokines, such as IL-1β, which cause expression of cyclooxygenase-2 
(COX-2).14-18 Importantly, CB2 signaling is a critical mediator of cytokine release in immune cells.6 Thus, the 
cannabinoid receptors modulate the central response to peripheral pain and can mediate the generation of 
cytokines, which amplify of painful stimuli. The signaling cascade of pain demonstrates a connection between 
cannabinoid receptor signaling, analgesia, inflammation, and COX-2. 
 In addition to its production of prostaglandins (PGs) from arachidonic acid (AA), COX-2 also 
oxygenates and inactivates 2-AG to form prostaglandin glyceryl esters (PG-Gs) and AEA to form prostaglandin 
ethanolamides (PG-EAs).19,20 PGE2-G has been shown to cause potent Ca2+ mobilization in RAW264.7 
macrophages and H1819 non-small cell lung carcinoma cells.21,22 PGE2-G also induces hyperalgesia and 
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mechanical allodynia in rats.23 Therefore, the oxygenation of 2-AG by COX-2 not only terminates analgesic 
endocannabinoid signaling, but also generates a series of nociceptive metabolites. 
 Although COX-2 oxygenates AEA and 2-AG, under physiological conditions both AEA and 2-AG are 
primarily regulated through their hydrolysis to AA. AEA is primarily degraded by the enzyme fatty acid amide 
hydrolase (FAAH) to form AA and ethanolamine.24-26 2-AG is hydrolyzed to AA and glycerol by several 
enzymes including monoacylglycerol lipase (MAGL), α/β-hydrolase domain 6 (ABHD6), α/β-hydrolase domain 
12  (ABHD12), carboxylesterases 1 and 2 (CES1 and CES2), and palmitoylprotein thioesterase 1 (PPT1).27-31 
While inhibition of these hydrolytic enzymes augments the levels of AEA or 2-AG in multiple settings, the 
impact of COX-2 inhibition on endocannabinoid levels in cellular systems has not been studied. 
 Two macrophage cell lines that synthesize PG-Gs have been identified, RAW 264.7 macrophages and 
resident peritoneal macrophages (RPMs).20,32-35 Interestingly, RPMs synthesize PG-Gs through the action of 
COX-1 despite previous studies identifying 2-AG as a poor substrate for COX-1 in vitro.34 To develop cellular 
assays for substrate-selective inhibition we focused first on RAW 264.7 macrophages due to their relative ease 
of use and extensive metabolomic profiling.  
 RAW 264.7 macrophages produce PG-Gs in response to overnight treatment with granulocyte 
macrophage colony-stimulating factor (GM-CSF) followed by lipopolysaccharide (LPS), interferon-γ (IFNγ), 
and ionomycin treatment the following day.32,33 Upon binding to its receptor on stem cells, GM-CSF induces 
differentiation into granulocytes (neutrophils, eosinophils, and basophils) and monocytes.36 LPS is a component 
of the outer membrane of gram-negative bacteria and consists of a lipid head group, a core oligosaccharide, and 
an O-antigen.37 LPS elicits a strong immune response in cells and animals through its binding and activation of 
toll-like receptor 4 (TLR4).38 IFNγ binds to a heterodimeric receptor consisting of two subunits, interferon 
gamma receptor 1 and 2, and activates the Janus kinase (JAK)-signal transducer and activator of transcription 
(STAT) pathway.39 Ionomycin is a calcium ionophore produced by Streptomyces conglobatus that robustly 
increases intracellular calcium and stimulates the production of IFN, perforin, interleukin-2, and interleukin-
4.40,41 Treatment of cells with these stimuli results in robust expression of COX-2 and the release of AA and 2-
AG, which are then converted to PGs and PG-Gs. 
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 In addition to characterizing RAW 264.7 macrophages, we sought to develop a model cell culture 
system containing neurons. To do this we utilized primary cultures of murine dorsal root ganglia (DRG). DRGs 
translate sensory information from the periphery into the dorsal horn of the spinal cord and consist of a mixture 
of both neurons and glia.42 We selected these cells because previous studies have determined that inflammatory 
stimuli induce COX-2 in DRGs, leading to hyperexcitability, hyperalgesia, and allodynia.14 Thus, DRGs may 
offer insights into the role of COX-2 in pain and inflammatory in vivo.   
Experimental Procedures 
Materials 
RAW 264.7 cells were obtained from American type culture collection (Rockville, MD). Cell culture reagents 
were purchased from Life Technologies (Gaithersburg, MD). PGE2-G, PGF2α-G, PGE2-d4, AA-d8, AEA-d8, and 
2-AG-d8 were purchased from Cayman Chemical (Ann Arbor, MI). LPS, ionomycin, and IFNγ were purchased 
from Sigma Aldrich (Milwaukee, WI). PGE2-G-d5 was synthesized as described previously using chemicals 
from Sigma Aldrich.20 Inhibitors were purchased from Sigma Aldrich and Cayman Chemical or synthesized as 
previously outlined.43,44 GM-CSF was purchased from R&D Systems (Minneapolis, MN). 
Inhibition of PG-G formation in RAW 264.7 macrophages  
Low passage (< 15) RAW 264.7 macrophages were plated onto 100 mM dishes at 3 x 106 cells per dish in 6 mL 
of DMEM containing 10% fetal bovine serum and 20 ng/mL GM-CSF. After a 22-hour incubation the media 
was removed and replaced with 6 mL of serum-free DMEM containing 1 µg/mL LPS and 20 units/mL IFNγ. At 
this point vehicle (DMSO) or inhibitors were added to the media. After 6 hours of stimulation the cells were 
treated with 2 µM ionomycin for 1 additional hour. After 7 total hours of stimulation the media was removed 
and extracted in 2 volumes of ethyl acetate containing 0.1% glacial acetic acid, PGE2-G-d5, and PGE2-d4. The 
cells were then scraped into 2 mL of methanol containing AA-d8 and 2-AG-d8 and added to the ethyl acetate 
solution. The extraction mixture was then vigorously mixed and placed in a -20°C refrigerator overnight. The 
next day the organic layer was removed and dried under a stream of nitrogen gas. The resulting film was 
reconstituted in 200 µL of 1:1 water:methanol and subjected to liquid chromatography/mass spectrometry 
(LC/MS) analysis.  
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Isolation of embryonic dorsal root ganglia  
DRGs were harvested as previously described.45 Briefly, pregnant (E14-15) mice were euthanized by CO2 
asyphyxiation. Embryos were then removed and the entire spinal column and DRGs were collected. The DRGs 
were washed in PBS and dissociated by incubation in 0.001% collagenase/DNase and 0.15% trypsin at 37°C for 
one hour. 80,000 cells were then plated onto acid-treated, collagen-coated coverslips in 35 mm dishes and 
incubated in 3 mL of UltraCulture Media (10% Hyclone fetal bovine serum, 1 mM L-glutamine, 1% penicillin-
streptomycin, and 50 ng/mL of nerve growth factor). Cells were cultured at 37°C and 5% CO2. 
Generation of pure neuronal dorsal root ganglia cultures 
Following the isolation of DRGs described above, cultures were allowed to acclimatize for 48 hours at 37°C 
and 5% CO2. Cells were then treated with 5 µM arabinoside (AraC) for 7 days. After 7 days the media was 
removed, the cells were washed once with PBS, and incubated with fresh media.   
DRG culture stimulation and inhibition 
After culturing the DRGs for 3-5 days the media was removed and replaced with media containing 20 ng/mL 
GM-CSF. Following a 22-hour incubation the media was then removed and replaced with fresh serum-free 
media containing LPS (1 µg/mL), IFNγ (20 units/mL), and 10 µM 15(S)-hydroxy-5,8,11,13-eicosatetraenoic 
acid for 6 hours. Inhibitors or vehicle (DMSO) were added concurrently with the media replacement. Following 
the 6-hour incubation, 2 µM ionomycin was added for 1 hour, after which the media and cells were harvested 
and extracted as described above for RAW 264.7 macrophages.     
Immunoblotting analysis of COX-2 in DRGs  
Unstimulated or stimulated cells were scraped into lysis buffer and immunoblotted for COX-2 expression as 
previously described with minor modifications.46 Cells were lysed in 200 µl M-PER lysis buffer containing 
mammalian protease inhibitors and phosphatase inhibitor mixtures I and II. Cell lysates were mixed by 
vortexing and placed on ice for 30 min. Cellular debris were then removed by centrifugation for 10 min at 
16,000 g. Samples were stored at -80°C until analyses. Equal quantities of protein (~20 µg) were resolved by 
gradient (2-12%) SDS-Polyacrylamide gel electrophoresis (SDS-PAGE) and transferred onto a polyvinylidene 
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difluoride membrane. Membranes were blocked (20 mM Tris, pH 7.6, 140 mM NaCl, 0.05% Tween 20, 5% 
nonfat dry milk) prior to incubation with antibodies. Primary antibodies were used at a 1:1000 dilution and the 
secondary antibody at a 1:5000 dilution. 
Staining for COX-2 in stimulated DRGs  
DRGs were stimulated as described above and imaged for COX-2 using Fluorocoxib A as described 
previously.47 
Mass spectrometry analysis  
Samples were analyzed for eicosanoids and endocannabinoids as previously described.48-51 
Results 
Inhibition of PG-G formation in RAW 264.7 macrophages  
 We sought to develop a cellular system in which we could analyze substrate-selective inhibitors in a 
biological setting after in vitro analyses. To do this we first utilized stimulated RAW 264.7 macrophages, which 
produce both PGs and PG-Gs under the stimulation conditions outlined in the experimental methods. RAW 
264.7 macrophages are easily cultured and the effects of inflammatory stimuli treatments on PG and PG-G 
production have been extensively characterized on a metabolic level.52-55  
 We analyzed the effects of substrate-selective inhibitors on PG and PG-G levels in stimulated RAW 
264.7 macrophages. As with in vitro experiments, we found that substrate-selective inhibitors decreased the 
production of PG-Gs without having significant inhibition of PGs. For example, the non-substrate-selective 
inhibitor (S)-flurbiprofen inhibits the production of both PGs and PG-Gs with comparable IC50 values, while the 
substrate-selective inhibitor (R)-flurbiprofen retains inhibition of PG-Gs but does not inhibit PG production 
(Figure 1). These data reveal that substrate-selective inhibition occurs not only in vitro, but also in cellular 
systems with endogenous substrate pools and stimulated COX-2 expression. 
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Figure 1: Inhibition of PGs and PG-Gs in stimulated RAW 264.7 cells by (S)- and (R)-flurbiprofen. (S)-
flurbiprofen inhibits the production of both PGs and PG-Gs with comparable IC50 values, while (R)-flurbiprofen 
acts as a substrate-selective inhibitor with minimal inhibition of PGs and full inhibition of PG-G production. 
Data shown are mean ± s.e.m., n = 6.    
 
 In addition to monitoring PG and PG-G production, we also sought to determine if inhibition of COX-2 
modulates the levels of AA and 2-AG in stimulated RAW 264.7 cells. Both (S)-flurbiprofen and (R)-
flurbiprofen increased 2-AG in a concentration-dependent manner, with similar values for both PG-G inhibition 
and increasing 2-AG (Figure 2). While (S)-flurbiprofen also increased AA levels, (R)-flurbiprofen did not. 
These results demonstrate that inhibition of COX-2 not only decreases PGs and PG-Gs, it also increases the 
levels of AA and 2-AG. This is an important discovery because 2-AG counteracts the deleterious effects of PG-
Gs through its activation of the cannabinoid receptors. Thus, as oxygenation of 2-AG to PG-Gs results in 
hyperalgesia and the production of potent calcium mobilizers, substrate-selective inhibition of COX-2 
represents a potential therapeutic treatment for neuropathic pain and inflammation. 
 
Figure 2: Effects of (S)- and (R)-flurbiprofen on the levels of 2-AG and AA in RAW 264.7 cells. (S)-
flurbiprofen increases both 2-AG and AA, while (R)-flurbiprofen selectively increases 2-AG levels. Data shown 
are mean ± s.e.m., n = 6.    
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Evaluation of novel substrate-selective inhibitors in RAW 264.7 cells  
 Although (R)-flurbiprofen is a valuable substrate-selective inhibitor in vitro and ex vivo, it undergoes a 
unidirectional isomerization in mice (but to a lesser extent in rats, humans, or monkeys) to the non-substrate-
selective inhibitor (S)-flurbiprofen, rendering it unsuitable for preclinical studies in mice.56 To surmount this 
chiral inversion, Matt Windsor synthesized a series of achiral profen analogs and assessed them for in vitro 
substrate-selective inhibition (Figure 3).43 These studies identified a series of achiral profens that displayed 
substrate-selective inhibition against purified COX-2.  
 
Figure 3: Inhibition of COX-2-mediated 2-AG and AA oxygenation by achiral profen derivatives. The 
IC50 values were determined by incubating five concentrations of inhibitor and a DMSO control with purified 
murine COX-2 (40 nM) for 3 minutes followed by addition of 2-AG or AA (5 µM) at 37°C for 30 seconds. 
Dashes indicate <50% inhibition of 2-AG oxygenation at 10 µM inhibitor. Numbers in parentheses indicate 
maximal inhibition at 10 µM inhibitor. Percent inhibition of AA oxygenation reported as measured at 10 µM 
inhibitor. Values are mean ± s.d. (n = 6). Reproduced from.43 
  
 To further assess the potential of these achiral profen derivatives to serve as substrate-selective 
inhibitors we analyzed the effects of des-methyl-flurbiprofen, dimethyl-flurbiprofen, and cyclopropyl-
flurbiprofen in stimulated RAW 264.7 cells. While each inhibitor displayed substrate-selective inhibition in 
vitro, in the RAW 264.7 cells they had significantly reduced potency and were less selective for 2-AG 
inhibition than the in vitro assay and (R)-flurbiprofen (Figure 4). These studies suggest that achiral analogs of 
	   72	  
the profens could serve as substrate-selective inhibitors, although their performance in cellular systems is not as 
robust as (R)-flurbiprofen. 
 
Figure 4: Inhibition of PG and PG-G production in stimulated RAW 264.7 cells by achiral profen 
analogs. All three inhibitors display substrate-selective inhibition, albeit with some inhibition of PG production 
and reduced potency relative to in vitro assays. Data shown are mean ± s.e.m., n = 6.    
 
Optimization of DRG cultures for PG-G and PG-EA production  
 Although RAW 264.7 cells are a robust model system for studying substrate-selective inhibition of 2-
AG, they have very little AEA and do not produce detectable amounts of PG-EAs. As an alternative cell culture 
system, we utilized primary embryonic murine DRGs. This culture system consists of a combination of neurons 
and glia and initial studies revealed that treatment of DRG cultures with IFNγ and Il-1β, two cytokines that 
upregulate COX-2 expression physiologically, caused robust stimulation of COX-2 expression (Figure 5).57,58 
Thus, these primary DRG cultures respond to physiological inflammatory stimuli by expressing COX-2. 
 
 
Figure 5: Stimulation of COX-2 expression in DRG cultures treated with IFNγ  and IL-1β . Western blot 
analyses identify a robust stimulation of COX-2 expression upon treatment of DRGs with either IFNγ or IL-1β. 
Experiment performed by Joel Musee. 
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 To optimize the production of PGs and PG-Gs in DRGs we surveyed a series of stimulation paradigms. 
Treatment of cultures with GM-CSF overnight followed by LPS stimulation the following morning for 6 hours 
resulted in a robust production of PGs, but PG-Gs were not detected (Figure 6). Treatment of cultures with a 
combination of LPS and IFNγ resulted in a small amount of PG-G production. Treatment with 12-O-
tetradecanoylphorbol-13-acetate (TPA), an activator of protein kinase c, did not result in the production of PG-
Gs. However, treatment of cultures with a combination of LPS, IFNγ, and the calcium ionophore ionomycin 
resulted in robust production of PG-Gs. These studies were in agreement with studies by Joel Musee, which 
demonstrated that while PGs were produced by IFNγ or Il-1β treatment, the production of PG-Gs only occurred 
when stimulation was followed by ionomycin treatment. Although ionomycin was required to stimulate PG-G 
production, it did not produce PG-Gs without prior stimulation by IFNγ or Il-1β. This suggests that PG-G 
production in DRGs requires the stimulation of COX-2 expression by LPS and IFNγ and the levels of PG-Gs 
can be increased by subsequent stimulation of 2-AG production by ionomycin-mediated calcium influx. 
 
Figure 6: Production of PGs and PG-Gs in stimulated DRGs. While DRGs produce PGs in response to 
multiple stimulation conditions, PG-Gs are produced only by a combination of LPS and IFNγ. Treatment of 
cells stimulated by LPS and IFNγ with ionomycin results in a robust production of PG-Gs. Data shown are 
mean ± s.e.m., n = 6.  
 
 Further optimization of the stimulation conditions identified 15(S)-hydroxy-5,8,11,13-eicosatetraenoic 
acid (15(S)-HETE) as a potent inducer of not only PG-G, but also PG-EA production in DRGs. Treatment of 
DRGs with LPS, IFNγ, and 15(S)-HETE followed by ionomycin lead to a strong induction of COX-2 but did 
not alter the expression of COX-1, MAGL, ABHD6, or FAAH (Figure 7). Additionally, these stimulation 
conditions lead to the production of PGs, PG-Gs, and PG-EAs (Figure 8). To validate the identification of PG-G 
and PG-EA production we utilized MS/MS fragmentation to compare the fragmentation spectra from stimulated 
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DRGs to synthetic standards (Figure 9). The production of PG-Gs and PG-EAs in DRGs is notable as this is the 
first example of these products being produced in neuronal cells in response to endogenously generated 2-AG 
and AEA. Thus, we identified stimulation conditions that lead to the production of PGs, PG-Gs, and PG-EAs in 
DRGs. 
 
Figure 7: Expression of endocannabinoid metabolizing enzymes in basal and stimulated DRGs. While 
COX-2 expression is increased in stimulated cells, the expression of COX-1, FAAH, MAGL, and ABHD6 are 
unchanged. Reproduced from.59 
 
 
Figure 8: Representative LC-MS/MS chromatogram from stimulated DRGs detecting PGs, PG-EAs, and 
PG-Gs. Stimulation of DRGs with GM-CSF, LPS, IFNγ, 15(S)-HETE, and ionomycin leads to the production 
of PGs, PG-EAs, and PG-Gs. Reproduced from.59 
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Figure 9: MS/MS spectra of PGE2-EA and PGF2α-EA. Validation of the identification of PGE2-EA and 
PGF2α-EA generated by DRGs by matching MS/MS fragmentation patterns with synthetic standards of PGE2-
EA and PGF2α-EA. Reproduced from.59 
 
 We next analyzed the ability of pure neuronal DRG cultures and pure glial DRG cultures to produce 
PGs, PG-Gs, and PG-EAs in response to stimulation. Pure neuronal DRG cultures were generated by treating 
DRG cultures with 5 µM arabinoside for 7 days and pure glial DRG cultures were generated by culturing the 
DRGs in media lacking NGF. Stimulation of DRG cultures containing both neurons and glia resulted in the 
production of PGs, PG-Gs, and PG-EAs (Figure 10). However, stimulation of DRG cultures containing only 
glia or only neurons resulting in a significant blunting of the production of PGs, PG-Gs, and PG-EAs. This 
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suggests that the stimulation of COX-2 expression, release of substrates, and production of PG products 
requires both neurons and glia.  
    
Figure 10: Production of PGs, PG-Gs, and PG-EAs in DRG cultures containing neurons and glia, only 
glia, and only neurons. While cultures containing both neurons and glia produced PGs, PG-Gs, and PG-EAs, 
cultures containing only glia or only neurons did not display robust production after stimulation. Values shown 
are mean ± s.e.m., n = 3.  
 
 To further explore the roles of glia and neurons in the production of PGs, PG-Gs, and PG-EAs we 
sought to determine the localization of COX-2 after stimulation. To do this we utilized Fluorocoxib A, a COX-2 
selective inhibitor conjugated to a fluorescent tag.47 We stimulated DRG cultures and then incubated them with 
Fluruocoxib A to visualize COX-2, TuJ1 to visualize neurons, and DAPI to visualize cell nuclei (Figure 11). 
Surprisingly, COX-2 was localized mainly in neurons as evidenced by a co-localization of Fluorocoxib A 
staining with TuJ1 fluorescence. This suggests that although both neurons and glia are required for the 
production of PGs, PG-Gs, and PG-EAs, the site of biosynthesis by COX-2 is in neurons. The role that glia play 
in the production of PGs, PG-Gs, and PG-EAs is essential, but COX-2 is clearly not expressed in glial cells to 
the extent that it is expressed in neurons. 
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Figure 11: Fluorescent labeling of neurons, glia, and COX-2 in stimulated DRG cultures. COX-2 
expression was labeled using Fluorocoxib A (red), neurons were labeled with TuJ1 (green), and cell nuclei were 
labeled with DAPI (blue).    
 
Assessment of substrate-selective inhibitors in DRG cultures  
 After optimizing the stimulation conditions that produce PGs, PG-Gs, and PG-EAs in DRGs we sought 
to determine the effects of the (R)-profens on DRGs. As discussed in chapter II and above, the (R)-profens are 
substrate-selective inhibitors of COX-2 in vitro. In agreement with the in vitro data, (R)-flurbiprofen, (R)-
naproxen, and (R)-ibuprofen all display a concentration-dependent decrease in the production of PG-Gs and 
PG-EAs in DRGs while not inhibiting PG production (Figure 12). Thus, the (R)-profens retain substrate-
selective inhibition in a cellular setting.  
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Figure 12: Substrate-selective inhibition by (R)-profens in stimulated DRGs. The (R)-profens decrease the 
production of PG-Gs (dashed lines) and PG-EAs (dotted lines) but do not inhibit PG formation (solid lines) in 
DRGs. Data shown are mean ± s.e.m., n = 6. Reproduced from.59 
 
 To determine if substrate-selective COX-2 inhibition also modulates endocannabinoid levels in DRGs, 
as it modulates 2-AG levels in RAW 264.7 cells, we also measured the levels of AA, AEA, and 2-AG upon 
treatment of basal and stimulated DRGs with the (R)-profens. The (R)-profens had no significant effect on AA, 
AEA, or 2-AG in basal DRGs (Figure 13). However, in stimulated DRGs all three (R)-profens increased the 
levels of AEA and 2-AG in a concentration-dependent manner while having no significant effect on AA. Thus, 
the (R)-profens modulate the levels of not only PG-EAs and PG-Gs through substrate-selective COX-2 
inhibition, but also the levels of the endocannabinoids AEA and 2-AG. The effects of the (R)-profens on AEA 
and 2-AG are dependent upon the stimulation of COX-2 expression in DRGs, implicating COX-2 as a mediator 
of endocannabinoid tone under inflammatory settings in primary neuronal cultures. These studies identify 
DRGs as a novel cellular model for studying substrate-selective inhibition and elucidate a novel function of 
COX-2. 
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Figure 13: Comparison of the effects of the (R)-profens on AEA, 2-AG, and AA concentrations in basal 
and stimulated DRGs. The (R)-profens significantly increase the levels of AEA (blue) and 2-AG (red), but not 
AA (white), in stimulated DRGs in a concentration-dependent manner. In contrast, the (R)-profens have no 
significant effect on any of the analytes in basal DRGs. Data shown are mean ± s.e.m., n = 6.  
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Discussion 
 
 COX-2 oxygenation of 2-AG and AEA leads to the degradation of analgesic and anti-inflammatory 
lipids. The oxidative products of 2-AG and AEA, PG-Gs and PG-EAs, have a range of biological activities 
including calcium mobilization, hyperalgesia, and regulation of synaptic signaling, among others.21,23,60,61 While 
the receptors that mediate these effects have not been identified, they are distinct from classical PG and 
cannabinoid receptors.21,62 Thus, oxygenation of endocannabinoids by COX-2 degrades a series of 
antinociceptive lipids and generates a series of nociceptive lipid signaling molecules. This implicates COX-2 
oxygenation of AEA and 2-AG in the pathology of neuropathic pain and suggests that inhibition of COX-2 
could have therapeutic effects. 
 While NSAIDs have already been extensively validated as analgesic and anti-inflammatory in multiple 
settings, including neuropathic pain, substrate-selective inhibition represents a novel approach to COX-2 
inhibition. While under normal conditions the levels of AEA are regulated by FAAH and the levels of 2-AG are 
regulated by MAGL, the stimulation-dependent effects of the (R)-profens on endocannabinoid levels suggests 
that COX-2 regulates endocannabinoids in a state-dependent manner. The augmentation of AEA and 2-AG and 
inhibition of PG-G and PG-EA synthesis produced by the (R)-profens in stimulated DRGs suggests that they 
may also have analgesic and anti-inflammatory effects in neuropathic pain. These effects may be mediated by 
multiple mechanisms including increased cannabinoid receptor signaling mediated by an increase 
endocannabinoid levels or a reduction in pro-inflammatory and nociceptive PG-Gs and/or PG-EAs. Indeed, 
previous reports have already identified (R)-flurbiprofen as having endocannabinoid-mediated therapeutic 
effects in neuropathic pain models.63-65 
 Substrate-selective COX-2 inhibitors are also important tools to test the biological functions of PG-Gs 
and PG-EAs without confounding PG inhibition. These studies identify the (R)-profens as robust substrate-
selective inhibitors not only in vitro, but also in cellular systems. The complete lack of PG inhibition exhibited 
by the (R)-profens makes them valuable probes for identifying the contributions of COX-2 to cellular 
physiology or pathophysiology by uncoupling COX-2-mediated endocannabinoid oxygenation from AA 
oxygenation.   
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 Many studies have identified increases in COX-2 in the peripheral and central nervous system after 
injury and inflammation.14,57,66 These studies suggest that elevation of COX-2 in the peripheral or central 
nervous system may lead to the depletion of AEA and 2-AG and contribute to the development and progression 
of neuropathic pain. Thus, substrate-selective inhibition of COX-2 by (R)-profens could reverse this depletion 
of endocannabinoids and produce analgesic effects not only from removing hyperalgesic products such as 
PGE2-G, but also augmenting the pro-analgesic endocannabinoids. The hypothesis that substrate-selective 
inhibition of COX-2 can increase endocannabinoid tone and produce therapeutic effects is supported by the 
blockade of the analgesic effects of (R)-flurbiprofen by CB1 receptor antagonists.63 
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CHAPTER IV 
DEVELOPMENT AND CHARACTERIZATION OF IN VIVO  
SUBSTRATE-SELECTIVE INHIBITORS 
 
Introduction 
 Two decades of intense scientific inquiry have defined a prominent role for central endogenous 
cannabinoid (eCB) signaling in a variety of physiological and pathophysiological processes.1,2 eCBs are 
arachidonate-containing lipid signaling molecules that exert biological actions via activation of cannabinoid 
type 1 and 2 receptors (CB1 and CB2), in addition to other targets including vanilloid receptor 1 (TRPV1), 
peroxisome proliferator-activated receptor (PPAR), and some ion channels.1 The two most well studied eCBs, 
anandamide (AEA) and 2-arachidonoylglycerol (2-AG), are synthesized and degraded by discrete sets of 
enzymes.3-5 Elucidation of the molecular regulation of eCB metabolism has led to the development of 
pharmacological tools to enhance eCB signaling and probe the therapeutic utility of eCB augmentation for a 
variety of pathological conditions.6-8 
 In the brain AEA is primarily degraded by fatty acid amide hydrolase (FAAH) to ethanolamine and 
arachidonic acid (AA), and pharmacological inhibition of FAAH causes robust increases in brain AEA 
levels.9,10 However, FAAH also degrades a number of non-cannabinoid N-acylethanolamides (NAEs), which 
are elevated upon FAAH inhibition and active at molecular targets such as PPARs.11-13 Similarly, 2-AG is 
primarily degraded to AA and glycerol by monoacylglycerol lipase (MAGL), which also metabolizes a series of 
monoacylglycerols (MAGs).14 Inhibition of FAAH or MAGL has demonstrated preclinical efficacy in models 
of neuropathic pain, neurodegeneration, anxiety and depression, pain, hyperemesis, and drug withdrawal 
syndromes, many of which are mediated by CB receptor-dependent mechanisms.6,8,15-18 These studies 
demonstrate the pleiotropic therapeutic potential of eCB augmentation via FAAH and MAGL inhibition and the 
resulting modulation of cannabinoid receptor signaling.  
 In addition to FAAH and MAGL, a connection between COX-2 action and eCB inactivation has been 
suggested by a series of converging data. Inhibition of COX-2 potentiates retrograde eCB synaptic signaling in 
the hippocampus and decreases excitatory responses in a CB1-dependent manner, revealing a functional tie 
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between COX-2 activity and eCB tone at central synapses.19,20 NSAIDs inhibit the metabolism of AEA by rat 
cerebellar membrane preparations and extend the stability of exogenous AEA in mouse brain, suggesting that 
COX-2 directly metabolizes AEA in vivo.21,22 COX-2 is constitutively expressed in the spinal cord and mediates 
tissue injury-induced hyperalgesia.23 The NSAIDs indomethacin and nimesulide produce eCB-mediated spinal 
antinociception as evidenced by blockade of antinociceptive effects by the CB1 receptor antagonist AM251.24,25 
The peripheral antinociceptive effects of AEA and NSAIDs are synergistic and ibuprofen interacts with AEA in 
both acute and inflammatory pain models.26,27 COX-2 selective inhibitors, but not COX-1 selective inhibitors, 
also reverse spinal hyperexcitability in a CB1 receptor-dependent manner and reduce the breakdown of 2-AG.28 
These studies indicate that COX-2 plays a fundamental role as an eCB-inactivating enzyme in multiple settings 
and across a series of tissues.  
 Direct evidence of COX-2 as an eCB metabolizing enzyme has also been published. In addition to the 
oxygenation of AA, COX-2 also catalyzes the oxygenation of AEA and 2-AG to form prostaglandin 
ethanolamides (PG-EAs) and prostaglandin glyceryl esters (PG-Gs), respectively.29,30 While PGH2 is converted 
to PGE2, PGD2, PGF2α, PGI2, and TxA2 by downstream synthases, PGH2-EA and PGH2-G are not good 
substrates for thromboxane synthase; thus, they each only form four of the five downstream products.31 The 
production of PG-EAs has been demonstrated in several settings including in FAAH knockout mice treated with 
AEA, lipopolysaccharide-stimulated mouse dorsal root ganglia cultures, mouse renal medulla, rat spinal cord, 
and in mouse adipocytes.32-36 PG-Gs have been detected in rat paws and multiple stimulated macrophage cell 
lines including RAW 264.7 cells, resident peritoneal macrophages, and J774 macrophages.37-39 Several studies 
have demonstrated that PG-Gs are unstable due to enzymatic hydrolysis to PGs, which may account for the 
fewer reports of their formation in vivo compared to PG-EAs.40-42  
 While the two subunits of COX-2 are sequence homodimers, the heme prosthetic group binds to only a 
single monomer, creating functional heterodimers. The heme-containing subunit is the catalytic subunit, 
whereas the non-heme-containing subunit is the allosteric subunit.43,44 Binding of substrates, activators, and 
inhibitors to the allosteric subunit alters binding in the catalytic subunit through subunit communication via the 
dimer interface.45 COX-2 inhibitors bind in one of two kinetic modes, rapid-reversible or slow-tight binding. 
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Compounds that are rapid-reversible inhibitors of COX-2 inhibit eCB oxygenation at concentrations that are 
orders of magnitude lower than the concentrations required for inhibition of AA oxygenation, a phenomenon 
termed substrate-selective COX-2 inhibition.46 Substrate-selective inhibitors bind in the allosteric subunit and 
induce a conformational change that blocks eCB oxidation in the catalytic subunit. Binding of a second 
inhibitor molecule in the catalytic subunit blocks AA oxygenation, but this typically occurs at inhibitor 
concentrations orders of magnitude higher than the concentrations that block eCB oxygenation.46 Slow, tight-
binding inhibitors bind in the catalytic subunit and block the oxygenation of all substrates at similar 
concentrations.47,48  
 Substrate-selective COX-2 inhibition represents a novel pharmacological approach to COX-2 inhibition 
by inhibiting the oxygenation of 2-AG and AEA but not AA.33,46,49 Substrate-selective inhibition has been 
utilized to identify novel functions of eCB-derived prostanoids including that PGD2-G exhibits anti-
inflammatory activity in isolated macrophages and in vivo and PGF2α-EA negatively regulates adipogenesis.36,39 
Here we sought to determine the effects of different modes of COX inhibition, including substrate-selective 
COX-2 inhibition, in vivo. 
Experimental Procedures 
Materials  
Indomethacin and (S)-flurbiprofen were purchased from Sigma Aldrich Chemical (St. Louis, MO). (R)-
flurbiprofen, NS-398, SC-560, JZL-184, PF-3845, URB597, PGE2–d4, AA-d8, 2-AG-d8, and AEA-d8 were 
purchased from Cayman Chemical (Ann Arbor, MI). Indomethacin analogs, including LM-4131, were 
synthesized as previously described.50  
In vitro enzyme purification and activity assays  
Wild-type, R120Q, and Y355F COX-2 were expressed in insect cells and purified as described previously.51 In 
vitro COX-2 inhibition assays were performed as previously described.33 The RAW 264.7 macrophage 
inhibition assay was performed as previously described.52 MAGL was purified using BL21(DE3) pLysS E. coli 
transformed with pET-45b(+) plasmid containing human MGL-His. Cells were grown at 37ºC to a density of 
0.7 OD and then protein expression induced with IPTG (1 mM). Cells were harvested 4 hr later and proteins 
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purified using Ni-NTA Agarose (Qiagen) as previously described.53 After purification, the protein was dialyzed 
overnight at 4ºC into buffer containing 10 mM HEPES and 0.01% TritonX-100. MAGL inhibition was assessed 
as previously described.53 Humanized rat FAAH was a generous gift of R. Stevens and B. Cravatt (The Scripps 
Research Institute). FAAH inhibition was assessed as previously described.54 Human DAGLα in pcDNA3.1D 
was expressed in HEK293T cells for 24 hours then harvested and membranes prepared as described 
previously.55 DAGLα activity was assessed using 5µg of membrane protein in a 50 ul reaction of assay buffer 
containing 50 mM MES (pH 6.5) and 2.5 mM CaCl2. 1-steroyl-2-arachidonoyl glycerol (SAG) was added 
directly from a 100% methanol stock for a final concentration of 250 µM (5% final concentration of methanol 
in reaction). The reaction was terminated after 15 min by the addition of 200 µl methanol containing 125 pmol 
2-AG-d8. The samples were spun down at 2000 xg and the soluble material injected directly for LC/MS/MS 
analysis.  
Animals 
5-7 week old male ICR mice were used for all experiments with the exception of knockout animals (Harlan, 
Indianapolis, IN). Mice were housed 5 per cage. All behavioral tests were conducted during the light cycle 
between 0900 and 1700. Knockout and wild-type littermate controls for FAAH–/– and COX-2–/– mice were 
derived from heterozygote breeding pairs, bred and genotyped as previously described.32,56 CB1–/– mice were 
bred from homozygote breeding pairs and genotyped as previously described.57 Mice were group-housed on a 
12:12 light-dark cycle (lights on at 06:00), with food and water available ad libitum. All animal studies were 
approved by the Vanderbilt Institutional Animal Care and Use Committee and conducted in accordance with the 
NIH Guide for the Care and Use of Laboratory animals.  
Tissue preparation and lipid extraction  
Mice were sacrificed by cervical dislocation and decapitation. The brain, lungs, liver, stomach, small intestines, 
heart, and kidneys were then rapidly removed and frozen on a metal block in dry ice. The tissue was then placed 
in a tube and stored at -80ºC until extraction, usually one day after harvesting. For PG and eCB analysis, lipid 
extraction from tissue was carried out as described previously.58 
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Open field test 
Animals were tested for open-field activity in a novel environment one hour after i.p. injection of compound  as 
previously described.59 Briefly, one-hour sessions were performed using automated experimental chambers 
(27.9×27.9 cm; MED-OFA-510; MED Associates, Georgia, VT) under constant illumination within a sound-
attenuated room. Analysis of open field activity was performed using Activity Monitor v5.10 (MED 
Associates).  
Light-dark box 
Anxiety responses were assessed in a plastic light-dark chamber measuring 20 x 20 cm. Half of the chamber is 
opaque with a black Plexiglas insert; the other half remains transparent. Photocells recorded the movement of 
the mice between compartments. Mice were placed individually into the dark compartment at the beginning of 
the session. Total time spent in the light and dark compartments, the number of light to dark transitions, and 
total distance travelled during the 20-minute session were measured.  
Elevated plus-maze  
EPM analyses were conducted using Any Maze tracking software as described previously.59  
Rectal temperature, catalepsy, and antinociception 
Mice were treated with either LM 4131 (10 mg/kg) or WIN-55,212-2 (10 mg/kg), or vehicle (DMSO) by i.p. 
injection. Every 15 minutes, the rectal temperature of the mice was taken using a lubricated rectal thermometer 
for a total of 1 hour post drug injection. To test catalepsy the hindpaws of the mice were rested on a table and 
the front paws of the mouse were placed on a metal ring attached to a stand elevated 16 cm above the table 
every 15 minutes. The time for the mouse to place its front paws on the table was recorded. For the hot plate 
antinociception test, mice were placed on a flat surface that was electrically-heated to 55°C within an open 
Plexiglas tube, which was cleaned in between testing each mouse with Vimoba, a chlorine dioxide solution. The 
latency of the mouse to respond by shaking, hindpaw licking, jumping, or tucking of the forepaws or hindpaws 
after placement on the hot plate apparatus was recorded.   
Novel object recognition  
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Mice were handled 4 days prior to training for at least 1 min per day. During pre-training, mice were placed in 
an open Plexiglas rectangular chamber for 10 minutes to sensitize the mice to the testing environment. Twenty-
four hours later, the mice were placed into the same rectangular chamber with two identical sample objects, 
yellow rubber ducks, for 10 minutes in order for the mice to become familiar with the objects. During training, 
the sample objects were placed in opposite corners in the back of the chamber 5 cm from each wall and secured 
by weight to the floor of the chamber. Twenty-four hours later, the mice were placed into the chamber again 
with one sample or familiar object and a novel object, a white leaf statue, for 5 min. During testing, the objects 
were placed in opposite corners in the back of the chamber 5 cm from each wall and secured by weight to the 
floor of the chamber. Two hours prior to testing, the mice were treated either with vehicle (DMSO) or LM-4131 
(10 mg/kg) by i.p. injection. To determine exploration time with the sample and novel objects, each mouse was 
timed when interacting, defined as when the nose of the mouse was in contact with the object or directed toward 
the object, within a 2 cm distance of the object of the sample or novel object. The time the mouse spent on top 
of the objects was not included in the exploration time analyses. In addition, a discrimination ratio (e.g., ratio of 
a mouse’s interaction with a novel object to that mouse’s total interaction with both sample and novel objects) 
was determined. If the discrimination ratio was above 0.5, it was considered that the mouse interacted more 
with the novel object than with the sample or familiar object.  
Mass spectrometry analysis 
Analytes were quantified using LC-MS/MS on a Quantum triple-quadrupole mass spectrometer in positive-ion 
mode using selected reaction monitoring. Detection of eicosanoids was performed as previously described.60 
For fatty acid analysis the mobile phases used were 80 µM AgOAc with 0.1% (v/v) acetic acid in H2O (solvent 
A) and 120 µM AgOAc with 0.1% (v/v) acetic acid in MeOH (solvent B). The analytes were eluted using a 
gradient from 20% A to 99% B over 5 minutes. The transitions used were m/z 300→282 for PEA, m/z 
328→310 for SEA, m/z 434→416 for OEA, m/z 456→438 for AEA, m/z 464→446 for AEA-d8, m/z 331→257 
for 2-PG, m/z 359→285 for 2-SG, m/z 463→389 for 2-OG, m/z 485→411 for 2-AG, m/z 493→419 for 2-AG-
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d8, m/z 519→409 for AA, and m/z 527→417 for AA-d8. Peak areas for the analytes were normalized to the 
appropriate internal standard and then normalized to tissue mass for in vivo samples.  
 
Statistical analysis 
Statistical analysis was performed using GraphPad Prism® Version 6.0c. For determining statistical 
significance between groups a two-tailed t-test, one-way ANOVA, or two-way ANOVA with a Sidak’s post-test 
analysis, or multiple t-tests with Holm-Sidak α correction for multiple comparisons was used throughout. F and 
P values shown correspond to the value obtained from the test used. Error bars represent S.E.M. throughout. N 
for each group represents number of mice, i.e. independent biological replicate. Mice were arbitrarily assigned 
to treatment group in a manner that resulted in approximately equal sample sizes per treatment group. Each 
treatment group was represented at least once per cage of mice.  
Results 
In vivo effects of (R)- and (S)-flurbiprofen  
 We first sought to determine the effects of (R)- and (S)-flurbiprofen on brain eCBs by injecting mice 
with 10 mg/kg i.p. of compound or vehicle (DMSO) and harvesting the brain 4 hours later. We also treated mice 
with 10 mg/kg of URB-597, a FAAH inhibitor, as a comparator.61 The brains were harvested and extracted and 
then analyzed for AA, 2-AG, AEA, and PGs. As expected, URB-597 significantly increased the levels of AEA 
while having no effect on 2-AG, AA, and PGs (Figure 1). Somewhat surprisingly, (R)-flurbiprofen and (S)-
flurbiprofen also significantly increased the levels of AEA. While (R)-flurbiprofen and (S)-flurbiprofen had no 
significant effect on 2-AG or AA, both molecules caused significant inhibition of PG production. These results 
suggest that while (R)-flurbiprofen acts as a substrate-selective inhibitor in vitro and in cellular settings, in mice 
it does not. A likely mechanism for this lack of substrate-selective inhibition in the brain is that previous reports 
have found that (R)-flurbiprofen undergoes a one-way isomerization to (S)-flurbiprofen in mice.62 Thus, (R)-
flurbiprofen is not a suitable substrate-selective inhibitor in mice despite its utility in vitro and in cellular 
studies. 
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Figure 1: Effects of (R)-flurbiprofen, (S)-flurbiprofen, and URB597 on brain eCBs and PGs. Mice were 
treated with compounds via i.p. injection and sacrificed 4 hours later. Brain levels of eCBs and PGs were then 
analyzed by mass spectrometry. Data shown are mean ± s.e.m., n = 16 for vehicle, (R)-flurbiprofen, URB597, 
and n = 8 for (S)-flurbiprofen.  
 
Development of novel in vivo substrate-selective inhibitors  
 Initial efforts to develop achiral profen analogs did not result in probes suitable for in vivo use, so we 
sought to develop substrate-selective inhibitors from alternative inhibitor scaffolds.63 To do this, we sought to 
understand the key molecular interactions required for substrate-selective inhibition. Based on the studies 
outlined in chapter II, we hypothesized that while ion pairing and hydrogen bonding with COX-2 are required 
for slow, tight binding inhibition, they may be less important for rapid, reversible inhibition.  
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 To test this hypothesis, we utilized the slow, tight binding inhibitor indomethacin, which binds to the 
constriction site of COX-2 via ion pairing and hydrogen bonding interactions with Arg-120 and Tyr-355.64 In 
accordance with previous reports, mutation of Arg-120 to Gln or Tyr-355 to Phe resulted in abrogation of AA 
inhibition by indomethacin (Figure 2). Surprisingly, indomethacin still potently inhibited eCB oxygenation by 
the mutant proteins. Thus, removal of an interaction between indomethacin and the COX-2 active site converts 
it from a slow, tight-binding inhibitor to a rapid, reversible inhibitor. 
 
Figure 2: Indomethacin inhibition of AA and 2-AG oxygenation by wild-type, R120Q, and Y355F COX-2. 
Indomethacin acts as a slow, tight binding inhibitor and inhibits AA and 2-AG oxygenation with comparable 
IC50 values with wild-type COX-2. However, R120Q and Y355F mutant COX-2 causes indomethacin to 
become a substrate-selective inhibitor. Data shown are mean ± s.e.m., n = 3. Reproduced from.49 
 
 To explore the generalizability of this phenomenon, we also analyzed the ability of the slow, tight 
binding inhibitor diclofenac to inhibit a series of COX-2 mutants. Diclofenac binds in an inverted conformation 
relative to indomethacin, forming hydrogen bonds between its carboxylate and Tyr-385 and Ser-530.65 While 
diclofenac inhibits the oxygenation of AA and 2-AG with comparable IC50 values in wild-type and R120Q 
COX-2, it acts as a substrate-selective inhibitor against S530A COX-2 (Figure 3). This suggests that, as with 
indomethacin, removal of an interaction between a slow, tight binding inhibitor and the enzyme converts it to a 
substrate-selective inhibitor. These studies indicate that substrate-selective inhibitors can be rationally designed 
by modifying the ability of slow, tight binders to interact with the active site of COX-2. 
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Figure 3: Inhibition of AA and 2-AG oxygenation by wild-type, S530A, and Y355F COX-2 by diclofenac. 
Diclofenac acts as a slow, tight binding inhibitor and inhibits AA and 2-AG oxygenation with comparable IC50 
values with wild-type and R120Q COX-2. However, in mutant S530A COX-2 diclofenac acts as a substrate-
selective inhibitor. Data shown are mean ± s.e.m., n = 3. 
 
 We sought to leverage the finding that removal of an interaction between a slow, tight binding inhibitor 
and COX-2 results in substrate-selective inhibition by synthesizing and screening a small library of tertiary 
amide derivatives of indomethacin. Modification of indomethacin to a tertiary amide results in molecules with a 
reduced capacity to ion-pair and hydrogen bond with Arg-120 and Tyr-355 at the constriction site. We screened 
the ability of these inhibitors to inhibit AA and 2-AG oxygenation by COX-2 and found that all of the tertiary 
amides of indomethacin exhibit substrate-selective inhibition (Table 1). In contrast, indomethacin, primary, and 
secondary amides of indomethacin are potent inhibitors of COX-2 oxygenation of both AA and 2-AG. This is in 
agreement with previous studies identifying primary and secondary amides of indomethacin as potent selective 
inhibitors of COX-2.50,64 These studies identify a facile method for developing substrate-selective inhibitors 
from slow, tight binding inhibitors by modulation of their ability to bind to the COX-2 active site.  
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Table 1: Inhibition of COX-2-mediated AA and 2-AG oxygenation by indomethacin and derivatives. 
While indomethacin and primary or secondary amides of indomethacin inhibit AA and 2-AG oxygenation, 
tertiary amides exhibit substrate-selective inhibition. Reproduced from.49 
 
 We selected LM-4131, the morpholino amide of indomethacin, as a candidate for further investigation. 
While indomethacin potently inhibits the COX-2-mediated oxygenation of AA, 2-AG, and AEA with similar 
potencies in vitro, LM-4131 selectively inhibited AEA and 2-AG oxygenation by COX-2 while displaying no 
inhibition of AA oxygenation (Figure 4). To further characterize LM-4131 we also analyzed its effects in 
stimulated RAW 264.7 cells. In stimulated RAW 264.7 cells LM-4131 selectively inhibited the production of 
PG-Gs with no apparent inhibition of PG production. As with (R)-flurbiprofen, LM-4131 also increased the 
levels of 2-AG but had no significant effect on AA levels in stimulated RAW 264.7 cells. These studies validate 
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LM-4131 as a substrate-selective inhibitor in vitro and in stimulated RAW 264.7 cells. 
 
Figure 4: In vitro and cellular validation of substrate-selective COX-2 inhibition by LM-4131. While 
indomethacin potently inhibits the oxygenation of AA, 2-AG, and AEA, LM-4131 selectively inhibits the 
oxygenation of 2-AG and AEA. LM-4131 inhibits the production of PG-Gs and increases the levels of 2-AG in 
stimulated RAW 264.7 macrophages. Data shown are mean ± s.e.m., n = 3. Reproduced from.49 
 
 To further assess the viability of LM-4131 to serve as an in vivo substrate-selective inhibitor we 
analyzed its ability to inhibit the eCB metabolizing enzymes FAAH and MAGL in vitro. LM-4131 did not 
display inhibition of FAAH, while the previously characterized FAAH inhibitors URB597 and PF-3845 did in 
parallel (Figure 5). Similarly, LM-4131 did not inhibit MAGL hydrolysis of 2-AG to AA, while the previously 
characterized MAGL inhibitor JZL-184 displayed potent inhibition. Additionally, LM-4131 did not inhibit 
DAGLα, the primary synthetic source of 2-AG in the brain, while the DAGL inhibitor THL displayed robust 
inhibition.66 Taken together, these in vitro and cellular studies validate LM-4131 as a substrate-selective COX-2 
inhibitor that is selective for COX-2 inhibition over other eCB-metabolizing enzymes. 
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Figure 5: Inhibition of eCB metabolizing and synthetic enzymes by LM-4131. LM-4131 does not display 
inhibition of FAAH, MAGL, or DAGL in vitro. In contrast, previously identified inhibitors display robust 
inhibition in parallel. Data shown are mean ± s.e.m., n = 3. Reproduced from.49 
 
Biochemical effects of COX inhibitors in vivo  
 Based on our preliminary finding that (R)- and (S)-flurbiprofen increase the levels of AEA in the brain 
we sought to assess the ability of LM-4131 to modulate eCB levels in the brain. LM-4131 was administered to 
male ICR mice via intraperitoneal injection and the mice were then sacrificed 2 hours after treatment. The 
brains were harvested and flash frozen on a metal block in dry ice then extracted and analyzed for eCBs, PGs, 
and AA levels by mass spectrometry. We first sought to determine the optimal dosing of LM-4131, by treating 
mice with vehicle, 0.3, 1, 3, and 10 mg/kg. LM-4131 significantly increased AEA levels at the 3 and 10 mg/kg 
doses with a non-significant trend to increase 2-AG at 10 mg/kg (Figure 6). Importantly, LM-4131 did not 
affect AA or PG levels at any of the doses tested. Thus, unlike (R)-flurbiprofen, LM-4131 appears to retain 
substrate-selective inhibition in vivo as it increases AEA but does not inhibit PG production in the brain. 
 
Figure 6: Dose-response of LM-4131 on brain eCBs, AA, and PGs. LM-4131 significantly increases AEA 
levels with a trending increase in 2-AG at higher doses. LM-4131 appears to retain substrate-selectivity as it 
does not modulate AA or PGs in the brain 2 hours after intraperitoneal injection. F and P values are shown for 
one-way ANOVA and P values for Dunnett’s post hoc analysis. Data shown are mean ± s.e.m., n = 11.  
Reproduced from.49  
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 To quantify the effects of LM-4131 treatment on brain eCBs, we conducted a meta-analysis of data 
obtained from 12 cohorts of mice, normalizing eCB levels in each mouse to mean eCB levels in the respective 
vehicle control group. This meta-analysis revealed that, on average, treatment with 10 mg/kg LM-4131 
significantly increased AEA levels to 139% of those observed when treated with vehicle and increased 2-AG 
levels to 109% of those observed when treated with vehicle (Figure 7). Thus, LM-4131 increases the levels of 
AEA and 2-AG, but appears to modulate AEA levels to a greater extent than 2-AG levels based on percent 
change. 
 
Figure 7: Meta-analysis of brain AEA and 2-AG levels after vehicle and LM-4131 treatment. LM-4131 
significantly increases the levels of both AEA and 2-AG relative to vehicle treatment. Data shown are mean ± 
s.e.m., vehicle n = 128 and LM-4131 n = 122. Reproduced from.49 
 
 We also analyzed brain extracts to determine if LM-4131 was present after treatment. We found that 
LM-4131 was present in the brain 2 hours after treatment (Figure 8). Importantly, LM-4131 was not converted 
to indomethacin during this 2 hour treatment. Thus, LM-4131 selectively increases eCB levels without affecting 
AA or PGs in the brain 2 hours after intraperitoneal injection and is not metabolized to indomethacin within this 
timeframe. Therefore, LM-4131 acts as an in vivo substrate-selective inhibitor at 2 hours after intraperitoneal 
injection. 
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Figure 8: Detection of LM-4131 in brain 2 hours after intraperitoneal injection. Representative detection 
of LM-4131 in brain extract by mass spectrometry. LM-4131 (bottom) was detected using SRM LC-MS/MS 
with a parent ion of 427.1 and a fragment ion of 139.1 at a CID of 25. Indomethacin (top) was not detected as 
measured by a parent ion of 357.9 and a fragment ion of 139.1 at a CID of 15. Reproduced from.49 
 
 To compare the in vivo profile of LM-4131 to other COX inhibition modes we determined the ability of 
indomethacin (10 mg/kg, a nonselective COX-1/COX-2 inhibitor and the parent compound of LM-4131), the 
COX-2 selective inhibitor NS-398 (10 mg/kg), and the COX-1 selective inhibitor SC-560 (10 mg/kg) to 
modulate eCB, AA, and PG levels in vivo. LM-4131, indomethacin, NS-398, and SC-560 all significantly 
increased AEA levels, whereas only LM-4131 and indomethacin significantly increased 2-AG levels (Figure 9). 
Importantly, while LM-4131 had no effect on AA levels, indomethacin, NS-398, and SC-560 all significantly 
increased AA levels. In addition, indomethacin, NS-398, and SC-560, but not LM-4131, decreased brain PG 
levels. These data indicate that the in vivo substrate-selective pharmacological profile of LM-4131 is unique and 
is not shared by traditional modes of COX inhibition. 
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Figure 9: Differential effects of COX inhibitors on eCB, AA, and PG levels. Substrate-selective inhibition 
by LM-4131 has a unique biochemical profile relative to other classes of COX inhibitors. While LM-4131 
significantly increases AEA and 2-AG, indomethacin, NS-398, and SC-560 significantly increase not only 
AEA, but also AA and significantly decrease PGs. Data shown are mean ± s.e.m., n values are shown on the 
bars. Reproduced from.49   
 
 We then sought to validate COX-2 as the in vivo molecular target of LM-4131. To do this we utilized 
Ptgs2–/– mice treated with vehicle or LM-4131 (10 mg/kg) compared to wild-type littermates treated with 
vehicle or LM-4131 (10 mg/kg). LM-4131 treatment significantly increased AEA and 2-AG levels in wild-type 
but not Ptgs2–/– littermates (Figure 10). Intriguingly, Ptgs2–/– mice had significantly higher brain AEA levels 
than their wild-type littermates in vehicle treated mice. LM-4131 retained the profile demonstrated in figures 6 
and 9, as it increased brain AEA and 2-AG but had no effect on AA or PG levels in either wild type or Ptgs2–/– 
mice. Thus, LM-4131 increases brain eCB levels via a COX-2-dependent mechanism. Additionally, COX-2 
regulates basal brain AEA levels in vivo. 
 
Figure 10: Effects of LM-4131 in COX-2 knockout and wild-type littermates. While LM-4131 significantly 
increases AEA and 2-AG in wild-type mice, it has no significant effect in COX-2 knockout littermates. Data 
shown are mean ± s.e.m., n values are shown on the bars. Reproduced from.49   
 
 
Ve
hic
le 
(L
M)
LM
-4
13
1
Ve
hic
le 
(in
do
)
Ind
om
eth
ac
in
Ve
hic
le 
(N
S)
NS
-3
98
Ve
hic
le 
(S
C)
SC
-5
60
50
75
100
125
150
A
E
A
 (%
 V
eh
ic
le
)
n
=
1
2
2
n
=
2
6
n
=
1
7
n
=
1
0
n
=
1
2
8
n
=
2
7
n
=
1
6
n
=
1
0
t(288)=7.5
p<0.0001
t(31)=3.7
p=0.0008
t(51)=7.8
p<0.0001
t(18)=3.2
p=0.0049
Ve
hic
le 
(L
M)
LM
-4
13
1
Ve
hic
le 
(in
do
)
Ind
om
eth
ac
in
Ve
hic
le 
(N
S)
NS
-3
98
Ve
hic
le 
(S
C)
SC
-5
60
50
75
100
125
150
2-
A
G
 (%
 V
eh
ic
le
)
n
=
1
2
2
n
=
2
5
n
=
1
7
n
=
1
0
n
=
1
2
8
n
=
2
6
n
=
1
6
n
=
1
0
t(51)=2.9
p=0.005
t(248)=3.9
p=0.0035
Ve
hic
le 
(L
M)
LM
-4
13
1
Ve
hic
le 
(in
do
)
Ind
om
eth
ac
in
Ve
hic
le 
(N
S)
NS
-3
98
Ve
hic
le 
(S
C)
SC
-5
60
75
100
125
A
A
 (%
 V
eh
ic
le
)
n
=
1
0
2
n
=
2
6
n
=
1
7
n
=
1
0
n
=
1
0
2
n
=
2
7
n
=
1
6
n
=
1
0
t(51)=4.1
p=0.0001
t(31)=3.0
p=0.0052
t(18)=3.9
p=0.001
Ve
hic
le 
(L
M)
LM
-4
13
1
Ve
hic
le 
(in
do
)
Ind
om
eth
ac
in
Ve
hic
le 
(N
S)
NS
-3
98
Ve
hic
le
SC
-5
60
0
25
50
75
100
125
P
G
s 
(%
 V
eh
ic
le
)
n
=
1
0
2
n
=
1
0
n
=
1
7
n
=
1
0
n
=
1
0
2
n
=
1
0
n
=
1
6
n
=
1
0
t(18)=6.6
p<0.0001
t(18)=8.9
p<0.0001
t(31)=7.2
p<0.0001
WT
 + 
Ve
h
WT
 + 
LM
-41
31
CO
X-
2 K
O 
+ V
eh
KO
 + 
LM
-41
31
50
100
150
200
250
A
E
A
 (%
 V
eh
ic
le
)
P = 0.0161
F (1, 48) = 6.229G X T int
n=
13
n=
13
n=
13
n=
13
p=0.0083
p<0.0001
WT
 + 
Ve
h
WT
 + 
LM
-41
31
CO
X-
2 K
O 
+ V
eh
KO
 + 
LM
-41
31
50
100
150
2-
A
G
 (%
 V
eh
ic
le
)
F (1, 48) = 6.289G X T int
P = 0.0156
n=
13
n=
13
n=
13
n=
13
p=0.035
WT
 + 
Ve
h
WT
 + 
LM
-41
31
CO
X-
2 K
O 
+ V
eh
KO
 + 
LM
-41
31
50
100
150
A
A
 (%
 V
eh
ic
le
)
F (1, 48) = 0.1943
P = 0.6613
G X T int
n=
13
n=
13
n=
13
n=
13
WT
 + 
Ve
h
WT
 + 
LM
-41
31
CO
X-
2 K
O 
+ V
eh
KO
 + 
LM
-41
31
0
50
100
150
P
G
s 
(%
 V
eh
ic
le
)
F (1, 44) = 0.2257
P = 0.6371
G X T int
n=
12
n=
12
n=
12
n=
12
	   102	  
 Although LM-4131 increases both AEA and 2-AG, the magnitude of effect is smaller than that elicited 
by either FAAH or MAGL inhibition, respectively. However, a major limitation of FAAH and MAGL 
inhibitors is their lack of selectivity to increase eCBs over related non-eCB lipids. FAAH inhibition increases 
AEA levels, but also increases N-acylethanolamides (NAEs; oleoylethanolamide (OEA), 
palmitoylethanolamide (PEA), and stearoylethanolamide (SEA)). Similarly, MAGL inhibition increases 2-AG 
levels, but also increases the levels of related monoacylglcyerols (MAGs; 2-oleoylglycerol (2-OG), 2-
palmitoylglycerol (2-PG), and 2-stearoylglycerol (2-SG)). Since COX-2 selectively oxygenates AA-containing 
lipids, we hypothesized that LM-4131 could be selective for increasing AEA and 2-AG levels over those of 
other NAEs and MAGs. We conducted targeted lipid profiling of NAEs and MAGs after LM-4131 treatment, 
and while LM-4131 significantly increased brain AEA levels, it did not increase the levels of other NAEs 
(Figure 11). In contrast, the FAAH inhibitor PF-3845 (10 m/kg) increases the levels of all NAEs, including 
AEA.67,68 Thus, LM-4131 selectively increases brain AEA levels over those of other NAEs. In addition to the 
lack of effect of LM-4131 on AEA in Ptgs2–/– mice, these studies further suggest that its mechanism of action is 
not via FAAH inhibition, as one would expect to see increases in the levels of other NAEs if this were the case. 
 
Figure 11: Effects of LM-4131 and the FAAH inhibitor PF-3845 on brain NAEs. LM-4131 significantly 
increases AEA but not other NAEs in the brain. In contrast, PF-3845 increases all NAEs in the brain. Data 
shown are mean ± s.e.m., n values are shown above the graphs. Reproduced from.49 
 
 To further exclude FAAH inhibition as contributing to the AEA-elevating effect of LM-4131, we 
analyzed the effects of LM-4131 co-treatment with PF-3845 compared to PF-3845 alone. Co-treatment of LM-
4131 and PF-3845 caused a significant additional increase in AEA levels compared to PF-3845 alone (Figure 
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12). We also analyzed the effects of LM-4131 in the liver, which has very high FAAH expression, compared to 
the effects of PF-3845. While LM-4131 had no significant effects on any NAE in the liver, PF-3845 caused 
substantial increases in the levels of all NAEs. We also analyzed the effects of LM-4131 on brain AEA levels in 
wild-type and Faah–/– littermates. LM-4131 caused similar increases in brain AEA levels in wild-type and 
Faah–/– mice. Finally, we also analyzed the effects of LM-4131 on NAEs in Ptgs2–/– mice. While both LM-4131 
and Ptgs2–/– mice had increased AEA levels relative to vehicle treated wild type mice, neither LM-4131 nor 
Ptgs2–/– mice had increased levels of other NAEs. Taken together with the lack of in vitro FAAH inhibition by 
LM-4131, these converging in vivo studies identify a unique COX-2-mediated mechanism of action for the 
increase in AEA levels elicited by LM-4131. 
 
Figure 12: Effects of LM-4131 on NAEs. LM-4131 increases the levels of AEA, but not other NAEs, in the 
brain when co-treated with the FAAH inhibitor PF-3845. LM-4131 has no effect in the liver, while PF-3845 
increases a series of NAEs. LM-4131 also increases the levels of AEA to a similar extent in both wild-type and 
Faah–/– mice. Ptgs2–/– mice have increased levels of AEA but not other NAEs in the brain. Data shown are 
mean ± s.e.m., n values are shown on the bars or above the graphs. Reproduced from.49   
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 We also sought to determine the differences between MAGL inhibition and substrate-selective COX-2 
inhibition by comparing the MAGL inhibitor JZL-184 to LM-4131. LM-4131 significantly increased brain 2-
AG levels but did not increase the levels of any other MAG (Figure 13). In contrast, the MAGL inhibitor JZL-
184 (40 mg/kg) increased the levels of 2-AG and three other MAGs. We further analyzed the effects of LM-
4131 by treating mice with JZL-184 alone or a combination of LM-4131 and JZL-184. Co-treatment of LM-
4131 and JZL-184 produced an additional significant increase in 2-AG levels over JZL-184 treatment alone. As 
with the FAAH experiments, these in vivo data combined with the fact that LM-4131 did not inhibit MAGL in 
vitro suggest that the ability of LM-4131 to increase 2-AG levels in the brain is not mediated via MAGL 
inhibition. 
 
Figure 13: Effects of LM-4131 and JZL-184 on brain MAGs. LM-4131 significantly increases 2-AG but not 
other MAGs, while JZL-184 increases a series of MAGs in the brain. Co-treatment of LM-4131 and JZL-184 
results in an increase in 2-AG relative to JZL-184 treatment alone. Data shown are mean ± s.e.m., n values are 
shown above the graphs. Reproduced from.49   
 
 As with FAAH and MAGL, COX-2 is expressed not only in the brain but several other tissues. We 
tested the effects of LM-4131 on eCB, NAE, MAG, and PG levels in a variety of peripheral tissues to determine 
if COX-2 modulates eCB levels in tissues other than the brain. LM-4131 (10 mg/kg) significantly increased 
AEA levels in the stomach, small intestine, kidney, and lung, but not in the heart or liver (Figure 14). As with 
the brain, LM-4131 did not affect the levels of any other NAE in any tissue. Although LM-4131 increased 2-
AG in the brain, it had no effect on 2-AG or any other MAG in any of the peripheral tissues examined. We also 
treated mice with vehicle, LM-4131, or indomethacin to compare the effects on PG levels in the same tissues. 
Indomethacin robustly decreased PG levels in all of the tissues examined, whereas LM-4131 had no significant 
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PG inhibition in any of the tissues analyzed. Thus, LM-4131 can augment AEA levels in both central and 
peripheral tissues and retains in vivo substrate-selectivity in peripheral tissues.  
 
Figure 14: Effects of LM-4131 in peripheral tissues. LM-4131 selectively increases AEA in the stomach, 
small intestine, kidney, and lung. LM-4131 had no significant effect on other NAEs or MAGs in any of the 
peripheral tissues analyzed. While indomethacin significantly decreased PG levels in all of the tissues analyzed, 
LM-4131 did not. Data shown are mean ± s.e.m., n = 17. Reproduced from.49    
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Behavioral effects of LM-4131  
 Previous studies have identified pharmacological inhibition of FAAH as a potential therapeutic approach 
to the treatment of mood and anxiety disorders.7,10 Preliminary work has shown that FAAH inhibitors are 
anxiolytic in the novel open-field arena.69 Consistent with this, we found that the FAAH inhibitor PF-3845 (10 
mg/kg) increased center distance travelled and center time in the open-field arena (Figure 15). The increase in 
brain AEA produced by LM-4131 suggests that it may also display behavioral effects in pre-clinical models of 
anxiety. Indeed, LM-4131 (10 mg/kg) also increased center distance traveled and center time in a parallel 
fashion to PF-3845. Thus, LM-4131 exhibits anxiolytic-like effects in a similar fashion to a FAAH inhibitor. 
 
Figure 15: Behavioral effects of PF-3845 and LM-4131 in the novel open-field arena. Both PF-3845 and 
LM-4131 increase center distance and center time compared to vehicle treated mice. Data shown are mean ± 
s.e.m., n values are shown in the graphs. Reproduced from.49    
 
 Based on the effects of LM-4131, we hypothesized that all COX inhibitors that increase brain AEA can 
act as anxiolytics. To examine this hypothesis, we tested the effects of indomethacin (10 mg/kg), NS-398 (10 
mg/kg), and SC-560 (10 mg/kg) in the open-field arena. Indomethacin and NS-398, which both significantly 
increased brain AEA levels, increased center distance and center time in the open-field arena, suggestive of an 
anxiolytic behavioral effect (Figure 16). However, SC-560, which increased AEA levels to a lesser extent than 
the other COX inhibitors, did not have any behavioral effects in the open-field arena. Thus, COX-2 inhibitors 
that increase brain AEA levels produce anxiolytic-like effects in a pre-clinical test of anxiety in a parallel 
fashion to FAAH inhibitors.  
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Figure 16: Effects of COX inhibitors in the open-field arena. While indomethacin and NS-398 increased 
center distance, indicative of anxiolytic-like effects, the COX-1 selective inhibitor SC-560 had no effect on 
either center distance or center time. Data shown are mean ± s.e.m., n = 10. Reproduced from.49    
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 To determine if the behavioral effects of LM-4131 are mediated by substrate-selective COX-2 
inhibition, we tested the behavioral effects of LM-4131 in Ptgs2–/– mice and their wild-type littermates. While 
LM-4131 produced anxiolytic-like effects in wild-type littermates, LM-4131 did not produce behavioral effects 
in Ptgs2–/– mice (Figure 17). This is consistent with the lack of AEA augmentation after LM-4131 
administration in Ptgs2–/– mice. Intriguingly, Ptgs2–/– mice also showed a slight anxiolytic phenotype relative to 
wild-type littermates based on an increased center time. Thus, the biochemical and behavioral effects of LM-
4131 are mediated by COX-2. 
 
Figure 17: Behavioral effects of LM-4131 in Ptgs2+/+ and Ptgs2–/– mice in the open-field arena. LM-4131 
increases center distance and time in wild-type littermates, but not Ptgs2–/– mice. Data shown are mean ± s.e.m., 
n = 8. Reproduced from.49    
 
 Previous studies have identified that the anxiolytic effects of FAAH inhibition are mediated via AEA 
activation of CB1 receptors.10,70 We sought to determine if the anxiolytic-like effects of LM-4131 in the open-
field arena are also mediated by increasing CB1 receptor activation through AEA augmentation. While exerting 
anxiolytic effect in vehicle-pretreated mice, LM-4131 had no significant behavioral effects in mice co-treated 
with the CB1 antagonist Rimonabant (3 mg/kg) (Figure 18). Furthermore, LM-4131 did not produce behavioral 
effects in CB1 receptor knockout mice (Cnr1–/–), despite increasing the levels of AEA and 2-AG in the knockout 
mice (Figure 19). Thus, the behavioral effects of LM-4131 are mediated via substrate-selective inhibition of 
COX-2, which selectively increases brain eCB levels, leading to increased activation of central CB1 receptors 
and anxiolytic behavioral effects.  
0 20 40 60
0
50
100
150
200
250
Time (min)
C
en
te
r d
is
ta
nc
e 
(c
m
)
LM-4131 (n = 8)
Vehicle (n = 8)
F (1, 168) = 31.77
P < 0.0001****
Drug
1–
20
 m
in
21
–4
0 m
in
41
–6
0 m
in
0
20
40
60
80
C
en
te
r t
im
e 
(s
)
F (2, 39) = 36.60
P < 0.0001
p = 0.0018
****
t(13) = 1.8
Drug
Ptgs2+/+
0 20 40 60
0
50
100
150
200
250
Time (min)
C
en
te
r D
is
ta
nc
e 
(c
m
)
Vehicle (n = 8)
LM-4131 (n = 8)
F (1, 168) = 2.441
P = 0.1201 NS
Drug
Ptgs2–/–
1–
20
 m
in
21
–4
0 m
in
41
–6
0 m
in
0
50
100
150
C
en
te
r t
im
e 
(s
)
F (1, 42) = 1.865
P = 0.1793 NS
Drug
WT KO
0
100
200
300
400
C
en
te
r d
is
ta
nc
e 
(c
m
)
m
in
 4
1 
– 
60
P < 0.0001
Drug X Gene INT
****
p < 0.0001
NS
F (1, 28) = 21.42
	   109	  
 
Figure 18: Abrogation of the anxiolytic behavioral effects of LM-4131 in the open-field arena by 
Rimonabant. While LM-4131 increases center distance and time in the open-field arena, co-treatment with the 
CB1 antagonist Rimonabant abolishes these effects. Data shown are mean ± s.e.m., n values are shown in the 
graphs. Reproduced from.49    
 
Figure 19: LM-4131 behavioral and biochemical effects in CB1 knockout mice. LM-4131 does not produce 
behavioral effects in Cnr1–/– mice despite increasing the levels of AEA and 2-AG. Data shown are mean ± 
s.e.m., vehicle n = 9 and LM-4131 n = 10. Reproduced from.49    
 
 To further characterize the anxiolytic-like effects of LM-4131, we analyzed the effects of LM-4131 and 
the FAAH inhibitor PF-3845 in the light-dark box test. Both PF-3845 (10 mg/kg) and LM-4131 (10 mg/kg) 
significantly increased light-zone time and the number of light-zone entries without affecting overall locomotor 
activity (Figure 20). Again the anxiolytic effects of LM-4131 were blocked by pretreatment with the CB1 
receptor antagonist Rimonabant (3 mg/kg), suggesting that the anxiolytic effects of LM-4131 are mediated via 
CB1 receptor activation in the light-dark box.  
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Figure 20: Effects of PF-3845 and LM-4131 in the light-dark box. Both PF-3845 and LM-4131 increase 
light zone time and entries but have no effect on total distance. The effects of LM-4131 are abolished by co-
treatment with the CB1 antagonist Rimonabant. Data shown are mean ± s.e.m., n values are listed on the graphs. 
Reproduced from.49     
 
 We also analyzed the anxiolytic potential of PF-3845 and LM-4131 in the elevated plus-maze. Both PF-
3845 (10 mg/kg) and LM-4131 (10 mg/kg) significantly reduced open arm latency but did not affect other 
parameters, including total distance travelled (Figure 21). Taken together, these behavioral studies reveal that 
the anxiolytic effects of LM-4131 parallel the effects of PF-3845 in multiple pre-clinical tests of anxiety. Thus, 
substrate-selective COX-2 inhibition can exert anxiolytic effects via eCB augmentation in a similar manner to 
FAAH inhibition. These proof-of-concept studies suggest that substrate-selective COX-2 inhibitors could 
represent a class of COX-2-based eCB augmenting agents with therapeutic anxiolytic effects. 
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Figure 21: Effects of PF-3845 and LM-4131 in the elevated plus-maze. Both PF-3845 and LM-4131 
significantly decrease open arm latency but have no effect on other measures including open arm time or total 
distance traveled. Data shown are mean ± s.e.m., PF-3845 vehicle n = 10, PF-3845 n = 10, LM-4131 vehicle n = 
28, and LM-4131 n = 31. Reproduced from.49 
 
 Finally, we examined the potential cannabimimetic and gastrointestinal side effects of LM-4131. Direct 
agonists of CB1 receptors produce a classical ‘tetrad’ of behavioral effects consisting of hypolocomotion, 
analgesia, catalepsy, and hypothermia.71 The open-field assay, light-dark box, and elevated plus-maze data 
demonstrate that LM-4131 does not cause hypolocomotion. We also analyzed the effects of LM-4131 and the 
CB1 agonist Win-55212-2 on rectal temperature, ring-stand catalepsy, and hot plate nociception (Figure 22). 
LM-4131 did not cause hypothermia, catalepsy, or analgesia in these tests. In contrast, Win-55212-2 induced 
hypothermia, catalepsy, and analgesia. We also assessed the effect of LM-4131 on memory using the novel 
object recognition assay. LM-4131 did not induce memory deficits when administered before object memory 
retrieval. Finally, LM-4131 did not cause overt gastrointestinal hemorrhage, a primary adverse effect of COX 
inhibitors, including indomethacin, the parent compound of LM-4131 (Figure 23). Taken together, these data 
indicate that LM-4131 induces a subset of behavioral effects that are mediated via eCB activation, but does not 
cause overt cannabimimetic effects or overt gastrointestinal toxicity observed with direct CB1 agonists or 
traditional COX inhibitors, respectively. 
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Figure 22: Effects of LM-4131 and Win-55212-2 on cannabinoid tetrad. LM-4131 does not cause 
hypothermia based on rectal temperature measurements, catalepsy as measured by the ring stand test, or 
antinociception as measured by hot plate paw withdrawal latency, while Win-55212-2 causes all three. LM-
4131 also does not cause memory deficits in the novel object recognition assay. Data shown are mean ± s.e.m., 
n values are listed on the graphs. Reproduced from.49 
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Figure 23: Comparison of overt gastrointestinal bleeding caused by vehicle, LM-4131, and indomethacin. 
While vehicle and LM-4131 treated intestines do not display overt gastrointestinal bleeding, indomethacin treat 
intestines display significant blackening indicative of gastrointestinal hemorrhage.  
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Discussion 
 Pharmacological inhibition of FAAH and MAGL have previously been validated to robustly augment 
eCB levels in vivo and exert preclinical therapeutic effects in a variety of pathological conditions.10,72 However, 
both approaches also increase non-eCB lipids, NAEs for FAAH inhibition and MAGs for MAGL inhibition, 
that have biological actions at targets other than cannabinoid receptors.73 Our studies demonstrate that, in 
addition to FAAH and MAGL, COX-2 is a key regulator of eCB levels in vivo and substrate-selective COX-2 
inhibition represents a viable alternative approach to augment eCB levels with a high degree of selectivity for 
eCBs over related non-eCB lipids. 
 In contrast to traditional modes of COX inhibition, substrate-selective COX-2 inhibition augments eCB 
levels without inhibiting central or peripheral PG production. The development and validation of an in vivo 
substrate-selective COX-2 inhibitor, LM-4131, provides a new and effective pharmacological strategy to 
selectively augment AEA signaling via COX-2 inhibition. Although LM-4131 treatment significantly increased 
the levels of 2-AG, the effect was small and not recapitulated in every experiment; thus, the biological 
relevance of 2-AG augmentation remains to be determined. Consequently, our data suggest that COX-2 
preferentially regulates AEA over 2-AG.  
 The larger relative effects of COX-2 inhibition on AEA over 2-AG may be a result of the closer 
proximity between COX-2 and the site of AEA biosynthesis and may explain its relative lack of overt 
cannabimimetic effects compared to dual FAAH and MAGL inhibition.67 Interestingly, FAAH and COX-2 are 
localized to the same postsynaptic cellular compartment.74 The co-localization of FAAH and COX-2 and 
similar effects of PF-3845 and LM-4131 suggests that they mutually regulate AEA with similar biological 
effects. However, as pharmacological inhibition or genetic deletion of COX-2 selectively increases AEA and 2-
AG, but does not affect the levels of non-eCB NAEs or MAGs, targeting COX-2 provides enhanced eCB 
selectivity over FAAH or MAGL inhibition.   
 Consistent with previous findings that elevating AEA levels via FAAH inhibition exerts anxiolytic-like 
actions in pre-clinical models, we found that LM-4131 decreased anxiety-like behaviors in multiple validated 
pre-clinical assays.10,69,70,75 Our studies suggest that substrate-selective COX-2 inhibitors could represent a 
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viable approach to the treatment of mood and anxiety disorders. Clinical support for this hypothesis has been 
put forth, as COX-2 inhibition has demonstrated clinical antidepressant efficacy as an adjunct to traditional 
antidepressants.76 Our identification of COX-2 inhibitors as eCB augmenting agents provides a potential 
mechanism for the anxiolytic effects of COX-2 inhibitors. 
 In addition to having beneficial effects in the brain, the substrate-selectivity of LM-4131 could 
potentially reduce some of the common side effects mediated by the inhibition of PG synthesis by traditional 
NSAIDs. Gastrointestinal PG production is essential for the stimulation of mucosal bicarbonate and mucus 
secretion as well as increasing mucosal blood flow.77 Thus, inhibition of gastrointestinal PG production by 
traditional NSAIDs leads to gastrointestinal complications such as ulcers. Our studies indicate that LM-4131 
does not cause overt gastrointestinal hemorrhage, which is a major side effect of indomethacin. 
A second major clinical concern for the chronic use of COX inhibitors is cardiovascular and 
cerebrovascular toxicity manifested by an increased incidence of heart attack and stroke. Cardiovascular side 
effects are exhibited by most NSAIDs, regardless of their selectivity for COX-2, due to a reduction in vascular 
PGI2 biosynthesis.78,79 As LM-4131 does not affect central or peripheral levels of PGs, including PGI2, it is 
possible that this pharmacological class of inhibitors could be devoid of or exhibit significantly reduced 
cardio/cerebrovascular toxicity compared to NSAIDs. Indeed, clinical trials conducted with the substrate-
selective COX-2 inhibitor (R)-flurbiprofen suggest that it does not increase cardiovascular events in 
humans.80,81 Additional studies evaluating the side effects of substrate-selective COX-2 inhibitors relative to 
those of traditional COX inhibitors will be required to identify potential adverse effects of substrate-selective 
COX-2 inhibitors on a compound-by-compound basis.   
These studies demonstrate that COX-2 is a key regulator of brain eCB signaling in vivo and that 
substrate-selective inhibition of COX-2 represents a novel pharmacological approach to augmenting eCBs. 
Given the numerous pathological processes in which dysregulation of eCB signaling has been demonstrated, 
coupled with the high degree of selectivity of substrate-selective COX-2 inhibitors for eCBs over related non-
eCB lipids, this class of pharmaceutical agents could have broad therapeutic potential. Further research into the 
therapeutic effects of substrate-selective COX-2 inhibitors will identify their potential for use in diseases. 
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CHAPTER V 
THE PHARMACOKINETICS AND PHARMACODYNAMICS OF LM-4131 IN MICE 
Introduction 
 The endocannabinoids (eCBs), anandamide (AEA) and 2-arachidonoylglycerol (2-AG), are the 
endogenous ligands of the cannabinoid 1 and 2 receptors (CB1 and CB2).1-3 eCBs are synthesized from 
phospholipids through distinct pathways in response to calcium influx or the activation of certain G-protein-
coupled receptors.4-6 After synthesis, eCB levels are mainly regulated through deactivation by hydrolysis. AEA 
is primarily hydrolyzed by fatty acid amide hydrolase to arachidonic acid (AA) and ethanolamine, whereas 2-
AG is hydrolyzed to AA and glycerol by several enzymes including monoacylglycerol lipase, α/β-hydrolase 
domain 6, α/β-hydrolase domain 12, carboxylesterases 1 and 2, and palmitoylprotein thioesterase 1.7-12  
 In addition to hydrolysis, AEA and 2-AG can undergo oxygenation by a variety of enzymes including 
lipoxygenases, cyclooxygenases, and cytochromes P450.13-17 Although the extent to which each oxygenation 
pathway is involved in the turnover of eCBs is uncertain, our work demonstrates that cyclooxygenase-2 (COX-
2) can become a third pathway of eCB metabolism at sites of constitutive expression or at sites of inflammation, 
as discussed in chapters III and IV.18,19 COX-1 and COX-2 catalyze the committed step in the biosynthesis of 
prostaglandins (PGs) from AA. In addition to metabolizing AA, COX-2 also oxygenates AEA to form 
prostaglandin ethanolamides (PG-EAs) and 2-AG to form prostaglandin glycerol esters (PG-Gs).13,14 These 
prostaglandin products are not ligands for the cannabinoid receptors, so COX-2 activity inactivates eCBs while 
also synthesizing a series of bioactive eCB-derived prostanoids.   
 Non-steroidal anti-inflammatory drugs (NSAIDs) produce their effects by inhibiting COX-1 and/or 
COX-2. Most NSAIDs inhibit the oxygenation of AA, 2-AG, and AEA with similar potencies, but a subset of 
NSAIDs selectively inhibit the oxygenation of 2-AG and AEA by COX-2 without inhibiting AA oxygenation, a 
phenomenon termed substrate-selective inhibition of COX-2.20 For example, indomethacin inhibits the 
oxygenation of AA, 2-AG, and AEA with similar potencies, but the morpholino analog of indomethacin, LM-
4131, selectively inhibits endocannabinoid oxygenation in vitro and in vivo, as discussed in chapter IV.18 
Intraperitoneal (i.p.) administration of LM-4131 (10 mg/kg) elevates the levels of brain AEA and 2-AG without 
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affecting the levels of AA or PGs 2 hours after treatment.18 The elevation of eCBs elicited by LM-4131 is COX-
2 dependent and produces anxiolytic effects through CB1 receptor activation in pre-clinical models of anxiety.18 
 Substrate-selective COX-2 inhibitors are important tools for dissecting the role of COX-2 oxygenation 
in eCB metabolism due to their lack of confounding PG inhibition. While LM-4131 has robust effects at 2 hours 
after i.p. injection, its effects have not been investigated over longer times in vivo. Previous studies have 
demonstrated that LM-4131 (also known as BML-190) is extensively metabolized by rat liver microsomes in 
vitro.21 LM-4131 metabolism by rat liver microsomes parallels the metabolism of indomethacin, in that the p-
chlorobenzoyl group is hydrolyzed and the indole methoxy group is oxidatively demethylated.21,22 In addition, 
LM-4131 can be hydroxylated on either the indole or morpholine rings.21 Following hydroxylation of the 
morpholino group, the ether of some of the metabolites can ring-open, leading to additional metabolites.21  
 The in vivo pharmacokinetics and pharmacodynamics of LM-4131 are critical to evaluating its 
usefulness as a COX-2-dependent eCB-augmenting probe in both acute and chronic settings. Thus, we 
investigated the time-course of LM-4131 accumulation in the brain and plasma after a single 10 mg/kg i.p. 
injection and compared it to the distribution of indomethacin after a single 10 mg/kg i.p. injection in mice. We 
also analyzed the tissue distribution of LM-4131 2 hours after a 10 mg/kg i.p. injection. The effects of LM-4131 
or indomethacin on brain eCBs and PGs were determined over a 24-hour period to analyze the duration of 
action of the compounds. We found that LM-4131 is present in the brain up to 6 hours after dosing and that it 
loses substrate-selectivity at that time, apparently due to partial hydrolysis to indomethacin. Thus, these results 
define the parameters under which LM-4131 is a useful probe for studying substrate-selective COX-2 inhibition 
in vivo. 
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Experimental Procedures 
 
Reagents  
Indomethacin was purchased from Sigma Aldrich (St. Louis, MO). LM-4131 was synthesized as described 
previously.23 PGE2-d4, AEA-d8, 2-AG-d8, and AA-d8 were purchased from Cayman Chemical (Ann Arbor, MI). 
Indomethacin-d4 and morpholine-d8 were purchased from C/D/N isotopes (Pointe-Claire, Quebec, Canada). 
LM-4131-d8 was synthesized using morpholine-d8 under the same conditions as the LM-4131 synthesis.   
In vivo experiments  
4-5 week old male ICR mice were used for all experiments (Harlan, Indianapolis, IN). Mice were group-housed 
on a 12:12 light-dark cycle (lights on at 06:00), with food and water available ad libitum. Mice received a single 
i.p. injection of either compound or vehicle (DMSO) and were sacrificed by cervical dislocation and 
decapitation at various times after injection as noted in the text. All animal studies were approved by the 
Vanderbilt Institutional Animal Care and Use Committee and conducted in accordance with the NIH Guide for 
the Care and Use of Laboratory animals.  
Tissue preparation and lipid extraction  
After mice were sacrificed by cervical dislocation and decapitation, the brain, lungs, heart, liver, stomach, small 
intestine, and kidneys were immediately removed and washed with ice-cold calcium and magnesium-free 
Dulbecco’s phosphate-buffered saline (GIBCO, Carlsbad, CA) and flash frozen on a metal block in dry ice. The 
tissue was placed in a tube and stored at -80ºC until extraction, usually within 24 hours. For PG, eCB, LM-
4131, and indomethacin analysis, lipid extraction from tissue was carried out as described previously.24 
Plasma preparation and precipitation 
After mice were sacrificed by cervical dislocation and decapitation, trunk blood was collected in a 50 mL 
conical tube coated with 200 µL of 1,000 ISP units/mL heparin (Hospira, Inc. Lake Forest, IL). The blood 
volume was then measured into a 2 mL tube and put on ice. The plasma was separated by centrifuging the tube 
at 3,000 RPM for 5 minutes and then removed. Protein was precipitated by addition of 2 mL of ice-cold 
acetonitrile spiked with LM-4131-d8 and indomethacin-d4. After vigorous mixing, 1.5 mL of acetonitirile was 
dried down under a stream of nitrogen and reconstituted in 200 µL of 1:1 methanol:water for analysis by mass 
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spectrometry. For analysis of ex vivo plasma hydrolysis, mouse trunk blood samples were collected as outlined 
above or were collected into tubes fortified with paraoxon (~50 µM). 
In vitro plasma hydrolysis 
CD-1 mouse plasma with K2 EDTA (Bioreclamation, Westbury, NY) was incubated with 1 µM LM-4131 or 
indomethacin for 0, 1, and 4 hours at 4°C, room temperature, 37°C, or at 37°C with 1 mM paraoxon in 
duplicate. The samples were then extracted with 2 volumes of acetonitrile containing 1 nM LM-4131-d8 and 1 
nM of indomethacin-d4 and centrifuged at 3,000 RPM for 5 minutes and placed into a 96-well plate for liquid 
chromatography-mass spectrometry (LC-MS) analysis.  
Mass spectrometry analysis 
Analytes were quantified using LC-MS/MS on a Thermo Finnigan Quantum triple-quadrupole mass 
spectrometer in positive-ion mode using selected reaction monitoring. Detection of eicosanoids was performed 
as previously described.25 Fatty acid and eCB analyses were performed as previously described.18 Indomethacin 
and LM-4131 were analyzed using the same gradient and mobile phases as the eicosanoids. The transitions 
monitored were indomethacin m/z 358→139, indomethacin-d4 m/z 362→143, LM-4131 m/z 427→139, and 
LM-4131-d8 m/z 435→139. The transitions and retention times for indomethacin and LM-4131 were validated 
using standards prior to the analysis of tissues and plasma. In vitro plasma hydrolysis metabolites were 
identified using a Finnigan LCQ Deca XPPLUS ion trap mass spectrometer (Thermo Fisher Scientific, Waltham, 
MA) operated in positive ionization mode as described previously.26 Peak areas for the analytes were 
normalized to the appropriate internal standard and then normalized to tissue mass or plasma volume.  
Statistical Analysis 
Statistical analyses were performed using GraphPad Prism® Version 6.0c as described in the text. For 
determining statistical significance between groups, a two-tailed t-test, multiple t-test with Holm-Sidak multiple 
comparisons post-hoc test, or one-way ANOVA with a Holm-Sidak multiple comparisons post-hoc test were 
used as indicated. Error bars represent mean ± s.e.m throughout. 
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Results 
 
Distribution of LM-4131 in plasma and brain over time 
 We analyzed the time-concentration profiles of LM-4131 in the brain and plasma over 24-hours 
following a single 10 mg/kg i.p. injection. The 10 mg/kg dose was selected as it was previously shown to be 
maximally efficacious at increasing brain AEA levels 2 hours after i.p. injection, as discussed in chapter IV.18 
LM-4131 was detected in plasma at 30 minutes (770 ± 280 ng/mL), but its concentration declined rapidly and 
was below the limit of detection at 4 hours (Figure 1). The levels of LM-4131 in the brain displayed a similar 
pharmacokinetic profile as in plasma. LM-4131 was initially present in high levels in the brain (4240 ± 475 
ng/g), but the levels declined over 6 hours. 
 Given the approximately 5:1 ratio between the detected brain and plasma levels of LM-4131, we 
hypothesized that LM-4131 may be hydrolyzed by plasma ex vivo. To test the possibility of in vitro plasma 
hydrolysis of LM-4131 we incubated mouse plasma with 1 µM LM-4131 or indomethacin for 0, 1, and 4 hours 
at 4°C, room temperature, 37°C, or 37°C with 1 mM paraoxon. Paraoxon is a broad-spectrum serine hydrolase 
inhibitor and has previously been shown to impair the ex vivo plasma hydrolysis of ester or amide containing 
compounds.27 We found that LM-4131, but not indomethacin, was hydrolyzed in plasma in vitro and that this 
hydrolysis was both temperature and paraoxon sensitive. LC-MS/MS analyses of the plasma extracts indicated 
that the product of hydrolysis was the N-des-chlorobenzoyl metabolite. Interestingly, the analogous p-
chlorobenzoyl group of indomethacin is stable in plasma and plasma extracts. 
 To substantiate the ex vivo hydrolysis of LM-4131 as the basis for its low apparent plasma levels, we 
administered a 10 mg/kg i.p. dose to mice and collected trunk blood at 30 minutes, 2 hours, and 4 hours post 
administration in tubes that had been fortified with ~50 µM paraoxon or no paraoxon in parallel. In agreement 
with the in vitro hydrolysis experiment, addition of paraoxon protected LM-4131 from ex vivo hydrolysis, as a 
significant increase in the plasma concentration of LM-4131 was observed. A corresponding reduction of the N-
des-chlorobenzoyl metabolite of LM-4131 was observed in plasma samples collected in the paraoxon-fortified 
collection tubes. Thus, LM-4131 levels in plasma are lowered through hydrolysis by a paraoxon-sensitive 
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enzyme ex vivo to form N-des-chlorobenzoyl LM-4131. Upon addition of paraoxon in the collection process the 
plasma:brain ratio of LM-4131 is approximately 2:1. 
 
Figure 1: Detection of LM-4131 in plasma and brain after a single 10 mg/kg i.p. injection. LM-4131 is 
detected in both the brain and plasma, but is present at lower levels in plasma and disappears after 4 hours. 
While indomethacin is stable in plasma ex vivo, LM-4131 displays temperature and paraoxon-sensitive 
breakdown. Addition of paraoxon to the blood collection tubes resulted in a greater recovery of LM-4131 and a 
reduction in the N-des-chlorobenzoyl LM-4131 metabolite. Data shown are mean ± s.e.m., n = 5-12 for LM-
4131 plasma and brain samples, n = 2 for in vitro plasma hydrolysis, and n = 5 for plasma paraoxon samples. 
 
Hydrolysis of LM-4131 to indomethacin 
 LM-4131 is not hydrolyzed to indomethacin in the brain 2 hours after i.p. injection of 10 mg/kg LM-
4131, as discussed in chapter IV.18 To determine if LM-4131 is hydrolyzed to indomethacin at later time points 
in brain or plasma, we also measured the levels of indomethacin after 10 mg/kg LM-4131 i.p. injection in both 
the brain and plasma. Although indomethacin was not detected in the brain at any time point, low levels of 
indomethacin (2 ± 2 ng/mL) were detected in plasma at 4 hours post administration and peak concentrations of 
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indomethacin (48 ± 11 ng/mL) at 6 hours post administration, implicating amide hydrolysis as a minor pathway 
of biotransformation for LM-4131 in vivo (Figure 2). Indeed, representative chromatograms depicting plasma 
profiles at 2 and 6 hours following a 10 mg/kg i.p. administration of LM-4131  reveal the presence of 
indomethacin in plasma after 6 hours. This finding suggests that LM-4131 may act as a substrate-selective 
inhibitor for only 4 hours after treatment due to the hydrolytic biotransformation of LM-4131 to indomethacin. 
 
Figure 2: Hydrolysis of LM-4131 to indomethacin over time. Treatment of mice with LM-4131 (10 mg/kg) 
leads to the presence of indomethacin starting at 4 hours after dosing. Representative chromatograms depict the 
lack of indomethacin 2 hours after treatment and the presence of indomethacin 6 hours after treatment. Data 
shown are mean ± s.e.m., n = 5-12. 
 
Time-dependent distribution of indomethacin in plasma and brain  
 To compare the time-course of LM-4131 to its parent compound, we measured the levels of 
indomethacin in plasma and brain over a 24-hour time period after a single 10 mg/kg i.p. injection of 
indomethacin. Indomethacin was initially present at high levels in the plasma and was detected over the entire 
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24-hour time period (Figure 3). Indomethacin displayed a characteristic long half-life in plasma after i.p. 
injection in mice, which has previously been shown in other species and using other routes of administration.28-
31 Indomethacin preferentially partitioned to the plasma, as in the brain it was present at approximately 20 
percent of the level found in plasma. Despite it being present in reduced amounts relative to plasma, 
indomethacin was also detected in the brain over the entire 24-hour period. This is in agreement with previous 
studies showing that indomethacin is highly plasma bound and does not have high brain penetrance.32 Thus, 
indomethacin has a similar pharmacokinetic profile in mice after i.p. injection as in other species and by 
different administration routes. 
 
Figure 3: Time-course of indomethacin in plasma and brain. Indomethacin was detected in plasma and brain 
over the entire 24-hour period after a single 10 mg/kg i.p. injection. Data shown are mean ± s.e.m., n = 5-7. 
 
Effects of indomethacin and LM-4131 on brain eCBs and PGs over time 
 To determine if the pharmacokinetic profiles of indomethacin and LM-4131 match their biochemical 
effects we measured the levels of brain eCBs and PGs over a 24-hour time course after 10 mg/kg i.p. injection 
of vehicle, indomethacin, or LM-4131. Both indomethacin and LM-4131 significantly increased brain AEA at 
the 2- and 4-hour time points, but not at later time points (Figure 4). The increase in AEA produced by LM-
4131 correlates well with the detection of LM-4131 in the brain. In contrast, while indomethacin was present in 
the brain over the entire 24-hour period, it only significantly increased AEA for 4 hours. Neither indomethacin 
nor LM-4131 significantly increased 2-AG in the brain at any time point. Indomethacin significantly decreased 
brain PGs at all time points, whereas LM-4131 decreased brain PGs starting only 6 hours after treatment. The 
inhibition of PGs starting at 6 hours by LM-4131 is consistent with the time course for the hydrolysis of LM-
4131 as estimated by the appearance of indomethacin in the plasma starting at 4 hours after LM-4131 dosing. 
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Figure 4: Effects of LM-4131 and indomethacin over time on brain eCBs and PGs. While LM-4131 and 
indomethacin significantly increase AEA at 2 and 4 hours after treatment, they had no significant effects on 
AEA at later time points or on 2-AG at any time points. Indomethacin significantly inhibited PG production at 
all time points, while LM-4131 significantly inhibited PG production starting at 6 hours after treatment. Data 
shown are mean ± s.e.m., n = 5-7. 
 
Effects of low-dose indomethacin 
 Although no indomethacin was detected in the brain after LM-4131 administration, the small amount of 
hydrolysis to indomethacin detected in plasma and the PG inhibition after 6 hours prompted us to test the effects 
of low-dose indomethacin (0.5 mg/kg i.p.) on brain eCB and PG levels. Indomethacin injected at 0.5 mg/kg i.p. 
did not increase brain AEA 2 hours after treatment (Figure 5). Low-dose indomethacin also had no effect on 2-
AG, but it did significantly decrease brain PG production. Thus, the biochemical effects of low-dose 
indomethacin do not mirror the effects of higher dose indomethacin or LM-4131 on brain AEA, but it does 
significantly inhibit PG production, suggesting that low doses of indomethacin inhibit COX-1 but not COX-2 in 
the brain. This further suggests that the PG inhibition observed starting at 6 hours after LM-4131 treatment 
could be due to the hydrolysis to indomethacin. 
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Figure 5: Effects of low-dose indomethacin on brain eCBs and PGs. Low-dose indomethacin (0.5 mg/kg) 
had no significant impact on AEA or 2-AG levels, but significantly decreased PG levels in the brain. Data 
shown are mean ± s.e.m., n = 10. 
 
Tissue distribution of LM-4131 and indomethacin 
 To further examine the effects of tertiary amide substitution on tissue distribution we analyzed the levels 
of indomethacin and LM-4131 in the brain, lungs, kidneys, heart, intestine, stomach, liver, and plasma 2 hours 
after a single 10 mg/kg i.p. injection of either indomethacin or LM-4131. LM-4131 was detected in similar 
amounts throughout each of the tissues analyzed with the exception of the liver (Figure 6). Indomethacin was 
present in the largest amounts in the stomach and intestine, but in sharp contrast to LM-4131, was present in 
low amounts in the brain. Both compounds were detected in all of the tissues analyzed. 
 
Figure 6: Tissue distribution of LM-4131 and indomethacin. LM-4131 and indomethacin were differentially 
distributed throughout the tissues analyzed. Data shown are mean ± s.e.m., n = 17. 
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Discussion 
 
 The addition of a morpholino amide functionality to indomethacin produces large changes in both 
activity and pharmacokinetics. Whereas indomethacin is a non-selective COX-1 and COX-2 inhibitor, LM-4131 
is a substrate-selective inhibitor of COX-2.18 This gives rise to a useful probe with the same core structure of 
indomethacin for studying the differential effects of COX inhibition in vivo. To understand the utility of these 
molecules, we characterized the pharmacokinetic and pharmacodynamic properties of LM-4131 and 
indomethacin and related them to eCB and PG modulation.  
 This is the first in vivo pharmacokinetic-pharmacodynamic profile of LM-4131, but the 
pharmacokinetics and pharmacodynamics of indomethacin have been extensively examined. Indomethacin is 
rapidly absorbed after dosing, although it is highly (>90%) bound to plasma proteins at therapeutic plasma 
concentrations.28,29 Indomethacin displays a characteristic long half-life between 5 and 10 hours depending on 
the species and route of administration.29,30,33 The long half-life of indomethacin is in part due to the 
glucuronidation of about 60 percent of indomethacin, which leads to extended entero-hepatic circulation.28,31 In 
addition to glucuronidation, indomethacin is metabolized to O-des-methylindomethacin, N-des-
chlorobenzoylindomethacin, and O-des-methylindomethacin-N-des-chlorobenzoylindomethacin, all of which 
can be detected in plasma following dosing (Figure 7).22,34 The demethylation of indomethacin is catalyzed by 
both CYP2C9 and CYP2D6, whereas the cleavage of the chlorobenzoyl group is achieved by a liver 
carboxylesterase.35,36 
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Figure 7: In vivo metabolism of indomethacin. 
 The modification of the carboxylate of indomethacin to a tertiary amide results in notable 
pharmacokinetic differences in vivo. The tissue distribution and half-life of LM-4131 are significantly different 
than indomethacin. LM-4131 has a much shorter half-life than indomethacin, suggesting that the morpholino 
ring contributes to metabolic instability. In particular, the morpholino ring of LM-4131 leads to paraoxon-
sensitive ex vivo plasma hydrolysis to N-des-chlorobenzoyl LM-4131; the analogous plasma hydrolysis does not 
occur with indomethacin. In contrast to indomethacin and other acidic NSAIDs, LM-4131 is more centrally 
penetrant as evidenced by the higher levels relative to indomethacin in the brain. Numerous efforts have been 
made to improve the brain penetrance of indomethacin including creating more lipophilic pro-drugs, using 
alternative methods of administration, or conjugation of indomethacin with endogenous substrates that are 
transported across the blood-brain barrier such as glucose.32,37,38 
 Although the in vivo metabolism of LM-4131 has not been previously studied, the metabolism of LM-
4131 by rat liver microsomes in vitro has been characterized. LM-4131 is extensively metabolized by rat liver 
microsomes, producing metabolites analogous to indomethacin metabolites including the loss of the 
chlorobenzoyl group and demethylation of the methoxy group of the indole ring (Figure 8).21 In addition, LM-
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4131 is converted to metabolites distinct from those formed from indomethacin. LM-4131 is hydroxylated on 
the morpholine ring and the morpholine ring can also be opened at the ether.21 
 
Figure 8: In vivo metabolism of LM-4131. 
  Of particular importance, LM-4131 is hydrolyzed in small amounts to indomethacin in a time-dependent 
manner in vivo. Indomethacin was detected in plasma starting at 4 hours after LM-4131 treatment and 
significant PG inhibition occurred in the brain starting at 6 hours after dosing. This reveals that LM-4131 acts as 
a substrate-selective inhibitor for 4 hours, but is then converted to a non-substrate-selective inhibitor at later 
time points. Whether this non-substrate-selective inhibition is due to the hydrolysis to indomethacin or 
conversion to a different active metabolite is unclear, however, we have found that a low dose of indomethacin 
is sufficient to cause PG inhibition but not AEA increases in the brain. The time course of LM-4131 action on 
AEA matches well with the presence of LM-4131 in the brain, as it increased AEA at 2 and 4 hours after 
treatment, and LM-4131 is present in the brain at these time points. In contrast, although indomethacin inhibits 
PG production over the entire 24-hour period after treatment, it only increased AEA levels at 2 and 4 hours after 
treatment.  
 Although LM-4131 is a useful probe for studying the acute effects of substrate-selective inhibition of 
COX-2, further drug discovery efforts focused on metabolically stable substrate-selective inhibitors are clearly 
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needed to fully investigate the in vivo effects of substrate-selective inhibition of COX-2 in both longer time-
course settings and chronic dosage studies. Although other excellent substrate-selective inhibitors such as (R)-
flurbiprofen are available for in vitro use in both purified protein and cellular systems, at this point, LM-4131 is 
the only substrate-selective inhibitor suitable for in vivo use.18,19 Although these studies identify that it is only 
useful in a very limited, short-term setting, it is still a useful in vivo probe to determine the impact of COX-2 on 
eCB metabolism, particularly in the brain.  
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CHAPTER VI 
IDENTIFICATION OF ALTERNATIVE IN VIVO SUBSTRATE-SELECTIVE COX-2 INHIBITORS 
Introduction 
 The endocannabinoids (eCBs), anandamide (AEA) and 2-arachidonoylglycerol (2-AG), are the 
endogenous ligands of the cannabinoid 1 and 2 receptors (CB1 and CB2).1-3 eCBs are synthesized from 
phospholipids through distinct pathways in response to calcium influx or the activation of certain G-protein-
coupled receptors.4-6 After synthesis, eCB levels are mainly regulated through deactivation by hydrolysis. AEA 
is primarily hydrolyzed by fatty acid amide hydrolase to arachidonic acid (AA) and ethanolamine, whereas 2-
AG is hydrolyzed to AA and glycerol by several enzymes including monoacylglycerol lipase, α/β-hydrolase 
domain 6, α/β-hydrolase domain 12, carboxylesterases 1 and 2, and palmitoylprotein thioesterase 1.7-12  
 In addition to hydrolysis, AEA and 2-AG can undergo oxygenation by a variety of enzymes including 
lipoxygenases, cyclooxygenases, and cytochromes P450.13-17 Although the extent to which each oxygenation 
pathway is involved in the turnover of eCBs is uncertain, our work demonstrates that cyclooxygenase-2 (COX-
2) can become a third pathway of eCB metabolism at sites of constitutive expression or at sites of inflammation, 
as discussed in chapters III and IV.18,19 COX-1 and COX-2 catalyze the committed step in the biosynthesis of 
prostaglandins (PGs) from AA. In addition to metabolizing AA, COX-2 oxygenates AEA to form prostaglandin 
ethanolamides and 2-AG to form prostaglandin glycerol esters (PG-Gs).13,14 These prostaglandin products are 
not ligands for the cannabinoid receptors, so COX-2 activity inactivates eCBs while also synthesizing a series 
of bioactive eCB-derived prostanoids.   
 Non-steroidal anti-inflammatory drugs (NSAIDs) produce their effects by inhibiting COX-1 and/or 
COX-2. Most NSAIDs inhibit the oxygenation of AA, 2-AG, and AEA with similar potencies, but a subset of 
NSAIDs selectively inhibit the oxygenation of 2-AG and AEA by COX-2 without inhibiting AA oxygenation, a 
phenomenon termed substrate-selective inhibition of COX-2.20 For example, indomethacin inhibits the 
oxygenation of AA, 2-AG, and AEA with similar potencies, but the morpholino analog of indomethacin, LM-
4131, selectively inhibits endocannabinoid oxygenation in vitro and in vivo, as discussed in chapter IV.18 
Intraperitoneal (i.p.) administration of LM-4131 (10 mg/kg) elevates the levels of brain AEA and 2-AG without 
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affecting the levels of AA or PGs 2 hours after treatment.18 The elevation of eCBs elicited by LM-4131 is COX-
2 dependent and produces anxiolytic effects in pre-clinical models of anxiety through CB1 receptor activation.18 
 Substrate-selective COX-2 inhibitors are important tools for dissecting the role of COX-2 oxygenation 
in eCB metabolism due to their lack of confounding PG inhibition. LM-4131 has robust effects at 2 hours after 
i.p. injection, but we found that while LM-4131 is present in the brain up to 6 hours after dosing, it loses 
substrate-selectivity at that time, apparently due to partial hydrolysis to indomethacin, as discussed in chapter V. 
Thus, LM-4131 is a not useful probe for studying substrate-selective COX-2 inhibition in vivo in acute settings 
beyond 4 hours or chronic settings. 
 To attempt to discover a more suitable in vivo probe, we explored alternative substrate-selective COX-2 
inhibitors in vivo. Preliminary in vitro studies identified that lumiracoxib, an analog of diclofenac, was an 
extremely potent substrate-selective COX-2 inhibitor.21 Lumiracoxib was originally classified as a COX-2-
selective inhibitor, and in the human whole blood assay it has the highest selectivity for COX-2 inhibition over 
COX-1 inhibition of any NSAID.22 Lumiracoxib is efficacious in multiple pre-clinical models of pain and 
inflammation.23 Following a series of promising clinical trials, Novartis brought lumiracoxib to market in 
several countries under the trade name Prexige for the treatment of pain and inflammation in patients with 
osteoarthritis.24-41  
 Although lumiracoxib was efficacious in patient populations, it was withdrawn from most markets due 
to idiosyncratic liver toxicity stemming from the formation of reactive quinone imine lumiracoxib metabolites 
by peroxidases and cytochromes P450 in the liver.42-45 These reactive quinone imine metabolites are formed by 
the oxidation of the 4’ position by CYP2C9, which results in the formation of 4’-hydroxylumiracoxib (Figure 
1). Further oxidation of the lower ring leads to the formation of reactive quinone imines, which are electrophilic 
species that can react to form glutathione and protein adducts. The hepatotoxicity of lumiracoxib is mirrored by 
diclofenac, which also can be metabolized to chemically reactive species by cytochrome P450-catalyzed 
hydroxylation at the 4’ position, but also can be oxidized at the 5 position, unlike lumiracoxib which contains a 
methyl group to protect the 5 position from oxidation.46,47 As with lumiracoxib, the hydroxylated diclofenac 
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metabolites can be further oxidized to reactive quinone imine intermediates, which have been characterized 
indirectly through the detection of glutathione and protein adducts.48-50 
 
Figure 1: Oxidative metabolism of lumiracoxib and diclofenac in the liver.  
 Despite the clinical metabolic toxicity exhibited by lumiracoxib, some studies suggest that the liver 
toxicity of lumiracoxib could be avoided by giving lower doses or by genotyping patients, as a specific allele 
can identify at risk patients.51,52 Lumiracoxib is an attractive possibility for an in vivo substrate-selective 
inhibitor due to the extensive studies identifying its therapeutic effects. In addition, lumiracoxib does not 
increase cardiovascular risk or cause increased gastrointestinal complications in patients, which are the two 
primary complications in individuals who take NSAIDs for prolonged periods.53-56 Thus, management of the 
metabolic toxicity of lumiracoxib by using a lower dose or development of an analog that is not metabolized to 
reactive quinone imine metabolites could lead to a promising in vivo substrate-selective COX-2 inhibitor. 
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 To assess the potential of lumiracoxib to act as a substrate-selective COX-2 inhibitor we analyzed its 
ability to modulate brain eCB and PG levels in both acute and chronic settings after intraperitoneal injection. 
We found that lumiracoxib exhibits substrate-selective COX-2 inhibition at a 1 mg/kg dose in mice but not at 
higher concentrations. Additionally, lumiracoxib retains substrate-selective inhibition in chronic dosing 
regiments when given at 1 mg/kg once per day. The des-fluoro derivative of lumiracoxib, which may have a 
reduced capacity to form reactive quinone imine intermediates in vivo, also displayed substrate-selective COX-2 
inhibition in mice. 
Experimental Procedures 
Materials  
Lumiracoxib was purchased from LKT Laboratories (St. Paul, MN). JZL-184, PGE2–d4, AA-d8, 2-AG-d8, and 
AEA-d8 were purchased from Cayman Chemical (Ann Arbor, MI). LM-5703 was synthesized as previously 
described.57  
Animals 
5-7 week old male ICR mice were used for all experiments (Harlan, Indianapolis, IN). Mice were housed 5 per 
cage. Wild-type and knockout Faah–/– and Ptgs2–/– mice were derived from heterozygote breeding pairs, bred 
and genotyped as previously described.58,59 Mice were group-housed on a 12:12 light-dark cycle (lights on at 
06:00), with food and water available ad libitum. All animal studies were approved by the Vanderbilt 
Institutional Animal Care and Use Committee and conducted in accordance with the NIH Guide for the Care 
and Use of Laboratory animals.  
Tissue preparation and lipid extraction 
Mice were sacrificed by cervical dislocation and decapitation. The brain was then rapidly removed and frozen 
on a metal block in dry ice. The tissue was then placed in a tube and stored at -80ºC until extraction, usually one 
day after harvesting. For PG and eCB analysis, lipid extraction from tissue was carried out as described 
previously.60 
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In vitro enzyme purification and activity assays 
MAGL was purified using BL21(DE3) pLysS E. coli transformed with pET-45b(+) plasmid containing human 
MGL-His. Cells were grown at 37ºC to a density of 0.7 OD and then protein expression induced with IPTG (1 
mM). Cells were harvested 4 hr later and proteins purified using Ni-NTA Agarose (Qiagen) as previously 
described.61 After purification, the protein was dialyzed overnight at 4ºC into buffer containing 0 mM HEPES 
and 0.01% TritonX-100. MAGL inhibition was assessed as previously described.61 Humanized rat FAAH was a 
generous gift of R. Stevens and B. Cravatt (The Scripps Research Institute). FAAH inhibition was assessed as 
previously described.62  
Mass spectrometry analysis 
Analytes were quantified using LC-MS/MS on a Quantum triple-quadrupole mass spectrometer in positive-ion 
mode using selected reaction monitoring. Detection of eicosanoids was performed as previously described.63 
For fatty acid analysis the mobile phases used were 80 µM AgOAc with 0.1% (v/v) acetic acid in H2O (solvent 
A) and 120 µM AgOAc with 0.1% (v/v) acetic acid in MeOH (solvent B). The analytes were eluted using a 
gradient from 20% A to 99% B over 5 minutes. The transitions used were m/z 434→416 for OEA, m/z 
456→438 for AEA, m/z 464→446 for AEA-d8, m/z 463→389 for 2-OG, m/z 485→411 for 2-AG, m/z 
493→419 for 2-AG-d8, m/z 519→409 for AA, and m/z 527→417 for AA-d8. Peak areas for the analytes were 
normalized to the appropriate internal standard and then normalized to tissue mass for in vivo samples.  
Statistical analysis 
Statistical analyses were performed using GraphPad Prism® Version 6.0c. For determining statistical 
significance between groups a two-tailed t-test, one-way ANOVA, or two-way ANOVA with a Sidak’s post-test 
analysis were used as indicated. Error bars represent S.E.M. throughout. N for each group represents number of 
mice, i.e. independent biological replicate. Mice were arbitrarily assigned to treatment group in a manner that 
resulted in approximately equal sample sized per treatment group. Each treatment group was represented at least 
once per cage of mice.  
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Results 
In vivo effects of lumiracoxib 
 An important consideration for using compounds in chronic studies is the ability to administer a drug in 
an aqueous solution. While LM-4131 is only soluble in DMSO, lumiracoxib can be dissolved in aqueous 
buffers. One commonly used solution for intraperitoneal injections of eCB augmenting agents is 18:1:1 
saline:ethanol:emulphor.8 This buffer solubilizes lipophilic drugs in a solution that is not toxic to mice in 
chronic settings, which is not the case for DMSO.64-66 We first sought to determine the dose-response of 
lumiracoxib in the 18:1:1 saline:ethanol:emulphor vehicle to determine if lumiracoxib acts as a substrate-
selective COX-2 inhibitor in vivo. Mice were treated with vehicle or various doses of lumiracoxib by 
intraperitoneal injection and sacrificed 2 hours after treatment. The brains were then harvested, extracted, and 
analyzed for eCBs, AA, and PGs. Lumiracoxib caused significant increases in AEA and AA at all doses, but 
only caused a significant increase in 2-AG at the 10 mg/kg dose (Figure 2). Lumiracoxib did not significantly 
inhibit PG production in the brain until 10 mg/kg, although there was a slight non-significant decrease in PG 
production at the 5 mg/kg dose. Thus, lumiracoxib exhibits dose-dependent substrate-selective inhibition in the 
brain with no effect on PGs at 1 mg/kg but a significant increase AEA. Surprisingly, lumiracoxib caused a 
robust increase in AA and 2-oleoyl glycerol (2-OG) at all doses, which was not seen with LM-4131. While 
indomethacin and NS-398 also increased AA, we had hypothesized that this was a direct result of inhibition PG 
production. As lumiracoxib had no effect on PGs at the lowest dose but increased AA, it is possible that the 
increase in AA is a mediated by a separate mechanism. 
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Figure 2: Dose-response of lumiracoxib on brain lipids and PGs. Lumiracoxib significantly increased AEA, 
AA, and 2-OG at all doses, but only increased 2-AG at the 10 mg/kg dose. Lumiracoxib significantly decreased 
PG levels at the 10 mg/kg dose. Lumiracoxib had no significant effect on OEA at any dose. Data shown are 
mean ± s.e.m., n = 6-15. Statistical significance calculated using one-way ANOVAs followed by Holm-Sidak 
post-tests. 
 
 The increase in 2-OG prompted us to probe the potential of lumiracoxib to inhibit MAGL. To do this we 
incubated various concentrations of lumiracoxib or the MAGL inhibitor JZL-184 with purified MAGL and 
assessed their ability to inhibit the hydrolysis of 2-AG to AA. While JZL-184 displayed potent inhibition of 
MAGL, lumiracoxib displayed approximately 20% inhibition with a 100 µM concentration (Figure 3). While 
lumiracoxib did not increase OEA, we also wanted to confirm that lumiracoxib is not a FAAH inhibitor in vitro. 
While the FAAH inhibitor PF-3845 displayed potent inhibition, lumiracoxib did not display any inhibition of 
FAAH activity up to a concentration of 100 µM. 
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Figure 3: In vitro inhibition of MAGL and FAAH. While the MAGL inhibitor JZL-184 potently inhibits the 
hydrolysis of 2-AG to AA by MAGL, lumiracoxib only displayed approximately 20% inhibition at a 
concentration of 100 µM. Data shown are mean ± s.e.m., n = 3. 
 
 To determine if the increase in AA, 2-AG, and 2-OG produced by lumiracoxib in vivo was mediated by 
MAGL, we treated mice with vehicle (DMSO), the MAGL inhibitor JZL-184 (40 mg/kg), lumiracoxib (1 
mg/kg), or a co-treatment of both JZL-184 and lumiracoxib. As seen previously, lumiracoxib caused a 
significant increase in AEA and AA (Figure 4). JZL-184 also caused a robust increase in 2-AG and 2-OG with a 
significant decrease in AA and PGs. Intriguingly, co-treatment of lumiracoxib with JZL-184 did not result in an 
additional increase in 2-AG or 2-OG over JZL-184 treatment alone. In addition, co-treatment of lumiracoxib 
with JZL-184 resulted in a decrease in AA, as seen with JZL-184 treatment alone. A potential explanation for 
these data is that lumiracoxib causes an increase in 2-AG through inhibition of COX-2, but the 2-AG is rapidly 
hydrolyzed to AA by MAGL. Taken together with the in vitro inhibition studies, lumiracoxib treatment does 
appear to have an impact on MAGL activity, but it could be through a secondary mechanism via its inhibition of 
2-AG oxygenation by COX-2. 
0 50 100
0
50
100
[Inhibitor] (μM)
M
AG
L a
cti
vit
y (
%
 of
 co
ntr
ol)
MAGL Inhibition
JZL-184
Lumiracoxib
0 20 40 60 80 100
0
50
100
[Inhibitor] (μM)
FA
AH
 ac
tiv
ity
 (%
 of
 co
ntr
ol)
FAAH Inhibition
PF-3845
Lumiracoxib
	   144	  
 
Figure 4: Effects of JZL-184, lumiracoxib, and co-treatment on brain lipids and PGs. Lumiracoxib caused 
a significant increase in AEA and AA, while JZL-184 caused an increase in 2-AG and 2-OG with a significant 
decrease in AA and PGs. Co-treatment of lumiracoxib with JZL-184 did not result in an additional increase in 
2-AG or 2-OG over JZL-184 treatment alone. In addition, co-treatment of lumiracoxib with JZL-184 resulted in 
a decrease in AA, as seen with JZL-184 treatment alone. Data shown are mean ± s.e.m., vehicle and 
lumiracoxib n = 20, JZL-184 and JZL-184 + lumiracoxib n = 10. Statistical significance calculated using one-
way ANOVAs followed by Holm-Sidak post-tests. 
 
 We next sought to determine the time-course of lumiracoxib’s effects on brain lipids and PGs. We 
treated mice with vehicle (18:1:1 saline:ethanol:emulphor) or 1 mg/kg lumiracoxib and sacrificed the mice at 
the indicated time points after treatment. Lumiracoxib significantly increased AEA levels at 2, 4, 6, and 8 hours 
after treatment (Figure 5). Lumiracoxib treatment also significantly increased the levels of AA at all time points 
measured. Additionally, lumiracoxib caused a significant increase in 2-AG at 8 hours after treatment. There was 
no significant effect of lumiracoxib on either PGs or OEA at any time points. In contrast to earlier studies, 
lumiracoxib only significantly increased 2-OG 24 hours after treatment, but there was a strong trend toward 
increasing 2-OG at all time points. Thus, lumiracoxib displays a long duration of action after a single 1 mg/kg 
intraperitoneal injection with robust effects up to 8 hours after treatment.  
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Figure 5: Time-course of lumiracoxib treatment. Lumiracoxib increases AEA up to 8 hours after treatment 
with no significant inhibition of PGs at any time point. Lumiracoxib also significantly increased 2-AG at 8 
hours after treatment and 2-OG at 24 hours after treatment Lumiracoxib treatment significantly increased AA at 
all time points, but had no significant effect on OEA. Data shown are mean ± s.e.m., n = 5-26. Statistical 
significance calculated using one-way ANOVAs followed by Holm-Sidak post-tests. 
 
 Given the long duration of action of lumiracoxib and lack of PG inhibition, we next analyzed its effects 
after chronic treatment. Mice were treated with vehicle (18:1:1 saline:ethanol:emulphor) or lumiracoxib (1 
mg/kg) by intraperitoneal injection once daily for 5 days. Mice were sacrificed 2 hours after the final treatment 
and their brains were analyzed by mass spectrometry. Chronic treatment with lumiracoxib increased AEA and 
AA levels but had no significant effect on the other analytes (Figure 6). Thus, chronic treatment with 
lumiracoxib results in an increase in AEA and does not result in PG inhibition.  
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Figure 6: Effects of chronic lumiracoxib treatment on brain lipids and PGs. Chronic treatment with 
lumiracoxib significantly increases AEA and AA but has no significant effect on 2-AG, PGs, OEA, or 2-OG. 
Data shown are mean ± s.e.m., vehicle n = 10, LM-4131 n = 11. Statistical significance calculated using two-
tailed t-tests. 
 
 To extend the chronic treatment data, we also treated mice with vehicle (18:1:1 saline:ethanol:emulphor) 
or lumiracoxib (1 mg/kg) by intraperitoneal injection once daily for 5 days and then sacrificed the mice 8 hours 
after the final treatment. After this treatment regimen, lumiracoxib significantly increased AEA, 2-AG, AA, and 
2-OG levels but had no significant effect on PGs or OEA (Figure 7). Therefore, chronic treatment with 
lumiracoxib mirrors the time-course of acute treatment. These studies reveal that chronic lumiracoxib treatment 
does not result in a reduction of the effect of lumiracoxib on brain eCB or AA levels and does not cause PG 
inhibition. Taken together, these studies identify lumiracoxib as an in vivo substrate-selective COX-2 inhibitor 
in both acute and chronic settings with a long duration of action. 
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Figure 7: Effects of chronic lumiracoxib treatment on brain lipids and PGs 8 hours after last dosing. 
Lumiracoxib significantly increases AEA, 2-AG, AA, and 2-OG levels 8 hours after the last treatment of 1 
mg/kg once a day for 5 days. Under this treatment regimen lumiracoxib had no effect on either PGs or OEA. 
Data shown are mean ± s.e.m., n = 8. Statistical significance calculated using two-tailed t-tests. 
 
 Finally, we tested the effects of LM-5703, the des-fluoro analog of lumiracoxib. LM-5703 potentially is 
less likely to form reactive quinone imines than lumiracoxib or diclofenac due to the fact that its lower ring 
contains one less halogen and is thus less deactivated for enzymatic abstraction of its para hydrogen and 
subsequent oxidation. We treated mice by intraperitoneal injection with either vehicle (DMSO), 1 mg/kg LM-
5703, or 10 mg/kg LM-5703 and harvested their brains 4 hours after treatment. Both the 1 and 10 mg/kg 
treatments significantly increased the levels of AEA, 2-AG, AA, and 2-OG (Figure 8). While the 10 mg/kg 
treatment did not significantly decrease PGs, there was a reduction in the average amount of PGs detected. 
Thus, LM-5703 displays a similar dose-response profile to lumiracoxib in vivo, identifying this probe as a 
potential alternative in vivo substrate-selective inhibitor to lumiracoxib.   
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Figure 8: Dose-response of LM-5703. Treatment of mice with LM-5703 significantly increased the levels of 
AEA, 2-AG, AA, and 2-OG but had no significant effect on PGs or OEA. Data shown are mean ± s.e.m., n = 8. 
Statistical significance calculated using one-way ANOVAs followed by Holm-Sidak post-tests. 
 
 To further validate the biochemical effects of lumiracoxib as being mediated by substrate-selective 
COX-2 inhibition and not FAAH inhibition, we analyzed the effects of lumiracoxib compared to co-treatment 
of lumiracoxib with the FAAH inhibitor PF-3845 versus vehicle (DMSO) and PF-3845 treatment alone. After a 
4 hour treatment, lumiracoxib (1 mg/kg) significantly increased brain AEA, AA, and 2-OG with a trending 
increase in 2-AG (Figure 9). While PF-3845 (10 mg/kg) significantly increased AEA and OEA, co-treatment of 
PF-3845 with lumiracoxib resulted in an additional significant increase in AEA but not OEA. Comparison of 
the vehicle versus lumiracoxib treated mice to PF-3845 treated mice versus lumiracoxib co-treatment with PF-
3845 indicates that lumiracoxib treatment results in similar increases in AEA regardless of whether or not 
FAAH is inhibited. 
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Figure 9: Effects of vehicle, PF-3845, lumiracoxib, and co-treatment on brain lipids and PGs. Both PF-
3845 and lumiracoxib cause significant increases in AEA. While lumiracoxib has no significant effect on 2-AG, 
OEA, or PGs, it significantly increases AA and 2-OG 4 hours after treatment. PF-3845 also caused a significant 
increase in OEA, but co-treatment of lumiracoxib and PF-3845 resulted in additive increases in AEA but not 
OEA. Data shown are mean ± s.e.m., n = 10. Statistical significance calculated using one-way ANOVAs 
followed by Holm-Sidak post-tests.     
 
 We further analyzed the impact of FAAH on the effects of lumiracoxib by treating wild-type and Faah–
/– littermates with vehicle (DMSO) or lumiracoxib for 4 hours. While lumiracoxib did not significantly increase 
AEA in wild-type littermates in this experiment, it did produce an additional significant increase compared to 
vehicle treated Faah–/– mice (Figure 10). Lumiracoxib significantly increased 2-AG levels in both wild-type and 
Faah–/– mice to a similar extent, but significantly increased AA and 2-OG in Faah–/– but not wild-type mice. 
Lumiracoxib treatment had no significant effect on OEA or PG levels in either wild-type or Faah–/– mice. As 
expected, Faah–/– mice had significantly increased levels of AEA and OEA, but not other lipids or PGs. Thus, 
lumiracoxib treatment produces additive increases in AEA when co-treated with the FAAH inhibitor PF-3845 
and in Faah–/– mice. This suggests that the mechanism by which lumiracoxib increases AEA is independent of 
FAAH.  
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Figure 10: Effects of lumiracoxib on brain lipids and PGs in wild-type and Faah–/– littermates. 
Lumiracoxib had no significant increase of AEA in wild-type littermates, but produced an additional significant 
increase in AEA compared to vehicle treated Faah–/– mice. Lumiracoxib significantly increased 2-AG levels in 
both wild-type and Faah–/– mice, but significantly increased AA and 2-OG in Faah–/– but not wild-type mice. 
Lumiracoxib treatment had no significant effect on OEA or PG levels in either wild-type or Faah–/– mice. Data 
shown are mean ± s.e.m., vehicle n = 5, lumiracoxib n = 4, Faah–/– n = 5, Faah–/– + lumiracoxib n = 6. 
Statistical significance calculated using one-way ANOVAs followed by Holm-Sidak post-tests. 
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Discussion 
 
 These studies have identified lumiracoxib as an in vivo substrate-selective COX-2 inhibitor. While 
preliminary in vitro studies identified that lumiracoxib is an extremely potent substrate-selective COX-2 
inhibitor, the present studies extend that finding to in vivo settings.21 It is notable that lumiracoxib has the 
highest selectivity for COX-2 inhibition over COX-1 inhibition of any NSAID in the human whole blood 
assay.22 Interestingly, this assay measures COX-2 inhibition by the inhibition of PGE2 production elicited by 
lipopolysaccharide and COX-1 inhibition by the inhibition of thromboxane synthesis elicited by calcium 
ionophore treatment. The selective inhibition of PGE2 but not thromboxane by lumiracoxib is intriguing 
because PGH2-G is converted readily to PGE2 but is not a good substrate for thromboxane synthase.67 Thus, our 
studies suggest that the COX-2 selectivity of lumiracoxib may actually be due to substrate-selective inhibition 
of COX-2 and a reduction in PGE2-G formation, which can be hydrolyzed to PGE2. 
 Notably, lumiracoxib is efficacious in multiple pre-clinical models of pain and inflammation.23 Despite 
the clinical metabolic toxicity exhibited by lumiracoxib, some studies suggest that the liver toxicity of 
lumiracoxib could be avoided by giving lower doses or by genotyping patients, as a specific allele can identify 
at risk patients.51,52 Given our findings that lumiracoxib can increase brain eCBs at a dose of 1 mg/kg, it is 
possible that substrate-selective inhibition by lumiracoxib could be sufficient to provide therapeutic benefits 
without liver toxicity. In addition, as previous studies have identified that lumiracoxib does not increase 
cardiovascular risk or cause increased gastrointestinal complications in patients, the two primary complications 
in individuals who take NSAIDs for prolonged periods, it could be a promising therapeutic option.53-56  
 The aqueous solubility of lumiracoxib and efficacy in chronic settings make it a promising probe to 
study substrate-selective inhibition in vivo. Additionally, the des-fluoro derivative of lumiracoxib, which may 
have a reduced capacity to form reactive quinone imine metabolites in vivo, also displayed substrate-selective 
COX-2 inhibition in mice. These studies expand the probes available to study in vivo substrate-selective COX-2 
inhibition and advance a probe with an improved pharmacological profile relative to LM-4131.  
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CHAPTER VII 
 
SUBSTRATE-DEPENDENT ENDOCANNABINOID OXYGENATION BY CYCLOOXYGENASE-2 
 
Introduction 
 
 Since the discovery that 2-arachidonylglycerol (2-AG) is a substrate for cyclooxygenase-2 (COX-2) our 
laboratory has explored the synthesis and physiology of prostaglandin glycerol esters (PG-Gs).1 Several studies 
have demonstrated that COX-2-mediated endocannabinoid metabolism is an important alternative pathway to 
hydrolysis at sites of COX-2 constitutive or induced expression.2-4 Previous efforts have focused on the 
stimulatory conditions that produce PG-Gs, however, the biosynthetic pathway that is responsible for the 
synthesis of 2-AG for use by COX-2 has not been elucidated.5-7  
 The development and validation of several macrophage cell lines for the study of PG-G biosynthesis has 
provided a valuable set of model systems to define their full biosynthetic pathway. Although PG-G production 
has been demonstrated in several cell lines, the relative abundant levels of arachidonic acid (AA)-derived 
prostaglandins (PGs) compared to a dearth of 2-AG derived PG-Gs, even when correcting for the relative 
amounts of AA and 2-AG, suggests that the two substrates are not equally utilized by COX-2.5,6 Previous 
studies in our laboratory have identified that one mediator of this large difference between substrate utilization 
is based on the requirement of higher peroxide tone for 2-AG oxygenation.8  
 While both AA and 2-AG are oxygenated by COX-2, they are synthesized through distinct pathways. A 
primary source of AA is the hydrolysis of phospholipids at the sn-2 position catalyzed by cytosolic 
phospholipase A2 (cPLA2). There are six identified isoforms of cPLA2 in mice: α, β, γ, δ, ε, and ζ. These 
isoforms are expressed in different tissues and are activated in response to different stimuli. In activated 
macrophages, AA biosynthesis is primarily mediated by the action of cPLA2α, an 85 kDa protein containing an 
N-terminal C2 domain and a C-terminal catalytic domain.9 The activity of cPLA2α is regulated by intracellular 
calcium levels through the binding of calcium to the C2 domain, which results in translocation of the enzyme to 
the phospholipid membrane.10 In addition to calcium, cPLA2α activity is also modulated by ceramide-1-
phosphate, phosphatidylinositol 4,5-bis phosphate (PIP2), and phosphorylation by mitogen-activated protein 
kinase.11-13  
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 After translocation to the membrane, cPLA2α utilizes an active site Ser-228/Asp-549 dyad within its α/β 
hydrolase domain to catalyze the hydrolysis of the sn-2 position of phospholipids including phosphatidylcholine 
(PC), phosphatidylethanolamine (PE), and phosphatidylinositol (PI).14,15 Importantly, cPLA2α hydrolysis of 
phospholipid substrate has high substrate specificity for phospholipids containing AA at the sn-2 position.10 In 
addition to PLA2 activity, cPLA2α possesses calcium-independent lysophospholipase and transacylase 
activities.16 Intriguingly, genetic deletion of cPLA2α results in a robust reduction of AA and PG production in 
resident peritoneal macrophages (RPMs), but has no significant effect on 2-AG and PG-G levels.7 
 The identification of cPLA2α as the major mediator of AA production in macrophages has led to 
considerable interest in the development of pharmacological inhibitors of cPLA2α due to the potential to block 
AA production and metabolism along the COX or lipoxygenase pathways, which generate pro-inflammatory 
and nociceptive bioactive lipids including PGs, leukotrienes, and lipoxins. These eicosanoids are important in 
intracellular immunity and have been implicated in the pathogenesis of several diseases including thrombosis, 
cancer, atherosclerosis, asthma, arthritis, and rhinitis.17-21 A variety of different classes of cPLA2α inhibitors 
have been developed. The first series of inhibitors developed were AA analogs such as AA-trifluoromethyl 
ketone and methyl arachidonyl fluorophosphonate, although they also inhibit iPLA2α.22 These compounds 
prevent intraplantar carrageenan mediated thermal hyperalgesia and formalin-induced flinching.23 These initial 
studies spurred pharmaceutical companies to develop compounds of their own. Bristol-Myers Squibb developed 
and patented a series of α- and β-substituted trifluoromethyl ketones.24,25 Shionogi identified a series of 
pyrrolidines, including pyrrophenone, which inhibited PG and leukotriene formation in human whole blood and 
displayed anti-arthritic effects in a murine arthritis model.26,27 Additional scaffolds including 2-oxoamides and 
1,3-disubstituted propan-2-ones have been developed and validated by AstraZeneca.  
 The most concerted medicinal chemistry efforts have been advanced by Genetics Institute, which was 
later acquired by Wyeth, using an indole scaffold. These efforts lead to the development of ecopladib (Figure 
1), which displayed oral efficacy in the rat carrageenan air pouch and rat carrageenan-induced paw edema 
models and advanced to phase I clinical trials.28 Further efforts identified the optimal phenylmethane 
sulfonamide region substitution, giving rise to efipladib and WAY-196025, which both have shown efficacy 
	   158	  
when dosed orally in multiple acute and chronic PG- and leukotriene-dependent in vivo pain and inflammation 
models.29-31 Additional studies were performed on another analog, giripladib, which had efficacy in multiple 
mouse models of rheumatoid arthritis and was advanced into phase II clinical trails for osteoarthritis but failed 
to advance due to a lack of improvement over naproxen, a non-steroidal anti-inflammatory drug (NSAID) that 
inhibits both COX-1 and COX-2 and is the current standard of care.32 Additional efforts have optimized the in 
vitro potency and rat pharmacokinetics for oral efficacy, and Wyeth has also identified 1,2,4-oxadiazolidin-3,5-
diones and 1,3,5-triazin-2,4,6-triones as well as quinazoline-2,4(1H,3H)-dione cPLA2α inhibitors with reduced 
lipophilicity and improved aqueous solubility.31,33-35 These combined efforts have developed potent and 
selective cPLA2α inhibitors that are active in vivo, although most are not commercially available and require 
lengthy syntheses. 
 
Figure 1: Structures of cPLA2α inhibitors. 
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 While the synthesis of AA by macrophages proceeds primarily through the action of cPLA2α on 
phospholipids, it can also be formed by the hydrolysis of 2-AG in the brain and other settings.36 The primary 
source of 2-AG in most cells and tissues is the phospholipase C (PLC)-diacylglycerol lipase (DAGL) pathway 
(Figure 2).37 In this pathway, PLC hydrolyzes 2-arachidonoyl-PIP2 to form AA-containing diacylglycerols 
(DAGs), which are then hydrolyzed to 2-AG by diaclyglycerol lipase (DAGL).38,39 In neurons, PLCβ isoforms 
have been implicated in this pathway due to the formation of 2-AG in response to the stimulation of Gq/11-
coupled receptors.40 Interestingly, the 4 isoforms of PLCβ are expressed in a regiospecific manner throughout 
the brain and are stimulated by different Gq/11-coupled receptors including the group I metabotropic glutamate 
receptors (mGluRs) mGluR1 and mGluR5, as well as the muscarinic acetylcholine receptor M1.41 Alternative 
pathways to synthesize 2-arachidonoyl-DAG have been identified including the hydrolysis of phosphatidic acid 
(PA) in ionomycin-stimulated neuroblastoma cells and PC in phorbol ester treated mouse ear tissue.42,43 
Additionally, PI can be hydrolyzed by PLA1 to form lyso-PI (LPI), followed by LPI-PLC hydrolysis to form 2-
AG.44,45 2-AG can also be formed from 2-arachidonoyl-lysophosphatidic acid (LPA).46 While these lipases all 
have biological interest, very few selective inhibitors have been developed to probe the exact function of each 
of the enzymes. The only enzyme in the 2-AG biosynthetic pathways with a validated selective inhibitor is 
DAGLβ, however, that compound also inhibits the hydrolysis of 2-AG to AA by α/β-hydrolase domain 6 
(ABHD6).47 
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Figure 2: Biosynthetic pathways for 2-AG. 
 We sought to directly investigate the influence of AA on 2-AG oxygenation in vitro and in cellular 
settings. Utilizing the previously established biosynthetic routes of 2-AG and AA, we also sought to identify the 
biosynthetic source of 2-AG and AA in multiple macrophage cell lines using previously established stimulation 
conditions through lipidomic analyses. We identified AA as a non-competitive inhibitor of COX-2-mediated 2-
AG oxygenation in vitro. With this finding in hand, we identified the effects of the inhibition or deletion of 
cPLA2α and, thus, a reduction of AA production on the production of PG-Gs. These studies identified 38:4 PI as 
a major source of both 2-AG and AA in RAW 264.7 and bone-marrow-derived macrophages (BMDM). 
Inhibition or genetic deletion of cPLA2α led to decreased levels of AA and PGs, but increased levels of 38:4 PI, 
38:4 DAG, and PG-Gs in stimulated RAW 264.7 cells and BMDMs. The selectivity and mechanism of 
giripladib were validated using BMDMs harvested from cPLA2α+/+ and cPLA2α–/– mice. Finally, we established 
that the production of PG-Gs in BMDMs is mediated by COX-2. 
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Experimental Procedures 
Materials 
RAW 264.7 cells were obtained from American type culture collection (Rockville, MD). Cell culture reagents 
were purchased from Life Technologies (Gaithersburg, MD). PGE2-G, PGF2α-G, PGE2-d4, AA-d8, AEA-d8, 2-
AG-d8, and SAG-d8, were purchased from Cayman Chemical (Ann Arbor, MI). 17:1 LPC, 37:4 PC, 17:1 LPI, 
37:4 PI, 37:4 PE, 37:4 PS, 37:4 PA, and 37:4 PG were purchased from Avanti Polar Lipids (Alabaster, AL). 
Lipopolysaccharide (LPS), zymosan B, ionomycin, and interferon γ (IFNγ) were purchased from Sigma Aldrich 
(Milwaukee, WI). PGE2-G-d5 was synthesized as described previously using chemicals from Sigma Aldrich.48 
Macrophage colony stimulating factor (M-CSF) and granulocyte macrophage colony stimulating factor (GM-
CSF) were purchased from R&D Systems (Minneapolis, MN). Giripladib was a kind gift from Alex Brown 
(Vanderbilt University). 
Determination of the effects of AA on 2-AG oxygenation by mCOX-2 
A fixed concentration of mCOX-2 (250 nM) was suspended in a 100 mM Tris-HCl buffer, pH = 8 with 500 µM 
phenol and 2 equivalents of heme were added, the solution was vigorously mixed and then aliquoted out at 195 
µl per tube and pre-incubated for five minutes at 37°C. After pre-incubation, 5 µl of DMSO containing the 
specified amounts of AA and/or 2-AG was added in to the tube, vigorously mixed, and allowed to react for 30 
seconds. The reaction was quenched after 30 seconds by adding 200 µl of ethyl acetate containing 0.1% glacial 
acetic acid, 300 pmol of PGE2-d4, and 300 pmol of PGE2-G-d5. Tubes were frozen and the organic layer was 
separated and evaporated to dryness under nitrogen gas. The samples were then reconstituted in 200 µl of 1:1 
methanol:water and analyzed using liquid chromatography-tandem mass spectrometry (LC-MS/MS) analysis.  
RAW 264.7 Cell Culture 
Low passage RAW 264.7 cells (ATCC) were cultured in DMEM containing 10% HI-FBS. Cells were plated at 
3x106 cells onto 100 mm plates. Cells were treated with 20 ng/ml GM-CSF for 24 hours and then the media was 
removed and replaced with serum-free DMEM containing 1 µg/ml LPS (E. coli 011:B4) and 20 units/ml IFNγ. 
At this time point cells were treated with inhibitor or DMSO vehicle as described in the text. 6 hours after LPS 
and IFNγ stimulation the cells were treated with 2 µM ionomycin or vehicle. 45 minutes after ionomycin 
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treatment the media was removed and extracted with 2 equivalents (v/v) of ethyl acetate containing PGE2-d4 
and PGE2-G-d5. The cells were then scraped into 1 ml of ice-cold methanol containing AA-d8, 2-AG-d8, SAG-
d8, 17:1 LPC, 37:4 PC, 17:1 LPI, 37:4 PI, 37:4 PE, 37:4 PS, 37:4 PA, and 37:4 PG and added directly into the 
ethyl acetate solution. The solution was vigorously mixed and the organic layer was then removed and dried 
under a stream of nitrogen gas. The resultant film was then reconstituted in 200 µl of methanol and 100 µl of 
water for analysis by LC/MS/MS. 
BMDM Harvesting and Culture  
20-30g Female ICR (CD-1) cPLA2+/+, cPLA2–/–, Ptgs2+/+ and Ptgs2–/– mice were bred and genotyped as 
described previously.7 Mice were sacrificed by cervical dislocation and decapitation and the lower body was 
soaked in a 70% ethanol solution. The skin was removed from each hind leg and the femur was detached from 
the tibia at the knee joint. The femur and tibia of each leg were then detached and placed in ice-cold sterile 
Ca2+- and Mg2+-free phosphate-buffered saline (PBS). Under a tissue culture hood the soft tissue was removed 
from each bone using a sterile razor blade and forceps, the bone was rinsed in sterile PBS, and the ends were cut 
off using sterile scissors. The marrow was flushed from each bone with 5 ml of ice cold Minimum Essential 
Medium-Alpha with GlutaMAX (α-MEM, Gibco) using a syringe and 26 gauge needle. The resulting cell 
suspension was subjected to centrifugation at 1,000 rpm for 5 min, and the cells were resuspended in 1 
ml/mouse of lysis buffer (155 mM ammonium chloride, 10 mM potassium bicarbonate, 0.1 mM EDTA, pH 7.2 
– 7.4). Following a 2 minute incubation at room temperature, α-MEM (10 ml/mouse) was added and the cells 
were collected by centrifugation (1,000 rpm for 5 min). The resulting cell pellet was re-suspended in 42 
ml/mouse of α-MEM containing 10% heat-inactivated fetal bovine serum (Atlas Biologicals, Norcross, GA) 
plus 100 Units/ml penicillin and 0.10 mg/ml streptomycin (Sigma, St. Louis, MO) (α-MEM/FCS) supplemented 
with 50 ng/ml of M-CSF (R&D Systems). The cells were then plated at 7 ml/dish onto 100 mm Fisherbrand 
untreated polystyrene tissue culture dishes (cat. #08-757-13) and incubated for 4 days at 37oC.  
 After 4 days colonies of adherent macrophages had developed. The dishes were washed once with α-
MEM and overlaid with 10 ml of fresh α-MEM/FCS containing 50 ng/ml of m-CSF. Following an additional 
incubation of 2 days the cells were harvested. The dishes were washed once with 6 ml of PBS and overlaid with 
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6 ml of calcium- and magnesium-free Hanks Balanced Salt Solution containing 2 mM EDTA. The cells were 
incubated at 37°C for 30 min. The dishes then scraped and the cells from three dishes were combined into a 50 
ml sterile tube containing 20 ml of α-MEM and were then subjected to centrifugation (1,000 rpm for 5 min). 
This procedure yielded between 20 and 40 million cells per mouse on the day of harvest. 
 After centrifugation the cells were re-suspended and diluted to 0.5x106 cells/ml in α-MEM/FCS 
containing 50 ng/ml of m-CSF and 20 ng/ml of GM-CSF and plated at 3x106 cells onto 100 mm dishes (6 
ml/dish). The dishes were then incubated for 24 hours prior to experimental treatment. The following morning 
the media was removed and replaced with fresh serum-free α-MEM with LPS (1 µg/ml) and IFNγ (20 units/ml). 
At this point vehicle (DMSO) or inhibitors were added to the dishes. Cultures were then incubated as described 
in the text before the addition of zymosan (960 µg/dish) as indicated or ionomycin (2 µM) for 1 hour. The 
samples were then extracted in an identical fashion as described above for RAW 264.7 cells. 
LC-MS/MS Analysis  
Analyses of PGs, PG-Gs, 2-AG, AA, OEA, and 2-OG were performed as described previously.49-51 DAGs and 
PCs were analyzed using a C4 column and mobile phases of 1:1 H2O:MeOH with 5 mM ammonium acetate at 
pH 3.5 with formic acid (A) and 4:1 acetonitrile:2-propanol with 0.1% (v/v) formic acid (B). DAGs were 
analyzed with a Q1 of [M+NH4]+ (+18) and a Q3 of the loss of a fatty acid tail using 38:4 DAG-d8 as an internal 
standard. PCs and LPCs were analyzed with a Q1 of [M+H]+ and a Q3 of 184.1 using 37:4 PC and 17:1 LPC as 
internal standards. PAs, PGs, PEs, PSs, and PIs were analyzed using a C4 column and mobile phases of 1:1 
H2O:MeOH at pH 8.0 with piperidine (A) and 4:1 acetonitrile:2-propanol at pH 8.0 with piperidine (B). PAs 
were analyzed with a Q1 of [M-H]- and a Q3 of 153.1 using 37:4 PA as an internal standard, PGs were analyzed 
with a Q1 of [M-H]- and a Q3 of 153.1 using 37:4 PG as an internal standard, PEs were analyzed with a Q1 of 
[M-H]- and a Q3 of 196.1 using 37:4 PE as an internal standard, PSs were analyzed with a Q1 of [M-H]- and a 
Q3 of a loss of 87 using 37:4 PS as an internal standard, and PIs were analyzed with a Q1 of [M-H]- and a Q3 of 
241.1 using 37:4 PI and 17:1 LPI as internal standards. Analytes were quantitated by integrating the areas of the 
analyte peaks and normalizing them to the areas of their respective internal standard peaks.  
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Results 
In vitro competition between AA and 2-AG 
 We first sought to analyze the potential of AA and 2-AG to inhibit each other’s oxygenation by purified 
murine COX-2. To do this we analyzed the effect of adding increasing amounts of either AA or 2-AG to a fixed 
concentration of the other substrate (5 µM) with purified COX-2. While increasing concentrations of 2-AG had 
little effect on the production of PGs from AA, increasing the amounts of AA caused dramatic decreases in PG-
G formation from 2-AG (Figure 3). Thus, it appears that AA acts as an inhibitor of 2-AG oxygenation, but 2-
AG has little impact on the oxygenation of AA by COX-2 in vitro. 
 
Figure 3: Effects of increasing concentrations of 2-AG or AA on oxygenation of 5 µM AA or 2-AG by 
COX-2. While the addition of increasing amounts of 2-AG had little effect on the turnover of AA, addition of 
increasing amounts of AA potently inhibited the turnover of 2-AG. Data shown are mean ± s.e.m., n = 6. 
  
 To characterize the inhibition of 2-AG turnover elicited by increasing amounts of AA we then 
performed kinetic analyses by varying the amounts of AA and 2-AG added into the enzyme mixture and 
analyzing the resultant PG and PG-G production. These kinetic analyses identified that 2-AG again had little 
impact on the oxygenation of AA by COX-2 (Figure 4). In contrast, AA appears to be a non-competitive 
inhibitor of 2-AG oxygenation by COX-2 in vitro. This finding was quite surprising, as COX-2 oxygenates the 
two substrates to comparable extents with comparable efficiencies.52  
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Figure 4: Kinetic analyses of the effects of 2-AG on AA oxygenation and AA on 2-AG oxygenation by 
COX-2. While 2-AG had little effect on AA oxygenation, AA exerts non-competitive inhibition of 2-AG 
oxygenation. Data shown are mean ± s.e.m., n = 6. 
 
Modulation of cellular AA to augment PG-G formation in cells 
 The in vitro inhibition of 2-AG oxygenation by AA suggested that a potential method of increasing PG-
G formation would be to inhibit AA production. Indeed, previous studies have found that inhibition of MAGL, 
which hydrolyzes 2-AG to AA, increases the amount of PG-Gs in carrageenan inflamed rat paws.53 We first 
tested this hypothesis by culturing stimulated RAW 264.7 cells with DMSO vehicle or varying amounts of the 
cPLA2α inhibitor giripladib and then analyzing their production of PGs and PG-Gs. Giripladib caused a 
concentration-dependent decrease in the production of PGs with significant effects at all concentrations (Figure 
5). In contrast, giripladib increased the production of PG-Gs, with significant effects at 5, 10, 100 and 1000 nM. 
Consistent with its characterization as a cPLA2α inhibitor, giripladib caused a significant decrease in AA levels 
with all concentrations used. In contrast, giripladib significantly increased the levels of 2-AG at 2.5 and 5 nM 
concentrations, but not at higher concentrations. Thus, inhibition of cPLA2α by giripladib differentially 
modulates the levels of PGs and AA versus the levels of PG-Gs and 2-AG. 
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Figure 5: Concentration-dependent effects of giripladib on PGs, PG-Gs, AA, and 2-AG in stimulated 
RAW 264.7 cells. Inhibition of cPLA2α by giripladib decreases the production of PGs by stimulated RAW 
264.7 cells but increases the levels of PGGs. Giripladib decreases the levels of AA at all concentrations, but 
increases the levels of 2-AG at 2.5 nM but not higher concentrations. Values shown are mean ± s.e.m., n = 12. 
Significance was determined using a one-way ANOVA followed by a Holm-Sidak post-test. 
 
 To further characterize the effects of giripladib treatment in stimulated RAW 264.7 cells, we also 
performed a targeted lipidomic analysis of AA-containing phospholipids and DAGs, the biosynthetic precursors 
of AA and 2-AG. Giripladib treatment caused a significant concentration-dependent increase in the major AA-
containing PI, 38:4 (Figure 6). While giripladib also increased the levels of 36:4 and 38:5 PI, these increases 
were not significant. The augmentation of AA-containing PI caused by increasing concentrations of giripladib 
was complemented by significant decreases in the levels of 18:1 and 18:0 LPI. Giripladib treatment also caused 
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a concentration-dependent increase in the levels of AA-containing PCs and decreased the levels of LPCs in a 
concentration-dependent manner (Figure 7). Thus, the inhibition of cPLA2α by giripladib appears to inhibit the 
hydrolysis of AA-containing PIs or PCs to AA and LPI or LPC, respectively. While previous studies have 
identified AA-containing PI as a substrate for cPLA2α, it is not widely accepted as a major phospholipid 
precursor of AA.54-57   
 
Figure 6: Concentration-dependent effects of giripladib on PIs and LPIs in stimulated RAW 264.7 cells. 
Inhibition of cPLA2α by giripladib significantly increases the levels of 38:4 PI in a concentration-dependent 
manner with trending non-significant increases in 36:4 and 38:5 PI. Concomitantly, the levels of 18:1 and 18:0 
LPI are significantly decreased. Values shown are mean ± s.e.m., n = 9. Significance was determined using a 
two-way ANOVA followed by a Holm-Sidak post-test. 
 
 
Figure 7: Concentration-dependent effects of giripladib on PCs and LPCs in stimulated RAW 264.7 cells. 
Inhibition of cPLA2α by giripladib significantly increases the levels of 38:4 and 38:5 PC in a concentration-
dependent manner with trending non-significant increases in 36:4 PC. Additionally, the levels of 18:1 LPC are 
significantly decreased. Values shown are mean ± s.e.m., n = 9. Significance was determined using a two-way 
ANOVA followed by a Holm-Sidak post-test. 
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 Given the increases in 2-AG and PG-Gs produced by treatment of stimulated RAW 264.7 macrophages 
with giripladib, we also analyzed the levels of AA-containing DAGs. DAGs are primarily formed through the 
hydrolysis of PIP2 by PLC, but can also be formed through the cleavage of PC by PLC or other phospholipids 
through hydrolysis by PLD and a phosphatase.37-39,42,43 Although the PL and phosphatase pathways have been 
described in other cell lines, the levels of AA-containing PA were below the limit of detection in our stimulated 
RAW 264.7 macrophages. Thus, we focused on measurement of the levels of AA-containing DAGs. Giripladib 
treatment resulted in a concentration-dependent increase in the levels of 38:4 DAG but not other AA-containing 
DAGs (Figure 8). These experiments reveal that inhibition of cPLA2α in stimulated RAW 264.7 macrophages 
increases the production of PG-Gs and decreases the levels of PGs. This increase in PG-G production could be 
due to multiple factors including the increase in 2-AG synthesis or the decreased levels of AA. 
 
Figure 8: Concentration-dependent effects of giripladib on DAGs in stimulated RAW 264.7 cells. 
Inhibition of cPLA2α by giripladib significantly increases the levels of 38:4 DAG in a concentration-dependent 
manner but has no effect on 36:4 or 38:5 DAG. Values shown are mean ± s.e.m., n = 9. Significance was 
determined using a two-way ANOVA followed by a Holm-Sidak post-test. 
 
 We next sought to determine the impact of genetic deletion of cPLA2α on PG and PG-G production. To 
do this we utilized BMDMs harvested in parallel from either cPLA2α+/+ or cPLA2α–/– mice. After overnight 
stimulation with GM-CSF, the BMDMs were stimulated with LPS and IFNγ followed by zymosan for varying 
amounts of time. In agreement with the studies performed in RAW 264.7 cells with giripladib, BMDMs derived 
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from cPLA2α–/– mice produced fewer PGs and greater amounts of PG-Gs relative to BMDMs derived from 
cPLA2α+/+ mice in response to stimulation (Figure 9). While zymosan stimulation resulted in a robust synthesis 
of AA in wild-type derived BMDMs, the production of AA was blunted in cPLA2α–/– BMDMs. Zymosan 
treatment also stimulated 2-AG synthesis in both cPLA2α+/+ and cPLA2α–/– BMDMs, but the amount of 2-AG 
produced by the cPLA2α–/– BMDMs was significantly higher. Thus, the effect of genetic deletion of cPLA2α in 
BMDMs mirrors the effect of giripladib in RAW 264.7 cells. 
 
Figure 9: Effects of cPLA2α deletion on PGs, PG-Gs, AA, and 2-AG in zymosan stimulated BMDMs. 
Zymosan causes significant PG production in cPLA2α+/+ BMDMs, but less pronounced production in cPLA2α–/– 
BMDMs. Zymosan also caused PG-G production in both WT- and KO-derived BMDMs, but KO-derived 
BMDMs produced larger amounts of PG-Gs. Zymosan stimulated the synthesis of AA in cPLA2α+/+ but not 
cPLA2α–/– BMDMs. Treatment with zymosan also increased the levels of 2-AG in KO-derived BMDMs to a 
greater extent than WT-derived BMDMs. Values shown are mean ± s.e.m., n = 6. Significance was determined 
using a two-way ANOVA followed by a Holm-Sidak post-test (* p < .05, ** p < .01, *** p < .001, and **** p 
< .0001 vs vehicle; # p < .01 and ## p < .0001 vs wild-type).  
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 To further analyze the lipidomic consequences of genetic deletion of cPLA2α, the levels of 
phospholipids and DAGs were analyzed in parallel. Zymosan caused an initial significant decrease in 38:4 PI at 
30 minutes after treatment, which recovered back to non-zymosan treated levels at later time points in 
cPLA2α+/+ BMDMs (Figure 10). In contrast, in cPLA2α–/– BMDMs zymosan decreased 38:4 PI at all time points 
relative to non-zymosan treated cells. Interestingly, cPLA2α+/+ BMDMs displayed a reduction in AA-containing 
DAGs with 30 minutes of zymosan stimulation but little effect at later time points. In stark contrast, cPLA2α–/–
BMDMs basally had much higher levels of DAGs relative to cPLA2α+/+ BMDMs and zymosan treatment 
caused a large increase in AA-derived DAGs.  
 
Figure 10: Effects of cPLA2α deletion on PIs and DAGs in zymosan stimulated BMDMs. Zymosan 
treatment causes an initial decrease in AA-containing PIs and DAGs in WT-derived BMDMs that recovers over 
time. In contrast, KO-derived BMDMs have decreased levels of 38:4 at all time points after zymosan 
stimulation but higher levels of DAGs after zymosan treatment at all time points. Values shown are mean ± 
s.e.m., n = 6. Significance was determined using a one-way ANOVA followed by a Holm-Sidak post-test (* p < 
.05, ** p < .01, *** p < .001, and **** p < .0001 vs vehicle). 
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 Surprisingly, zymosan treatment had no significant effect on AA-containing PC species in both 
cPLA2α+/+ and cPLA2α–/–BMDMs (Figure 11). However, it should be noted that the levels of AA-containing PIs 
and PCs in BMDMs are substantially higher than in RAW 264.7 cells, consistent with previous reports 
identifying RAW 264.7 cells as being relatively arachidonate-deficient.58 Taken together, these data suggest that 
treatment of cPLA2α+/+ BMDMs with zymosan leads to rapid hydrolysis of 38:4 PI by cPLA2α to form AA. In 
contrast, cPLA2α–/– BMDMs treated with zymosan hydrolyze 38:4 PI via the PLC pathway to form DAGs, 
which are then converted to 2-AG and PG-Gs. 
 
Figure 11: Effects of cPLA2α deletion on PCs in zymosan stimulated BMDMs. Zymosan treatment causes 
no statistically significant effects on AA-containing PCs in either cPLA2α+/+ or cPLA2α–/– BMDMs. Values 
shown are mean ± s.e.m., n = 6.  
 
 We next sought to validate the effects of giripladib as being mediated by cPLA2α inhibition in BMDMs 
under multiple stimulation conditions. BMDMs derived from cPLA2α+/+ and cPLA2α–/– mice were stimulated 
with either ionomycin for 1 hour or zymosan for 2 hours with and without giripladib. Both zymosan and 
ionomycin caused a robust production of PGs in cPLA2α+/+ BMDMs, which was significantly reduced by 
treatment with 100 nM giripladib (Figure 12). In contrast, cPLA2α–/– BMDMs did not robustly produce PGs in 
response to either zymosan or ionomycin treatment and giripladib had no effect on the minimal production of 
PGs. Both zymosan and ionomycin induced the formation of PG-Gs in cPLA2α+/+ BMDMs, and giripladib 
significantly increased the levels of PG-Gs over the ionomycin alone stimulated values. In cPLA2α–/– BMDMs 
stimulated with ionomycin there were larger amounts of PG-Gs relative to cPLA2α+/+ BMDMs treated with 
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ionomycin. Importantly, in cPLA2α–/– BMDMs giripladib treatment had no effect on the production of PG-Gs. 
In agreement with the reduction in AA release produced by giripladib in RAW 264.7 cells, it also significantly 
reduced the levels of AA in zymosan and ionomycin treated cPLA2α+/+ BMDMs. Giripladib had no effect on 
AA in cPLA2α–/– BMDMs treated with either zymosan or ionomycin, although ionomycin treatment resulted in 
a significant increase in AA levels relative to vehicle treatment. Giripladib increased the levels of 2-AG in 
ionomycin-stimulated cPLA2α+/+ BMDMs, but not zymosan treated cPLA2α+/+ BMDMs, and had no effect on 2-
AG levels under any stimulation conditions in cPLA2α–/– BMDMs. BMDMs treated with ionomycin had 
significantly higher levels of 2-AG when derived from cPLA2α–/– versus cPLA2α+/+ mice. 
 
Figure 12: Effects of giripladib in cPLA2α+/+ and cPLA2α–/– BMDMs. The effects of giripladib are abolished 
in cPLA2α–/– mice. Values shown are mean ± s.e.m., n = 6. Significance was determined using a two-way 
ANOVA followed by a Holm-Sidak post-test (* p < .05, ** p < .01, *** p < .001, and **** p < .0001 versus 
respective genotype vehicle; & p < .05, && p < .01, &&& p < .0001 versus stimulation with no giripladib; # p 
< .01, ## p < .001, ### p < .0001 versus cPLA2α+/+). 
  
 To further assess effects of giripladib under different stimulation conditions in cPLA2α+/+ and cPLA2α–/–
BMDMs, full lipidomic analyses were performed in parallel. Giripladib (100 nM) demonstrated similar effects 
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in cPLA2α+/+ BMDMs as previously seen in RAW 264.7 cells, as it increased 38:4 PI and DAG but had no 
effect in cPLA2α–/– BMDMs (Figure 13). The effects of giripladib compared to cPLA2α+/+ were mirrored by 
cPLA2α–/– BMDMs, revealing they produce analogous effects. Thus, these data suggest that giripladib acts as a 
selective cPLA2α inhibitor to block the hydrolysis of AA from the sn-2 position of 38:4 PI, which can then be 
phosphorylated to PIP2 and cleaved by PLC to form 38:4 DAG. 38:4 DAG can then be hydrolyzed to 2-AG, 
which is oxygenated to form PG-Gs.  
   
Figure 13: Effects of giripladib in cPLA2α+/+ and cPLA2α–/– BMDMs. The effects of giripladib are abolished 
in cPLA2α–/– mice. Values shown are mean ± s.e.m., n = 6. Significance was determined using a two-way 
ANOVA followed by a Holm-Sidak post-test (* p < .05, *** p < .001, and **** p < .0001 versus respective 
genotype vehicle; & p < .05, && p < .0001 versus stimulation with no giripladib; # p < .001, ## p < .0001 
versus cPLA2α+/+). 
 
Identification of the COX isoform responsible for PG-G production in BMDMs 
 As the final step in characterizing the biosynthetic pathway for PG-G production in BMDMs, we also 
sought  to identify the enzyme responsible for the production of PG-Gs from 2-AG. While COX-1 does not 
utilize 2-AG as a substrate efficiently in vitro, previous studies identified COX-1 as the major mediator of PG-G 
formation in resident peritoneal macrophages.7,52 To assess the relative contributions of COX-1 and COX-2 to 
PG and PG-G production in stimulated BMDMs we harvested cells from Ptgs2+/+ and Ptgs2–/– mice. While 
Ptgs2+/+ BMDMs had robust production of both PGs and PG-Gs in response to zymosan or ionomycin 
stimulation, Ptgs2–/– BMDMs produced significantly less PGs and trace amounts of PG-Gs (Figure 14). 
Giripladib treatment significantly reduced the levels of PGs in both Ptgs2+/+ and Ptgs2–/– BMDMs. While 
giripladib treatment significantly increased the levels of PG-Gs in Ptgs2+/+ BMDMs relative to zymosan or 
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ionomycin alone, it was unable to rescue the lack of production of PG-Gs in Ptgs2–/– BMDMs. Thus, COX-2 
appears to be the major producer of PGs and PG-Gs in BMDMs under these stimulation conditions. 
 
Figure 14: Effect of COX-2 genetic deletion on PG and PG-G production elicited by zymosan and 
ionomycin stimulation with and without giripladib treatment. While Ptgs2+/+ BMDMs had robust 
production of both PGs and PG-Gs, Ptgs2–/– BMDMs produced significantly less PGs and trace amounts of PG-
Gs. Giripladib treatment significantly reduced the levels of PGs in both Ptgs2+/+ and Ptgs2–/– BMDMs. 
Giripladib treatment significantly increased the levels of PG-Gs in Ptgs2+/+ BMDMs, but did not lead to robust 
PG-G production in Ptgs2–/– BMDMs. Values shown are mean ± s.e.m., n = 3. Significance was determined 
using a two-way ANOVA followed by a Holm-Sidak post-test (* p < .05, ** p < .01, and **** p < .0001 versus 
respective genotype vehicle; & p < .05, && p < .01, &&& p < .001, &&&& p < .0001 versus stimulation with 
no giripladib; # p < .0001 versus cPLA2α+/+). 
 
 To determine if the lack of effect of giripladib on PG-G production in Ptgs2–/– BMDMs was due to a 
lack of inhibition of AA production, we also analyzed the levels of AA and 2-AG. Giripladib treatment 
significantly inhibited the production of AA in Ptgs2+/+ treated with zymosan and in Ptgs2–/– treated with either 
zymosan or ionomycin (Figure 15). Interestingly, the levels of AA in Ptgs2–/– BMDMs were significantly 
higher after zymosan or ionomycin treatment relative to the levels in Ptgs2+/+ BMDMs treated with zymosan or 
ionomycin. This suggests that COX-2 is a major determinant of AA levels in zymosan or ionomycin stimulated 
BMDMs. Both zymosan and ionomycin caused significant increases in 2-AG levels in both Ptgs2+/+ and Ptgs2–
/– BMDMs. Giripladib treatment led to a further significant enhancement of 2-AG levels compared to zymosan 
treatment alone in Ptgs2+/+ BMDMs and compared to both zymosan and ionomycin treatment alone in Ptgs2–/– 
BMDMs. Taken together, these studies demonstrate that AA may serve as an inhibitor of 2-AG oxygenation by 
COX-2. Pharmacological or genetic blockade of the hydrolysis of 38:4 PI by cPLA2α leads to augmentation of 
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38:4 DAG and 2-AG levels in both RAW 264.7 and BMDMs. Thus, a shunting of AA-containing PI to form 2-
AG occurs and a consequence of this is increased PG-G production by COX-2. The increase in PG-G 
production could be caused by multiple factors including release of inhibition of COX-2 oxygenation of 2-AG 
by reducing AA levels or an increase in 2-AG available to be oxygenated by COX-2. It is likely that both 
effects contribute to the increase in PG-G formation. 
 
Figure 15: Effect of COX-2 genetic deletion on AA and 2-AG production elicited by zymosan and 
ionomycin stimulation with and without giripladib treatment. Giripladib treatment significantly inhibited 
the production of AA in both Ptgs2+/+ and Ptgs2–/– BMDMs and significantly increased the levels of 2-AG in 
Ptgs2+/+ and Ptgs2–/– BMDMs. Values shown are mean ± s.e.m., n = 3. Significance was determined using a 
two-way ANOVA followed by a Holm-Sidak post-test (*** p < .001 and **** p < .0001 versus respective 
genotype vehicle; & p < .001 and && p < .0001 versus stimulation with no giripladib; # p < .01 and  ## p < 
.0001 versus cPLA2α+/+). 
 
In vivo production of PG-Gs 
 The increased production of PG-Gs in response to giripladib treatment in stimulated macrophages 
prompted us to explore the potential of increasing PG-G production in vivo by decreasing the levels of AA and 
increasing the levels of 2-AG. To do this, we utilized mice containing a human Thy-1-COX-2 transgene, which 
leads to expression of human COX-2 in neurons of the amygdala, striatum, cerebral cortex, and hippocampus.59-
61 These mice have PGE2 levels that are 25-40-fold higher than non-transgenic controls. The mice also develop 
an age-dependent deficit in both spatial and non-spatial memory tasks due to increases in cortical neuron 
apoptosis and glial activation.62 The mice also exhibit enhanced hippocampal long-term synaptic plasticity and 
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a lack of depolarization-induced suppression of inhibition, both of which are mediated by increased oxidative 
degradation of eCBs by COX-2.63  
 We first assessed the impact of overexpressing COX-2 by measuring the levels of PGs, AEA, 2-AG, and 
AA in the brain in transgenic COX-2 and wild-type littermates. The transgenic mice had significantly higher PG 
levels and significantly decreased AEA and 2-AG levels, with no change in AA (Figure 16). Thus, COX-2 
overexpression decreases the levels of AEA and 2-AG in whole brain, consistent with the previous studies 
identifying deficits in eCB signaling.63 These analyses also confirmed the striking increase in PG production in 
COX-2 transgenic mice compared to wild-type littermates. 
 
Figure 16: Effect of COX-2 overexpression on brain PGs, AEA, 2-AG, and AA. COX-2 transgenic mice 
have significantly increased PG levels in the brain. Overexpression of COX-2 in the brain also results in 
decreased AEA and 2-AG levels, but has no effect on AA levels. Values shown are mean ± s.e.m., vehicle n = 
24 and transgenic n = 21. Significance was determined using a two-tailed t-test (* p < .05 and **** p < .0001). 
 
 We hypothesized that PG-G production could be induced in these mice by blocking the hydrolysis of 2-
AG to AA in the brain by inhibiting MAGL with JZL-184. Previous studies have found that 2-AG is a major 
precursor for AA in the brain, suggesting that JZL-184 may produce similar effects in the brain to those elicited 
PGs
An
aly
te 
(p
m
ol/
g)
WT Tg
0
2000
4000
6000
****
2-AG
An
aly
te 
(n
m
ol/
g)
WT TG
0
5
10
15
20
25
*
AEA
An
aly
te 
(p
m
ol/
g)
WT Tg
0
2
4
6
8
*
AA
An
aly
te 
(n
m
ol/
g)
WT TG
0
50
100
150
200
	   177	  
by giripladib in macrophages.36 Treatment of COX-2 overexpressing mice with JZL-184 resulted in the 
production of PG-Gs in the brain (Figure 17). This is notable as it is the first detection of PG-Gs in the brain. 
These studies are also in line with previous reports demonstrating that JZL-184 increases PG-G formation in 
carrageenan-treated rat footpads.53 Thus, COX-2 overexpressing mice treated with JZL-184 could serve as an 
ideal in vivo platform to characterize substrate-selective COX-2 inhibitors for not just their effects on eCBs, but 
also with a direct measure of substrate-selective inhibition by monitoring PGs and PG-Gs. 
 
Figure 17: Effect of JZL-184 on production of PGs and PG-Gs in wild-type and COX-2 transgenic mice. 
While JZL-184 had no significant effect on PG production in either wild-type or COX-2 transgenic mice, it 
caused an increase in brain PG-Gs. Values shown are mean ± s.e.m., vehicle n = 8, JZL-184 n = 6, COX-2 
transgenic n = 5, COX-2 transgenic + JZL-184 n = 7. 
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Discussion 
 These studies identify AA as a non-competitive inhibitor of 2-AG oxygenation by COX-2. The in vitro 
competition between the substrates for oxygenation by COX-2 appears to mirror the effects of substrate-
selective inhibitors on 2-AG, which also display non-competitive inhibition.64 Whether the mechanisms that 
give rise to the non-competitive inhibition of 2-AG by AA and substrate-selective inhibitors are identical is 
unknown, but given the fact that AA and substrate-selective inhibitors bind to COX-2 in similar fashions, it is 
likely that they inhibit AA oxygenation via similar structural perturbations. 
 We have extended the in vitro studies by utilizing two macrophage cell lines to characterize the impact 
of manipulating AA levels on PG-G production. PG-G production has been demonstrated in several cell lines, 
but the relatively abundant levels of PGs compared to a dearth of 2-AG derived PG-Gs, even when correcting 
for the relative amounts of AA and 2-AG, suggests that the two substrates are not equally utilized by COX-2.5,6 
Previous studies in our laboratory had identified that one mediator of this large difference between substrate 
utilization is based on the requirement of higher peroxide tone for 2-AG oxygenation.8 We have now 
established AA levels as another determinant of 2-AG oxygenation. Although both of these factors clearly 
contribute to 2-AG turnover by COX-2, the production of PG-Gs in cells still is not comparable with the 
production of PGs. Although they are not produced in bulk amounts as PGs are, it is notable that PG-Gs have 
quite potent biological effects, suggesting that subtle manipulation of their levels may produce exponential 
biological effects, such as calcium mobilization, compared to similar perturbations of PGs.65 
 Beyond the characterization of PG-G biosynthesis, these studies identify 38:4 PI as a fundamentally 
limiting phospholipid precursor species in the synthesis of both AA and 2-AG in stimulated macrophages. 38:4 
PI can be hydrolyzed by cPLA2α to form AA and 18:0 LPI or alternatively can be hydrolyzed by PLC to form 
38:4 DAG. 38:4 DAG can be further hydrolyzed by DAGL, which forms a free fatty acid and 2-AG. Thus, 38:4 
PI serves as a source for AA and 2-AG in a mutually exclusive fashion at the phospholipid level, although 2-AG 
itself can also serve as a precursor to AA through hydrolytic enzymes. Inhibition or deletion of cPLA2α leads to 
augmentation of 38:4 PI, which is then utilized by stimulated RAW 264.7 or BMDMs to form 38:4 DAG, 2-
AG, and PG-Gs.  
	   179	  
 The increase in PG-G production could be due to a number of factors including the increase in 2-AG 
synthesis, but also through the removal of substrate competition from AA in the cellular milieu. Further studies 
defining the exact isoform(s) of PLC and DAGL that control this pathway and thorough examination of other 
pathways as possible routes to synthesize 2-AG for oxygenation by COX-2 are needed to fully elucidate 
biosynthetic pathway that produces PG-Gs.  
 To extend these cellular studies in vivo we also assessed the impact of the MAGL inhibitor JZL-184 on 
PG-G production in COX-2 transgenic mice. These mice produced significant amounts of PG-Gs when treated 
with JZL-184. Thus, inhibition of 2-AG hydrolysis to AA coupled with overexpression of COX-2 results in a 
robust production of PG-Gs in the brain in vivo. This system should prove valuable for future studies assessing 
substrate-selective inhibition, as it allows for a direct read out of PG-G inhibition as opposed to tangential 
measurements such as increases in AEA and 2-AG. Additionally, these COX-2 transgenic mice treated with 
JZL-184 could be useful for studying the biological effects of PG-Gs from behavioral responses to synaptic 
signaling.  
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CHAPTER VIII 
PERSPECTIVE AND FUTURE DIRECTIONS 
 Cyclooxygenase-2 (COX-2) catalyzes the bis-dioxygenation and cyclization of polyunsaturated fatty 
acid substrates such as arachidonic acid (AA), 2-arachidonoyl glycerol (2-AG), and arachidonoyl ethanolamide 
(AEA).1,2 This is the committed step in the generation of prostaglandin H2, prostaglandin H2-glycerol, and 
prostaglandin H2-ethanolamide, which are each then processed by downstream enzymes to form prostaglandins 
(PGs), prostaglandin glycerol esters (PG-Gs), and prostaglandin ethanolamides (PG-EAs). These bioactive 
species mediate a variety of physiological effects, including pain, inflammation, and fever, through their actions 
at G-protein coupled receptors (GPCRs). While the GPCRs that respond to PGs have been thoroughly studied, 
the receptors for PG-Gs and PG-EAs appear to be distinct from traditional prostanoid receptors.3  
 The oxygenation of AEA and 2-AG by COX-2 not only produces a distinct set of bioactive lipids, but it 
also modulates the levels of AEA and 2-AG. AEA and 2-AG are the endogenous ligands for the cannabinoid 
receptors 1 and 2 (CB1 and CB2), which mediate a variety of physiological and pathophysiological processes.4,5 
In addition to activating CB1 and CB2, they can also act at other targets including vanilloid receptor 1 (TRPV1), 
peroxisome proliferator-activated receptor (PPAR), and some ion channels.4 
 AEA and 2-AG are synthesized and degraded by discrete sets of enzymes.6-8 Elucidation of the 
molecular regulation of eCB metabolism has led to the development of pharmacological tools to enhance eCB 
signaling and probe the therapeutic utility of eCB augmentation for a variety of pathological conditions.9-11 
AEA is primarily degraded by fatty acid amide hydrolase (FAAH), and pharmacological inhibition of FAAH 
causes robust increases in brain AEA levels.12,13 However, FAAH also degrades a number of non-cannabinoid 
N-acylethanolamides (NAEs), which are elevated upon FAAH inhibition and are active at molecular targets  
such as PPARs.14-16 In parallel to AEA, 2-AG is primarily degraded by monoacylglycerol lipase (MAGL), 
which also metabolizes a series of monoacylglycerols (MAGs).17 Inhibition of FAAH or MAGL have 
demonstrated preclinical efficacy in models of neuropathic pain, neurodegeneration, anxiety and depression, 
pain, hyperemesis, and drug withdrawal syndromes, many of which are mediated by CB receptor-dependent 
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mechanisms.9,18-21 These studies demonstrate the pleiotropic therapeutic potential of eCB augmentation via 
FAAH and MAGL inhibition and the resulting modulation of cannabinoid receptor signaling.  
 The studies discussed in this dissertation reveal that, in addition to FAAH and MAGL, COX-2 action 
modulates the levels of AEA and 2-AG. While a connection between COX-2 action and endocannabinoid 
inactivation has been suggested by a series of converging data, our studies have demonstrated for the first time 
that COX-2 action can modulate endocannabinoid levels in multiple settings and across a series of tissues. This 
discovery opens exciting new frontiers to study the mechanism of action of clinically used non-steroidal anti-
inflammatory drugs (NSAIDs). Multiple studies have identified that CB1 receptor antagonists block the anti-
nociceptive effects of NSAIDs in spinal injury models.22-27  
 A novel class of COX-2 inhibitors termed “substrate-selective” COX-2 inhibitors, which prevent AEA 
and 2-AG oxygenation by COX-2 without inhibiting the oxygenation of AA to PGs, offers a novel 
pharmacological strategy to increase endocannabinoid levels without affecting AA-derived PG formation.28 The 
studies outlined in this dissertation have generalized that rapid, reversible COX-2 inhibitors are potent inhibitors 
of 2-AG oxygenation, but weak inhibitors of AA oxygenation. In contrast, slow, tight-binding COX-2 inhibitors 
inhibit AA and 2-AG oxygenation with comparable IC50 values. In addition, we have identified the (R)-profens 
as substrate-selective inhibitors in contrast to previous reports suggesting they are inactive against COX-2. 
 In addition to our identification of a series of novel substrate-selective inhibitors, we have identified a 
facile method of developing novel substrate-selective inhibitors. Our studies demonstrating that manipulation of 
hydrogen bonding and ion pairing between a slow, tight-binding inhibitor and active site residues of COX-2 can 
produce substrate-selective inhibition suggests that modification of slow, tight-binding inhibitors to reduce their 
capacity to hydrogen bond and/or ion pair with the active site can generate substrate-selective inhibitors. Given 
the plethora of scaffolds that have been identified as NSAIDs, substrate-selective inhibitors likely also exist in a 
vast chemical space. Along with rational design of substrate-selective inhibitors through modification of slow, 
tight-binding inhibitors, our studies suggest that a series of compounds previously identified as inactive against 
COX-2 may in fact be substrate-selective inhibitors. As significant libraries of NSAIDs and NSAID analogs 
have been developed through concerted drug discovery efforts, a method such as high throughput screening for 
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the ability of these compounds to act as substrate-selective inhibitors could rapidly identified these probes along 
with a series of scaffolds not previously characterized as having activities against COX-2 in vitro. 
 We have investigated the enzymatic mechanism of substrate-selective inhibition based on several studies 
examining the basic function of COX-2. While the two subunits of COX-2 are sequence homodimers, the heme 
prosthetic group binds to only a single monomer, creating functional heterodimers. The heme-containing 
subunit is the catalytic subunit, whereas the non-heme-containing subunit is the allosteric subunit.29,30 Binding 
of substrates, activators, and inhibitors to the allosteric subunit alters binding in the catalytic subunit through 
subunit communication via the dimer interface.31 Substrate-selective inhibitors bind in the allosteric subunit and 
induce a conformational change that blocks AEA and 2-AG oxidation in the catalytic subunit. Binding of a 
second inhibitor molecule in the catalytic subunit blocks AA oxygenation, but this typically occurs at inhibitor 
concentrations orders of magnitude higher than the concentrations that block AEA and 2-AG oxygenation.28 In 
contrast, slow, tight-binding inhibitors bind in the catalytic subunit and block the oxygenation of all substrates 
at similar concentrations.32,33  
 Consistent with this hypothesis, we have identified Leu-531 as a key mediator of substrate-selective 
inhibition. Leu-531 lies adjacent to the glycerol-binding pocket of 2-AG and mutation of Leu-531 to Ala results 
in abrogation of substrate-selective inhibition. This suggests that binding of a substrate-selective inhibitor to the 
allosteric site causes rotation of Leu-531 into the active site and a steric clash with the glycerol of 2-AG, 
resulting in inhibition. The exact mechanism that gives rise to the rotation of Leu-531 is still under 
investigation. These studies will assess the determinants of Leu-531 rotation and dimer crosstalk. One critical 
experiment will be mutation of Tyr-544 to Phe, which may mediate the translocation of the helix containing 
Leu-531 via a change in hydrogen bonding interactions with Pro-127 at the dimer interface. Further insight into 
the dynamics of substrate-selective inhibition could be gleaned from experiments with heterodimers containing 
one monomer of COX-2 lacking the ability to bind heme and a second monomer containing Leu-531 to Ala 
mutations. This mutant would force the Leu-531 to Ala monomer to serve as the catalytic site, while the 
monomer lacking heme binding would serve as the allosteric site. Thus, the through-space effects of binding to 
the allosteric site could be probed selectively with this heterodimer. The dynamics of substrate-selective 
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inhibition could also be identified with crystal structures containing only one molecule of a substrate-selective 
inhibitor bound to one active site with no occupancy at the second active site. These crystal structures could 
identify the structural perturbations in the second active site, such as a rotation of Leu-531, that give rise to 
substrate-selective inhibition. 
 In addition to establishing the in vitro determinants of substrate-selective inhibition we have also 
developed multiple cellular systems to characterize substrate-selective inhibitors. Both stimulated RAW 264.7 
macrophages and stimulated primary dorsal root ganglia cells (DRGs) produce PG-Gs. DRGs also produce PG-
EAs when treated with the calcium ionophore, ionomycin. We have utilized these model systems to validate 
that substrate-selective inhibitors selectively decrease the production of PG-Gs and PG-EAs while having no 
inhibition of PGs. In addition, we have discovered that substrate-selective inhibition leads not only to a 
reduction in PG-Gs and PG-EAs, but also an increase in 2-AG and AEA. This suggests that substrate-selective 
inhibition not only decreases compounds that induce hyperalgesia and mechanical allodynia, but also increases 
the levels of analgesic agents.34-36 These cellular systems, particularly RAW 264.7 macrophages, also provide a 
convenient and rapid system to assess potential substrate-selective inhibitors for activity prior to in vivo testing.    
 Despite our successes with the (R)-profens in cellular systems, their one-way conversion to (S)-profens 
in mice necessitated the development of novel substrate-selective inhibitors. We identified a facile method of 
converting slow, tight-binding inhibitors to substrate-selective inhibitors by removing binding interactions 
between the inhibitor and the COX-2 active site. These studies lead to LM-4131, which we validated as a 
substrate-selective inhibitor against purified COX-2, in cellular systems, and in vivo. LM-4131 treatment 
increased the levels of AEA and 2-AG in the brain and several peripheral organs without having any effect on 
AA or PG production. Thus, we have identified the biochemical effects of a substrate-selective inhibitor in vivo. 
 The effect of LM-4131 on brain AEA and 2-AG prompted us to test its effects in several behavioral 
paradigms. Of particular importance, LM-4131 demonstrated anxiolytic effects in several pre-clinical models of 
anxiety. While the use of COX inhibitors in the treatment of pain and inflammation dates back over three 
thousand years, the anxiolytic effects of LM-4131 suggest a novel potential therapeutic effect. Thus, substrate-
selective inhibition exhibits a novel therapeutic effect in vivo, although we clearly have not established the 
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scope of the potential therapeutic effects of substrate-selective inhibitors compared to traditional NSAIDs or 
endocannabinoid augmenting agents such as FAAH or MAGL inhibitors.  
 While substrate-selective inhibition exhibits anxiolytic effects in pre-clinical models of anxiety, we also 
sought to determine if they have reduced side effects relative to traditional NSAIDs and endocannabinoid 
augmenting agents. The potential side effects of substrate-selective COX-2 inhibitors could be produced from 
two biochemical effects. First, adverse effects such as gastrointestinal and cardiovascular or cerebrovascular 
toxicity are associated with most NSAIDs and are mediated by the inhibition of PG synthesis by COX-1, COX-
2, or both enzymes.37-40 Second, adverse cognitive, metabolic, and locomotor side effects are associated with 
direct CB1 receptor activation.  
A major clinical concern for the chronic use of COX inhibitors is cardiovascular and cerebrovascular 
toxicity manifested by an increased incidence of heart attack and stroke. Cardiovascular side effects are 
exhibited by most NSAIDs, regardless of their selectivity for COX-2, due to a reduction in vascular PGI2 
biosynthesis.41,42 As LM-4131 did not affect central or peripheral levels of PGs, including PGI2, it is possible 
that this pharmacological class of inhibitors could be devoid of or exhibit significantly reduced 
cardio/cerebrovascular toxicity compared to NSAIDs. Indeed, clinical trials conducted with the substrate-
selective COX-2 inhibitor (R)-flurbiprofen suggest that it does not increase cardiovascular events.43,44  
Gastrointestinal bleeding is also a well-known adverse effect of COX inhibition and is mediated by 
inhibition of gastroprotective PG synthesis in the gut.45,46 LM-4131 does not cause overt gastrointestinal 
bleeding after acute administration, whereas indomethacin causes significant overt bleeding at the same dose. 
Additionally, (R)-flurbiprofen does not display gastrointestinal toxicity in humans.43,44 These studies suggest 
that substrate-selective COX-2 inhibitors lack of an effect on PG synthesis may render them less prone to or 
even devoid of the complicating side effects of traditional COX inhibitors.  
Since LM-4131 leads to CB1 receptor activation in the central nervous system, and possibly in other 
tissues, cannabimimetic side effects could occur. Common adverse effects of direct acting cannabinoid agonists 
include motor suppression, cognitive impairment, hyperphagia, and dependence liability. LM-4131 does not 
cause motor suppression or object recognition memory deficits.47 This may be in part be due to the relative 
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preference to elevate AEA over 2-AG, since MAGL inhibition or combined MAGL and FAAH inhibition 
produces cannabimimetic effects such as pronounced motoric inhibition.48  
In addition to the potential lack of adverse cannabimimetic effects of LM-4131, distinct differences in 
the tissue-specificity of LM-4131 relative to FAAH inhibition suggest that it may lack some of the side effects 
of FAAH inhibition. FAAH inhibition in the liver causes robust increases in AEA and non-endocannabinoid 
NAE levels.47 In contrast, LM-4131 does not affect liver AEA or NAE levels.47 Activation of hepatic CB1 
receptors contributes to diet-induced metabolic pathology	  49,50and genetic FAAH deletion promotes a pre-
diabetic state and adversely affects energy metabolism.49,5051 The lack of effect of LM-4131 on hepatic AEA 
indicates that substrate-selective COX-2 inhibitors may lack adverse metabolic side effects relative to other 
indirect or direct acting cannabinoid agonists.47 Ongoing studies aimed at comparing and contrasting the 
relative cannabimimetic profiles of the three distinct endocannabinoid augmentation strategies will clarify the 
relative side-effect profiles of the three different enzymatic inhibition strategies.  
Despite the promising initial studies with LM-4131, further characterization uncovered critical problems 
with its use in vivo. Although LM-4131 acted as a substrate-selective COX-2 inhibitor 2 hours after 
administration, at later time points it underwent hydrolysis to indomethacin. This metabolism to indomethacin 
results in the inhibition of PGs and a lack of substrate-selectivity over time. Thus, LM-4131 is not a good probe 
for acute studies lasting over 2 hours or for chronic studies. 
To overcome the limitations of LM-4131 for in vivo time-course studies we turned to lumiracoxib. 
Lumiracoxib displayed robust substrate-selective inhibition in vitro, in cellular systems, and in vivo. In contrast 
to LM-4131, it has a long duration of action and is effective in chronic settings. However, lumiracoxib also 
displays a different biochemical profile than LM-4131 with significant increases in 2-OG and AA. Both of these 
increases are MAGL-dependent, as co-treatment of JZL-184 and lumiracoxib does not result in an additive 
increase of 2-OG and abolishes the increase in AA produced by lumiracoxib alone. While lumiracoxib does not 
display potent inhibition of MAGL in vitro, it is possible that lumiracoxib inhibits MAGL in vivo. Further 
determinations of the molecular mechanisms of lumiracoxib are required to define the parameters under which 
it would act exclusively as a substrate-selective COX-2 inhibitor. Although lumiracoxib does show initial 
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promise, further efforts to optimize the selectivity and pharmacological profile of in vivo substrate-selective 
inhibitors is needed. 
Future studies utilizing the probes we have developed aimed at examining the therapeutic landscape of 
substrate-selective inhibition will provide a comparison of the therapeutic potential of substrate-selective 
inhibitors compared to traditional NSAIDs along with FAAH or MAGL inhibitors. Given the vast array of 
effects mediated by endocannabinoids and the identified beneficial effects of NSAIDs, substrate-selective 
inhibitors could represent an important novel class of therapeutic agents. Of primary importance, the ability of 
substrate-selective inhibitors to act as analgesic and anti-inflammatory agents has not yet been directly 
evaluated, although (R)-flurbiprofen has shown some initial promise as both an analgesic and anti-inflammatory 
agent. The probes developed in our laboratory coupled with other tools, such as prostanoid receptor knockout 
mice, will serve as invaluable tools to pinpoint the biochemical basis of the therapeutic effects of substrate-
selective inhibitors.   
We have also explored the biosynthetic pathway of PG-Gs in stimulated macrophages. Our finding that 
AA is a non-competitive inhibitor of 2-AG oxygenation by COX-2 in vitro was quite surprising. However, we 
leveraged the in vitro studies by using pharmacological inhibition or genetic deletion of cPLA2α in 
macrophages, which resulted in significant decreases in PG production and significant increases in PG-G 
production. While these studies identified the 38:4 PI, 38:4 DAG, 2-AG, PG-G pathway as the likely source for 
increased PG-G production, further experiments identifying the enzymes responsible for the lipid remodeling 
are clearly required. While enrichment of 38:4 PI, 38:4 DAG, and 2-AG were readily apparent upon inhibition 
or deletion of cPLA2α, whether this pathway is actually directly coupled to COX-2 for oxygenation is unclear as 
the increases in these species is much larger than the increase in PG-G production. Additionally, whether 38:4 
PI itself is the substrate for PLC or whether it is phosphorylated to generate PIP species that are then hydrolyzed 
to DAGs is unknown at this point. Previous studies have identified that while PIP2 and PIP are preferred 
substrates for PLC, PI can also be hydrolyzed, albeit at a lower efficiency.52-54 Given the much larger pool of 
38:4 PI relative to 38:4 PIP and 38:4 PIP2, it is possible that the major precursor for 38:4 DAG is in fact 38:4 PI. 
Further identification of the phospholipases involved in the biosynthesis of PG-Gs will also be necessary. While 
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the PLC and DAGL pathway appears to be the most enriched pathway upon inhibition or deletion of cPLA2α, it 
is possible that other pathways, such as the PLD pathway, may actually be directly involved in the increase of 
PG-G production. Selective inhibition of PLD1, PLD2, and DAGLβ, the major enzymatic isoforms mediating 
these pathways in RAW 264.7 cells and BMDMs, will provide further insight into the exact biosynthetic 
pathway of PG-Gs. 
We also have not yet established a complete coverage of manipulating the production of AA in either 
RAW 264.7 macrophages or BMDMs. While cPLA2α is the major source of AA, it can also be produced 
through hydrolysis of 2-AG by ABHD6, MAGL, and ABHD12. Further experiments examining the impact of 
ABHD6 and/or MAGL inhibition with and without cPLA2α inhibition or deletion will provide a more complete 
picture of the interplay between 2-AG and AA oxygenation by COX-2. While no selective inhibitors of 
ABHD12 have been reported, previous studies have suggested that ABHD6 and MAGL are the major 
hydrolytic enzymes for 2-AG in macrophages. While we have not established each of the nodes of PG-G 
biosynthesis, we have identified that PG and PG-G production in stimulated BMDMs is mediated primarily by 
COX-2, as opposed to COX-1 in resident peritoneal macrophages.55 Thus, future studies examining the biology 
of PG-Gs in a COX-2-dependent manner should focus on BMDMs rather than RPMs. 
Taken together, these studies have identified and expanded our knowledge of the impact of COX-2 
action on endocannabinoids and endocannabinoid-derived prostaglandin products. The development and 
characterization of novel substrate-selective COX-2 inhibitors for use in vitro, in cellular systems, and in vivo 
has produced valuable probes for studying the role of COX-2 in endocannabinoid metabolism and for 
elucidating the function of PG-Gs and PG-EAs. Substrate-selective COX-2 inhibitors provide a novel 
pharmacological strategy to augment endocannabinoid signaling without affecting PG formation. Substrate-
selective inhibitors offer a novel mechanism for augmenting endocannabinoids and provide a valuable set of 
tools to elucidate the differential fundamental biology of endocannabinoid- and AA-derived COX-2 products.  
Further studies optimizing the in vivo pharmacological profile of substrate-selective inhibitors and 
elucidating the therapeutic potential of this class of compounds could have broad implications. The potential to 
develop a novel class of NSAIDs with therapeutic effects and reduced side effect profiles is quite promising. 
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The studies discussed in this dissertation put forward the basic biochemical principles that mediate substrate-
selective COX-2 inhibition, a series of probes to test the therapeutic potential and biological effects of substrate-
selective COX-2 inhibition, and a fundamental understanding of how substrate-selective COX-2 inhibition 
interacts with the endocannabinoid system. 
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